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Although the treatment of cancer continues to improve, the treatment of high-
grade gliomas remains a major challenge; current treatments are palliative
rather than curative. This is despite a variety of multimodal treatments op-
tions including surgery, chemotherapy and radiotherapy. The median survival
for patients with glioblastoma multiforme is less than one year after diagnosis
and generally no patients survive five years post treatment.
The hypothesis underlying the work presented in this thesis is that local tu-
mour control can be improved by exploiting elements with a high atomic num-
ber (Z) so as to increase the energy deposited in the tumour cells. The main
aim is to use in vitro experiments to better understand, and consequently opti-
mise, the role of the high-Z element for combination with chemo-radiotherapy
and dose enhancement radiotherapy. This work goes part of the way to prove
that combination chemo-radiotherapy can lead to outcomes that are more than
simply additive and that high-atomic number nanostructured particles can be
customised for radiotherapy to increase radiation-induced e↵ects for the very
radioresistant 9L cancer cells.
In preliminary studies carried out to develop and test all cell related proto-
cols an interesting and unexpected result was observed in in vitro experiments
that investigated the response of two asynchronous cancer cell lines, 9L (rat
gliosarcoma) and MCF-7 (human breast carcinoma), exposed to 10 MV X-ray
radiation at dose-rates of 0.5 Gy/min and 5 Gy/min. Namely that although
the 9L cells did not demonstrate any noticeable dose-rate e↵ect, the radiosensi-
tive cell line MCF-7 exhibited an inverse dose-rate e↵ect. The di↵erent e cacy
of the treatments was measure quantitatively by a significant increase of 20%
in the absorbed radiation dose necessary in the 5 Gy/min experiment to de-
liver the same 10% cell-surviving fraction as in the 0.5 Gy/min experiment.
A second strand of experiments investigated the e↵ect of ceramic nanoparticles
(NPs) containing high atomic number elements on the radiation response of
9L cells in vitro. The NPs investigated were cerium oxide (CeO2), tantalum
pentoxide (Ta2O5), and bismuth oxide (Bi2O3). I developed the cell culture
protocols, investigated cytotoxicity, performed experiments using flow cytom-
etry to determine internalisation of the NPs inside the cells and used confocal
microscopy to investigate the e↵ect of NPs upon reactive oxygen species (ROS)
production.
The bulk of the research carried out for this thesis involved an investigation into
the e↵ectiveness of concurrent chemo-radiotherapy (using BrUdR and MTX
drugs) in an attempt to reduce the radioresistivity of 9L cells. In vitro ex-
periments were performed by analysing cell cultures irradiated with common
radiation radiotherapy modalities, a conventional orthovoltage x-ray unit and
a LINAC in the radiotherapy clinic at the Prince of Wales Hospital, Sydney.
Results of the clonogenic assay show that the surviving fraction of 9L cells was
significantly reduced when BrUdR and MTX drugs were combined together
with photon irradiation, compared to the cases of irradiation alone or either
drug and irradiation. Cells irradiated in a 125 kVp X-ray field showed the
greatest sensitisation enhancement ratio (SER) value of 2.3 compared to all
other energies investigated (50 kVp, 250 kVp, 6MV, or 10MV). These results
support not only the feasibility of chemotherapy drug-enhanced radiotherapy
through the improved biological e↵ectiveness of the X-ray irradiation but also
validate the application of chemo-radiotherapy in conventional X-ray radio-
therapy modality fields.
The ability of high atomic number elements to act as radiosensitising compo-
nents has been demonstrated. The results presented in this thesis may have
future application in radiotherapy to increase the biological e↵ectiveness of
such treatment and consequently to improve local tumour control. Finally,
although the use of nanoparticles enhances the biological e↵ect of irradiation
halogenated pyrimidine is a more e↵ective radiosensitiser due to its ability to
be incorporated into the DNA of dividing cells.
This Ph.D. thesis is the first from the newly created Targeted Nano-Therapies
(TNT) Team at the University of Wollongong, which is a multidisciplinary
research team that brings together Medical Physicists, Materials Engineers,
Chemists, Biologists and Clinicians to improve the outcomes of cancer treat-
ment.
KEYWORDS: radiosensitiser, high-Z, bromodeoxyuridine, methotrexate,
nanoparticles, in vitro, conventional X-rays.
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Despite significant advances in surgery, radiotherapy, and chemotherapy, can-
cer is the second largest cause of death in developed countries. In Australia,
more than 80,000 people develop cancer every year with more than 60% of
patients surviving long term following an appropriate treatment plan. Radio-
therapy forms a major treatment strategy for cancer patients, being second
after surgery in contributing to the cure of cancer. In some cases radiotherapy
is used as an alternative to surgery, particularly for those cases where surgery
is not an option due to the need to preserve critial organs such as in the treat-
ment of deep-seated gliomas.
The ongoing challenge in radiation therapy treatment is the controlled delivery
of a lethal dose to the tumour whilst minimising damage to the surrounding
normal tissue. Improvements in radiation dose delivery techniques provide im-
provements in local tumour control, e.g. intensity modulation radiation therapy
(IMRT) and stereotactic radiotherapy (SRT) are two of the most commonly
used external beam radiation therapies (EBRT). IMRT is the most commonly
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used technique in radiotherapy of the central nervous system (CNS) while SRT
is an extremely precise radiation treatment technique for the delivery of a large
single dose fractionation within the brain (e.g. gamma knife).
In the most common form of clinical radiotherapy megavoltage linear acceler-
ators (LINACs) are used to irradiate the target by X-rays. Modern medical
LINACs are also used for electron beam radiotherapy where electrons are not
directed onto a target (x-ray target is retracted) but used directly to a tumour
site, which only be used in special procedures such as total body electron skin
irradiation [Metcalfe et al., 2007]. A less common form of radiotherapy, using
lower energy kilovolt (kV) X-rays from an orthovoltage machine, is primarily
used for superficial cancer treatment. Another type of radiotherapy is hadron
therapy, which uses particles such as neutrons, protons, and light or heavy ions
to treat cancer. Theoretically hadron therapy o↵ers the potential of both phys-
ical (protons and ions) and biological (neutrons and ions) advantages in the
treatment of localised tumours [Lodge et al., 2007] as well as the treatment of
radioresistant tumours and tumours located near critical body structures (e.g.
spinal cord) [Petti and Lennox, 1994].
All types of radiation therapy used in cancer treatment have been extensively
studied in terms of their quality of dose distributions, linear energy transfer
(LET), and most importantly, in terms of their ability to confine the high-
dose treatment to the tumour volume and thus minimise the radiation dose
delivered to the surrounding healthy tissue. In patients with more advanced
local-regional disease, tumour control is often unsatisfactory with 85% of pa-
tients with glioblastoma [Krex et al., 2007] and 30 – 40% of patients with
unresectable pancreatic carcinoma and head & neck cancers su↵ering a local
recurrence [Sohn et al., 2000]. For this reason considerable research has been
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Figure 1.1: Schematic diagram of increased lethal DNA damage by the combi-
nation of drugs and radiation in general (upper) modified from [Seiwert et al.,
2007] and in this study (lower) as the increased DNA damage by the presence
of drugs (i.e BrUdR and MTX) combined to radiation. Blue dots, red dots,
and green square represents platinating agents (cisplatin), methotrexate/5-FU,
and the high-Z agents (BrUdR/IUdR), respectively.
performed into enhancing the cytotoxicity e↵ect of radiotherapy focussing on
the use drugs-and/or nanoparticles (NPs) to enhance radiotherapy. This is
one of the strategies used in the work presented in this thesis, as illustrated in
Figure 1.1.
The combined use of chemotherapy and radiosensitiser drugs containing plat-
inum (Z = 78, K-edge at 78.4 keV) has recently shown promising results in
clinical radiotherapy [Rousseau et al., 2010]. This method is designed to in-
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crease the radiation dose delivered to the target tissue by using elements that
have large photoabsorption (i.e. photoelectric e↵ect) cross-sections. However,
in Rousseau et al. [2010] mega-electron X-rays were used. The photon absorp-
tion mechanisms present at these energies are not as e cient as those present
at kilo-voltage X-ray energies. This suggests that the technique can be im-
proved by using lower X-ray energies. In the presence of highly absorbing
elements in the tumours, X-ray photoabsorption in the tissue can theoretically
be enhanced by tuning the X-ray energy to that of the inner-shell absorption
edge of the targeted elements [Kobayashi et al., 2010].
In 2004, Corde et al. proposed the concept of radiotherapy enhancement in the
presence of iodine compounds by irradiating with photons of energy just above
the K-absorption edge of iodine (33.2 keV). They succeeded in demonstrating
that 50 keV photons were the most e↵ective for this element. More recently,
researchers have investigated using the combination of platinum nanoparti-
cles with hadron therapy. In both cases the required energy sources (intense
monochromatic X-rays and carbon or proton ions facilities) are very expensive
high-tech treatment options, making them less viable as a treatment option.
The strategy proposed in this thesis is based upon utilising more traditional
cancer treatment modalities such as conventional X-ray machines, which are
both much more readily available in hospitals worldwide and cheaper.
Other cancer radiation treatment options relevant to this thesis to obtain the
synergy of enhanced absorption and tumour specificity are brachytherapy and
radionuclide-targeted therapy. Brachytherapy (BT) is a form of radiotherapy
which involves the use of radioisotopes (e.g. low dose rate (LDR-BT) iodine-
125 seeds or a high dose rate (HDR-BT) Ir-192 seed) implanted directly into
the tumour, either temporarily (in the case of HDR-BT) or permanently (in
1.1. Background 5
the case of LDR-BT). BT is often used for treating cancer in organs that
incorporate or are in close proximity to critical structures (e.g. urethra, rec-
tum). In such cases dose escalation for better tumour treatment is di cult to
achieve without compromising the dose restrictions for these critical organs.
The nanoparticles (NPs) used in this thesis may allow such dose escalation via
direct injection of the NPs into the target prior to BT treatment. While BT
sources are not used in this thesis, low energy (kilovoltage) X-rays are used and
have some overlap with BT radiation fields. The associated findings therefore
have some relevance to BT.
In the case of radionuclide therapy radiolabelled pharmaceuticals (e.g. I-131,
P-32, Yt-90), more commonly used in nuclear medicine for diagnostic imaging,
are used to locate molecular and functional targets within tumor sites. Recent
studies have reported the use of radiosensitisers combined with radionuclide
therapy in order to improve the tumoricidal e↵ect of Auger electron ther-
apy [DeNardo and Denardo, 2006; Wong, 2006]. However, it is still a major
challenge to achieve the high dosage to the tumour necessary for satisfactory
therapeutic benefit. For this reason the strategy proposed in this thesis of
using external X-ray beams may be an e↵ective option to significantly further
boost the local dose delivered to the tumour.
In order to increase the radio-sensitivity of the tumour radiosensiter agents,
such as halogenated pyrimidine analogs, can be administered during radiother-
apy [Sano et al., 1965, 1968]. These agents are incorporated into the DNA of
dividing tumour cells; their uptake is aided by the addition of a very small
dosage of antimetabolites, methotrexate (MTX) or 5-fluorouracil (5-FU). It
should be noted that throughout this thesis, the term cell killing or cell death
refers to the loss of unlimited reproductive capability.
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1.2 Thesis Overview
1.2.1 Objectives
Improvements in radiation dose delivery to ensure a more e cient killing of
cancer cells is needed for targeted cancer treatments which aim to provide
an improvement in local tumour control and consequently reduced tumour
recurrence. The objective of this thesis work is to gain a better understanding
of how to significantly enhance tumour cell damage using:
1. Ceramic nanostructured particles (based on Ce, Ta and Bi) as com-
pounds of high-Z element, combined with external X-ray radiation beams
and
2. An experimental therapeutic combination of anticancer drugs (MTX or
5-FU) and halogenated thymidine analogs (BrUdR) with X-ray radiation
The experimental approach is discussed in detail below.
1.2.2 Aims
The research program outlined in this thesis aims to:
1. Establish tissue culture methods and techniques by growing cells, count-
ing and splitting them and by setting up clonogenic assays. (SECTION
4.1 & 4.2)
2. Test the cytotoxicity of the pharmacological drugs and ceramic NPs com-
bined with the radiosensitiser drugs for optimal enhancement of drug-
enhanced radiotherapy by measuring the viability of cells and clonogenic
survival. (SECTION 4.3)
3. Establish irradiation conditions for the optimal enhancement of the chemo-
pair therapy induced by conventional megavoltage X-ray beams by in-
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vestigating the e↵ect of dose rates of 0.5 and 5 Gy/min and by compar-
ing a radioresistant (9L) and radio-sensitive (MCF-7) cancer cell lines
(SECTION 4.4).
4. Determine the general applicability of the protocol by using ceramic NPs
(SECTION 4.5) and di↵erent chemo-drugs (i.e. 5-FU or Fluorodex)
(SECTION 4.3).
5. Establish irradiation conditions for the optimal enhancement of the chemo-
Auger therapy induced by conventional kilovoltage X-ray beams (SECTION
4.6).
6. Demonstrate radiation-induced increases in cell killing in the presence
of chemo- and radiosensitiser drugs combination assessed by clonogenic
survival analysis and quantification of the intra-cellular and intra-DNA
halogen uptake (SECTION 4.6).
7. Investigate the influence of energy dependence on enhanced radiosensi-
tising e↵ect by BrUdR plus MTX by investigating the e↵ect on di↵erent
energies range. (SECTION 4.7).
8. Establish the groundwork for confocal microscopy studies. (SECTION
4.8).
The remaining chapters of this study are arranged as follows.
CHAPTER 2 reviews the research literature pertaining to radiation therapy,
radiation biology, chemo-radiation, and the enhancement of radiobiological ef-
fects by high-Z elements. Additionally the chapter develops and validates the
theoretical hypothesis underpinning the proposed experimental investigation
combining pharmacological drugs with radiosensitiser drugs and/or nanopar-
ticles concomitantly with external therapeutic X-ray beams.
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CHAPTER 3 describes the materials and methods used in the experimental
procedures in this thesis.
CHAPTER 4 presents and discusses all of the experimental results in the
context of the aims and objectives of the thesis.
CHAPTER 5 contains the concluding remarks of this study.
The research reported in this thesis is original. Although the combination of
a high-Z material (i.e. radiosensitiser drugs), anti-cancer drugs and external
beam radiation in order to enhance biological e↵ects have been investigated
by previous researchers, these studies did not investigated the influence of the
X-ray energy. Our research hypothesis is driven by knowledge of the influence
of Auger electrons and the importance of cluster damage produced by these
low energy electrons.
This thesis work is part of a collaborative program between the Centre for
Medical Radiation Physics (CMRP), the Centre for Medical and Molecular
Bioscience (CMMB), and the Institute for Superconducting and Electronic Ma-
terials (ISEM) of the University of Wollongong (UOW). Research was mostly
conducted at the Illawarra Health and Medical Research Institute (IHMRI) of
the UOW utilising their cell and molecular biology research infrastructure and
using the X-ray irradiation facility in the Department of Radiation Oncology
in the Prince of Wales Hospital (POWH).
Chapter 2
Literature Review
2.1 Principles of Radiation Therapy and Ra-
diation Biology
2.1.1 Introduction to Radiotherapy
Cancer is a disease in which cell proliferation is out of control. The invasion
surrounding normal tissues by tumour cells and spread to other sites in the
body (by either entering the blood stream or the lymphatic system) is known
as metastasis and this is what makes cancer lethal. Radiation therapy (radio-
therapy) is a cancer treatment using a beam of ionising radiation which aims
to kill all cancer cells within a defined target volume and therefore leading to
significant tumour shrinkage or a curative clinical outcome.
The use of ionising radiation was a revolutionary step in the evolution of the
diagnosis and treatment of cancer. It is called ionising radiation because the
radiation is of enough energy to ionise the material it is traversing, thus forming
ions as it passes through human tissue. Without radiation, many conditions
would not be diagnosed and some cancers would not be treatable. Radiation
9
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is the primary treatment for many kinds of cancer and is also used in conjunc-
tion with surgery and/or chemotherapy for other types of cancer. Over the
past 100 years, radiotherapy has become an increasingly important modality
for most cancer treatment. Currently, radiotherapy plays an important role
in the management of benign and malignant disease throughout the body in
both children and adults with over 50% of cancer patients receiving some form
of radiotherapy treatment as part of their cancer management plan [Delaney
et al., 2005]. Radiotherapy also o↵ers an e↵ective means of palliative care
when a curative outcome is not possible [Mundt et al., 2000].
2.1.2 Introduction to Radiobiology
Cells may eventually die or lose their ability to divide when they are exposed
to ionising radiation. The explanation of this e↵ect lies partially in physics
and partially in biology [Hirst, 2007]. Some of the interesting aspects of radio-
biology are concerned with attempts to link these two fields [Lawrence, 1971].
Radiobiology is a field that studies fundamental changes in irradiated cells and
helps understand the responses of normal tissue and tumours to ionising radi-
ation [Bernier et al., 2004]. In other words, radiobiology is a branch of science
that combines two disciplines: radiation physics and biology, and is concerned
with the action of ionising radiation on biological tissue and living organism
[Hall and Giaccia, 2012; Suntharalingam et al., 2005].
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2.1.3 Physical Basis of Radiotherapy
2.1.3.1 Ionising radiation
Ionising radiation is a form of electromagnetic radiation and is physical con-
cept in which energy is transmitted through space without necessarily the need
or aid of a material medium [Lawrence, 1971]. The ionisation process involves
the ejection of electrons from the atoms that make up the medium in which
the radiation is traversing and this initial interaction is the major event in the
action of radiation. Radiation absorbed by aqueous systems such as cells can
cause excitation and ionisation, as well as free radical production. The bio-
logical consequences of exposure to ionising radiation are mediated by a series
of processes, which can be classified into four stages [Adams, 1989]: physical,
chemical, biochemical, and cellular responses, which are initiated after the de-
position of the radiation in the medium [Mitchell et al., 2000] (Figure 2.1).
The time scale over which energy is transferred to an atom or a small molecule
during irradiation is extremely short (less than 10 15 s) and is governed by the
particle velocity, the dimensions of the atom or molecule, and the amount of
energy lost in the process [Adams, 1989], which then produces water radicals
and other chemical lesions (less than 1 s) that di↵use through and/or react
with molecules in the cell, thereby creating biomolecular lesions which can last
a relatively long time [Curtis, 1986].
2.1.3.2 Interaction of ionising radiation
In modern clinical radiotherapy, ionising radiation is delivered to tissues pri-
marily with high-energy photons (gamma rays and X-rays) and charged par-
ticles (electrons, protons, heavy ions, pions etc). Gamma rays (such as those
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Figure 2.1: Time scale of events initiated by ionising radiation deposition in
biological systems BIM biologically important molecule [Mitchell et al., 2000].
.
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used in brachytherapy) originate from within the nucleus of an atom while
X-rays (such as those used in external beam radiotherapy) originate from the
outside the nucleus of an atom. Within a linear accelerator (LINAC), a narrow
beam of electrons is accelerated to nearly the speed of light before striking a
tungsten target [Khan, 2010]. As the electrons decelerate, bremsstrahlung radi-
ation (X-rays) is emitted with a spectrum ranging from zero to their maximum
kinetic energy. The beam quality is expressed in terms of the highest-energy
photons related to the electron accelerating voltage, kVp (kilovolts peak) or
MV (megavoltage) [Mundt et al., 2000]. In the energy range most widely used
in external X-ray beam radiotherapy (50kVp up to 25MV), the relevant inter-
actions of X-rays photons with tissue are the photoelectric e↵ect, the Compton
e↵ect, and pair production [Attix, 2004; Khan, 2010].
Photoelectric E↵ect
The photoelectric e↵ect refers to light (photo-) causing the ejection of electrons
(electric) from a material. In the photoelectric e↵ect, an incident photon is
completely absorbed by an inner shell electron with the subsequent ejection
of an electron known as a photoelectron (Figure 2.2). The probability of








where ⇢ is the density (g/cm3) and hv is the energy of the incident photon.
Therefore, photoelectric absorption becomes more important as the atomic
number increases and as the photon energy decreases.
Compton E↵ect
In the Compton e↵ect, the photon behaves like a particle as it collides with a
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Figure 2.2: Schematic diagram of the photoelectric e↵ect and other processes
that can occur as a result of the photoelectric e↵ect (characteristic X-ray and
Auger electron production).
.
loosely bound outer orbital electron. The incident photon is deflected (scat-
tered) and imparts kinetic energy to the electron (Figure 2.3). The probability
of this interaction is proportional to the number of electrons per unit mass (/
Z/A) and is related inversely to the energy of photon [Attix, 2004; Khan, 2010;
Metcalfe et al., 2007].
Pair Production
A photon may decay to an electron and a positron provided the energy of the
photon greater than 1.022 MeV. After losing all or some of its kinetic energy,
the positron annihilates with an electron. In the case where the photon loses
all of energy prior to annihilation, two 511 keV photons travelling in opposite
directions are produced [Attix, 2004; Khan, 2010] (Figure 2.4). The probability
of pair production is roughly proportional to Z2, which varies with Z2 per
atom, Z per electron and Z per gram [Khan, 2010].
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Figure 2.3: Schematic diagram of the Compton e↵ect.
Figure 2.4: Schematic diagram of pair production (hv is greater than 1.02
MeV).
.
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2.1.3.3 Radiation quality
In radiation biology, radiation quality refers to beam characteristics that must
be specified in order to determine interactions at the microscopic level that may
influence the ability of an irradiation field to produce biological e↵ects. Prin-
cipally, radiation quality refers to those radiation characteristics that describe
the spatial distribution of energy transfer by charged particles when other
physical factors are kept constant (e.g. absorbed dose) [on Radiation Units
and Measurements, 1979].
Radiation absorbed dose
Absorbed dose is the accepted unit of measurement that represents the energy
absorbed per unit mass. The SI unit of absorbed dose is the Gray (Gy), which
is defined as the absorption of 1 Joule of energy per kilogram of mass (J/kg).
Linear energy transfer (LET)
Linear energy transfer (LET) is a physical quantity expressing radiation qual-
ity for radiobiological purposes. The International Commission on Radiation
Units and Measurements (ICRU) defines the LET as: LET of charged parti-
cles in a medium is the quotient dE/dl, where dE is the average energy locally
imparted to the medium by a charged particle of specified energy in traversing
a distance of dl. The unit of LET is keV/µm di cult to measure but, in the
case of electrons, can be approximated by dividing the energy of the electron
by the range of the electron in a given material [Suntharalingam et al., 2005].
High LET radiations such as neutrons and ↵-particles normally deposit sub-
stantial amounts of energy by individual heavily ionising tracks [Hill et al.,
2002]. These could have a greater biological e↵ectiveness than the sparsely
ionising radiation fields with low LET such as that from X-rays and  -rays
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[Goodhead, 1999]. However, it should be noted that the photoionisation pro-
cesses in matter due to Auger processes can also produce significant enhance-
ment of the energy deposition events surrounding photoabsorption sites. Thus,
one of the major aims of this project is to increase the dose delivery to the
tumour target by the presence of highly absorbing elements in the tumours (i.e
high-Z elements) that have large photo-absorption cross-sections (as detailed
in section 2.4).
2.1.4 Biochemical and Biological Basis of Radiotherapy
2.1.4.1 Radiation damage within the cell
As described in section 2.1.3.1 , the interaction of ionising radiation with bi-
ological matter proceeds through several stages which results in a variety of
biological end e↵ects. More specifically, deoxyribonucleic acid (DNA) damage
caused by X-ray radiation is mediated through direct ionisation and indirect
mechanisms. In direct actions, the radiation interacts directly with DNA as a
critical target in the cell (i.e. electrons ionise DNA molecules). The atoms of
DNA itself may be ionised or excited through interactions (e.g. photoelectric
e↵ect) that lead to a chain of physical and chemical events, eventually resulting
in biological damage. In indirect actions, the radiation interacts with other
molecules and atoms, mainly water (80% of a cell is composed of water), within
the cell to produce free radicals (e.g. hydroxyl radicals). Both H2O
+(water
ion) and the OH• (hydroxyl radical) are extremely reactive free radicals, which
can di↵use and attack DNA [Gofman, 1990; Nias, 1990; Casarett, 1968].
Direct action – primary and secondary electron
Between collisions, electrons primarily travel through a medium in straight
lines, although one will occasionally su↵er a major deflection and travel in
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Figure 2.5: Distribution of excitations and ionisations along particle tracks in
water [Feinendegen, 1990].
.
another straight line. The distance travelled depends on the initial electron
energy as well as the composition and density of the medium. A primary
electron sets secondary electrons, which have their own tracks, into motion at
irregular intervals. These electrons are called delta rays, and several hundreds
of such ionisations are produced per µm of track [Feinendegen, 1990]. Their
tracks, being typically only a few nanometres long [Gofman, 1990], are gen-
erally much shorter than the track of the primary electron. A set of particle
tracks in matter with a density close to that of tissue (i.e. water), including
those from electrons (photon absorption and 125I Auger e↵ect), a recoil proton,
a ↵-particle, and a heavy ion is shown in (Figure 2.5).
Indirect action - free radicals formation
The indirect action of X-ray radiation in producing biological damage involves
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several steps described below:
Pairs of abnormal ions, formed as the consequences of X-ray irradiation, are
called free radical ions. An excited water molecule transfers its energy and
forms a positive ion and a free electron as a result of the ejection of an electron
[Gofman, 1990; Nias, 1990]:
H2O+ ionisation energy ! H2O+• + e  (2.2)
H2O
+• is a free radical ion (with the dot representing an unpaired electron),
which is very unstable and extremely reactive. This is the primary event of
water molecule ionisation and is followed by a series of reactions leading to the
formation of various free radicals. The electron, e , is picked up by another
water molecule and will become hydrated (e•aq):
e  +H2O ! H2O  (2.3)
The free radical ion H2O
+• reacts with a water molecule to produce the highly
reactive hydroxy radical OH•:
H2O
+• +H2O ! H2O+ +OH• (2.4)
The indirect e↵ect of radiation is especially important in aqueous systems,
where a water molecule may be ionised and then transfer this energy to an-
other molecule [Gofman, 1990; Casarett, 1968]. Molecules produced by the
irradiation of water molecules such as hydrogen peroxide (H2O2), can have
a variety of e↵ects on other molecules in biological systems [Tubiana et al.,
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1990]:
OH• +OH• ! H2O2 (2.5)
Secondary electrons, which cause the direct e↵ects, are responsible for the
majority of the ionisations and excitations produced in DNA. The indirect
mechanism is mediated free radical formation within the cell, mostly from
water (H2O) molecules (Figure 2.6). Through the chain reaction above water is
also sequentially converted to free radicals, such as H• and HO•, and peroxides,
such as ROO• (radical peroxide) and ROOH + R’• (hydroperoxide). These are
highly reactive molecules which are known as reactive oxygen species (ROS)
[Tubiana et al., 1990]. The indirect mechanism is thought to account for about
two-thirds of all mammalian DNA damage caused by X-rays [Hall and Giaccia,
2012].
2.1.4.2 Relative biological e↵ectiveness (RBE)
As mentioned above, di↵erent types of radiations have di↵erent degrees of
relative biological e↵ectiveness (RBE). RBE compares the dose of given test
radiation to the dose of standard radiation to produce the same biological
e↵ect. The RBE is defined by the following ratio [on Radiation Units and
Measurements, 1979; Lawrence, 1971; Suntharalingam et al., 2005]:
RBE =
Dose from standard radiation to produce a given biological e↵ect
Dose from test radiation to produce a given biological e↵ect
For historical reasons, the standard radiation is 250 kVp X-rays, but the use of
60Co   rays is now recommended. RBE depends on radiation quality (LET).
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Figure 2.6: Direct and indirect mechanism of DNA damage by X-rays irradi-
ation (on upper part) [Powsner and Powsner, 2006].
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Figure 2.7: Illustration of RBE against LET [Hall and Giaccia, 2012].
.
As the LET of radiation increases, the ability of radiation to produce biological
damage also increases. The RBE depends on the radiation dose, the number
of dose fractions, the dose rate, and the biological system. In general, the RBE
increases with the LET to reach a maximum RBE of 3 – 8, depending on the
level of cell kill [Suntharalingam et al., 2005] at a LET of 100 keV/µm [Hall
and Giaccia, 2012] and then decreases with a further increase in the LET due
to energy overkill (Figure 2.7).
2.1.4.3 Track structure model
Ionising radiation di↵ers from other DNA damage agents due to its ability to
produce clusters of adjacent damages over distances of a few nanometers and
is characterised by the radiation track structure reflecting this critical property
could be suitable for DNA lesions yields calculation [Michalik, 1992]. Studies
of track structure provide a powerful tool for investigating the microscopic
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Figure 2.8: Typical example of strand breakage (solid symbol) as well as base
damage (open symbol)[Goodhead, 2006].
features of ionising radiation and the nature of molecular damage to DNA
[Nikjoo et al., 1998]. Based on the physical and chemical analysis of micro-
scopic features of radiation tracks, it has been demonstrated that clustered
damage (Figure 2.8) is a major factor in the biological e↵ectiveness of radia-
tion [Nikjoo et al., 1998; Goodhead et al., 1980; Goodhead, 1994].
The e ciency with which ionising radiations produce clustered damage de-
pends on the local ionisation clusters within the tracks, both directly in the
DNA (direct mechanism) and also via hydroxyl radicals from water within
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Figure 2.9: Schematic representation of DNA segment with randomly selected
simulated track from low-energy electron (upper) and short ↵-particle track
(lower). Large and small dots are represent ionisations and excitations, re-
spectively [Goodhead, 1994].
a few nanometers of the DNA (indirect mechanism) [Goodhead, 2006]. The
complex clustered damage in DNA that can be produced from low energy X-
rays is shown in a track structure simulation (Figure 2.9).
2.1.4.4 Dose-e↵ect relationship
Cell survival curves
Principally, the survival fraction of a cell population is measured rather than
the fraction that is killed [on Radiation Units and Measurements, 1979]. The
cell survival curves, which are exponentially based, are shown as the response
of a population of single cells as a function of dose, D [Metcalfe et al., 2007].
In this case, the surviving fraction of cells is the fraction of irradiated cells
that maintain their reproductive integrity (clonogenic cells). Graphically, cell
survival as a function of radiation dose is represented by plotting the surviving
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fraction on a logarithmic scale (on y-axis) against dose on a linear scale (on
x-axis).
Linear-quadratic (LQ) model
The clonogenic impairment of mammalian cells, which is commonly known as
a cell reproductive death, can be described adequately by a linear-quadratic
function of radiation dose, D, [Barendsen, 1991]:
F (D) = ↵D +  D2 (2.6)
This yields the survival curve, assuming that there are two components to




= exp( ↵D    D2) (2.7)
where S(D) is the cell survival fraction at dose D, S(0) is the cell survival frac-
tion at a dose equal to 0, ↵ is a constant which measures the initial slope of the
cell survival curve, representing single-hit killing kinetics which dominates the
radiation responses at low doses, and   represents the quadratic component of
cell killing (i.e. two hit, single target – quadratic model). The non-zero value
of   causes the curve to bend at higher doses (Figure 2.10). The broad initial
shoulder at low doses indicates that X-rays are relatively ine cient at killing
cells [Borek and Hall, 1973].
This is the simplest and most widely used form for the cell-survival relationship
[Deschavanne et al., 1990; Steel, 1989]. From the view point of radiobiology,




= ↵ +  D (2.8)
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Figure 2.10: The classic linear-quadratic model as a result of the summation
components of the equation (2.7): linear (log S = -↵D) and quadratic term
(log S = - D2) [Suntharalingam et al., 2005].
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Figure 2.11: The interpretation of survival curves based on intracellular repair
model [Tubiana et al., 1990].
where SF is the cell survival fraction at dose, D, the parameter ↵(Gy 1) repre-
sents the initial slope of the cell survival curve related to the radio-sensitivity,
and  (Gy 2) represents the accumulation of damage repair. This is according
to a model based on intracellular repair showen figure 2.11, where curve A and
curve B represent the surviving fraction due to cellular damage without repair
and modified by repair, respectively [Tubiana et al., 1990].
2.1.5 Cellular Basis of Radiobiology: Mechanisms of
Cell Killing
2.1.5.1 Cellular DNA target
Deoxyribonucleic acid (DNA) molecules, as the genetic material, are the most
important targets for biological damage induced by ionising radiation. DNA
organised into chromosome is located within the nucleus of the eukaryotic cell
(Figure 2.12).
DNA is a polymer, a large molecule consisting of many similar smaller molecules
monomers that are linked together. The monomers that make up DNA are
called nucleotides. Nucleotides as the building blocks of DNA have three dis-
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Figure 2.12: DNA within the nucleus of the cell in the chromosomes [of General
Medical Science, 2006].
tinct components: a pentose (five-carbon) sugar (deoxyribose), a nitrogenous
(nitrogen-containing) base, and a phosphate group (Figure 2.13).
Two classes of nitrogenous bases are purine and pyrimidine. DNA contain two
major purine bases: adenine (A) and guanine (G), and two major pyrimidines
bases: cytosine (C) and thymine (T). The hydrogen-bonding patterns in the
base pairs are A bonds specifically to T (double hydrogen bond) and G bonds
to C (triple hydrogen bond). These two types of base pairs predominate in
double-stranded DNA, which was defined by Watson and Crick in 1953 (Figure
2.14) [Nelson and Cox, 2005].
In other words, DNA exists as a double-stranded helix. Each strand consists of
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Figure 2.13: Nucleotides as the building block of DNA.
Figure 2.14: Complementary base pairing predominate in DNA[Nelson and
Cox, 2005].
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Figure 2.15: Molecular structure of DNA. a) Three-dimensional structure of
DNA prepared by Watson and Crick. b) Stylised diagram of the DNA double
helix [Russell, 2006].
.
base-sugar-phosphates. The strands are linked by hydrogen bonds between the
bases, and the entire structure is coiled into a helical configuration [Casarett,
1968]. The distance from one base pair to the next is 0.34 nm and one full
turn of the DNA helix is 3.4 nm, so there are 10 base pair (bp) in a complete
turn. The diameter of a double-stranded DNA helix is 2 nm shown in Figure
2.15.
To make DNA more compact, double-stranded DNA molecules are wound
around globular protein complexes (two each of histones H2A, H2B, H3 and
H4) to make DNA more compact, which made up the nucleosome, the basic
structural units of chromatin (complex of DNA and proteins in cell nucleus)
[Felsenfeld and Groudine, 2003] (Figure 2.16). Hence, the least compact form
is the 10 nm chromatin fibre that has a characteristic bead-on-a-string with
about 10 nm diameter of the beads [Russell, 2006], which are then piled up to
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Figure 2.16: Organisation of DNA package [Wouters and Begg, 2009].
form chromatin fibres of nucleosomes, folded and rolled up in irregular spirals
to form the chromosome which are visible under the microscope [Wouters and
Begg, 2009; Tubiana et al., 1990].
2.1.5.2 Radiation-induced damage to DNA
There are three main types of damage induced in DNA: direct strand breakage
(single-strand breaks, SSBs and double strand breaks, DSBs), base damage,
and cross-linkage [Bryant, 1989; Radford, 1986]. The proportion of these dam-
age types leads to di↵erences in radiosensitivity and RBE [Barendsen, 1994].
Even at doses as low as ⇠1 Gy, ionising radiation is capable of inducing all of
three types of DNA damage type in both isolated and clustered lesions (1–10
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bp apart) [Georgakilas, 2008]. For instance, 1 Gy of irradiation will cause
approximately 105 ionisations, more than 1000 DNA bases damages, around
1000 SSBs and around 20–40 DSBs [Wouters and Begg, 2009].
Based on theoretical calculations, it is predicted that in addition to isolated le-
sions, low-LET radiation can create clusters with as many as 10 lesions [Good-
head, 1994; Sutherland et al., 2000]. Low-LET radiation produces SSB, which
are relatively easily repaired whereas radiation of relatively high-LET or a
high dose of low-LET may produce SSB in close proximity to each other in
both strands (DSB) (Figure 2.17). It is generally accepted that DSBs are the
most important lesions in terms of cell death, as well as latent e↵ect such as
chromosomal aberrations and tumourigenesis, following exposure to ionising
radiation [Collis et al., 2004, 2002]. Another lesions produced by ionising ra-
diation is destructions of the deoxyribose sugars. These are rare and not well
understood [Tubiana et al., 1990].
Clustered DNA damage
Ward [1981] introduced the idea of clustered DNA damage as local multiply
damaged sites (LMDS), which are several closely spaced lesions within a short
DNA segment produced by ionising radiation. LMDS are caused by the non-
uniform energy deposition events followed the passage of secondary electrons
through matter and the presence of radicals that attack DNA [Ward, 1981,
1994]. Clustered lesions are estimated to be 50–80% of the total complex
DNA damage (DSB and non-DSB clustered DNA lesions) produced by ionis-
ing radiation [Georgakilas, 2008]. Clustered DNA damage in cells is produced
by low doses of ionising radiation [Sutherland et al., 2000].
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Figure 2.17: Low and high LET traversing a section of the DNA helix [Powsner
and Powsner, 2006].
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2.1.5.3 DNA damage repair in irradiated cells
Numerous studies have shown that most radiation-induced DNA damage can
be repaired. However, the rates of repair of di↵erent types of lesions vary
[Bryant, 1989]. As DSB are both the most important lesion and the main
focus of this project, only the repair of DSB DNA is explained.
DNA DSB repair
DNA DSB can result in permanent cell cycle arrest, apoptosis, or mitotic cell
death if left unrepaired [Olive, 1998]. The two major repair mechanisms of
DNA double-strand breaks are non-homologous end joining (NHEJ) and ho-
mologous recombination (HR) ([Khanna and Jackson, 2001; Helleday et al.,
2007]. These involve di↵erent multi-protein processes [Friedberg, 2003] (Fig-
ure 2.18).
Non-homologous end joining (NHEJ) is due to the ligation of DNA double
strand breaks that do not require sequence homology. The process of NHEJ
is divided into four steps [Hall and Giaccia, 2012]. These are end recognition,
end processing, fill-in synthesis, and ligation. DNA-dependent protein kinase
(DNA-PKc), DNA end-binding protein KU (Ku70 and Ku80), DNA ligase
IV, and XRCC4 in human are all the critical components of the NHEJ repair
pathway [Norbury and Hikcson, 2001].
End-recognition occurs when DNA-PK, which is composed of a heterodimer
DNA-binding component, named Ku70/Ku80, forms a ring that binds specifi-
cally to either blunt or staggered DNA ends at the double-strand break. This
DNA-KU complex then activates and recruits the large catalytic subunit ki-
nase (DNA-PKc), a serine/threonine protein kinase.
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Figure 2.18: Repair mechanism of DNA double-strand break [Norbury and
Hikcson, 2001].
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After binding to the two ends of the DNA the Ku/DNA-PKc complex under-
goes autophosphorylation and may recruit additional proteins to the damaged
site as potential phosphorylation substrate such as the NBS1, MRE111, and
RAD50 proteins and the Artemis. The XRCC4 bind to DNA ligase IV (Lig
IV) and then finally ligates the breaks to create intact DNA strands. It is un-
clear what signal is used for the fill-in reaction, but the XRCC4 gene products
bound to DNA Lig IV have been found to be associated and may serve as the
polymerase for the fill-in reaction when the broken ends become available for
ligation [Helleday et al., 2007; Kao et al., 2005].
In contrast, HR is much more accurate and complex than NHEJ [Kao et al.,
2005] but appears to be less important than NHEJ for repairing IR-induced
breaks in higher eukaryotes [Rothkamm et al., 2003]. HR utilises extensive
homology to restore the sequence at break site and processing involve the me-
diator protein Rad52 that plays a role in the search for a homologous DNA
sequence [Kao et al., 2005]. Briefly, Rad51 as primary recombinase in eukary-
otic cells initiates HR through catalysing homologous pairing and DNA strand
exchange. Rad52 also acts during the single-strand annealing (SSA) [Norbury
and Hikcson, 2001].
Moreover, Rothkamm et al. [2003] first showed that both NHEJ and HR con-
tribute to repair and radioresistance. As NHEJ is important in all cell cycle
phases, HR is particularly important in late S/G2 phases of the cell cycle
[Willers et al., 2004] (Figure 2.19).
2.1.5.4 Cell growth arrest
Cell cycle
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Figure 2.19: Schematic model of cell cycle phase as well as the contributions
of homologous recombination (HR) and non-homologous end joining (NHEJ)
of ionising radiation IR-induced DSB [Rothkamm et al., 2003].
In a population of dividing cells, whether inside the body (in vivo) or in a cul-
ture dish (in vitro), each cell passes through a series of defined stages, which
constitutes the cell cycle [Karp, 2005] and is depicted in Figure 2.20. In con-
trast, the cell cycle for stem cells is up to 10 days [Suntharalingam et al., 2005].
The four phases of the cell cycle are the pre-DNA synthetic phase (G1), the
DNA synthetic phase (S), the post-DNA synthetic phase (G2), and mitosis
(M). Another phase, G0, which is not part of the cell cycle, is a state where
cells are not actively proliferating and have exited the cell cycle [Prasad, 1995].
As temporarily resting cells, the cells in G0 phase may enter the cell cycle or
remain permanently outside (di↵erentiated cells). By knowing the doubling
time of cells in the culture, the timescale of the cell cycle (i.e the duration of
each phase) can be estimated from the percentage of cells in this phase de-
termined by flow cytometry (i.e univariate analysis of cellular DNA – section
3.9.2). For instance, for mammalian cells growing in culture: the S-phase (6–8
h), the M-phase (less than an hour), G2 (2–4 h), and G1 (1–8 h), making the
total cell cycle of the order of 10–20 h [Suntharalingam et al., 2005].
Cells radiosensitivity
Radiation sensitivity, expressed as loss of reproductive ability, depends on the
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Figure 2.20: Stages of a standard eukaryotic cell cycle.
cell cycle phase in which the cells are exposed [Kiefer, 1990] (Figure 2.21).
Generally, cells are most radiosensitive in the M and G2 phase, and most
radioresistant in the late S-phase (Figure 2.22), depending on the cell line
studied.
DNA damage checkpoints
A checkpoint was defined originally as a specific point in the cell cycle when
the DNA integrity was examined (checked) before allowing progression through
the cell cycle. There are four distinct checkpoints in response to irradiation.
Firstly, a checkpoint at the transition between G1 and S phases, which plays an
important role in deciding whether the cells initiate division or not. Secondly,
the S-phase checkpoint causing the reduction of DNA synthesis which results
in increasing the overall length of time to replicate DNA. Thirdly, the G2 early
checkpoint, which is activated by relatively low doses of radiation (e.g ⇠ 1 Gy)
and blocks the cell cycle progression at the end of G2. The final checkpoint,
the G2 late checkpoint, is commonly observed after irradiation. It causes a
long G2 delay before entry into mitosis [Wouters and Begg, 2009]. There-
fore, the DNA damage checkpoints are biochemical pathways that delay or
arrest cell-cycle progression in response to DNA damage [Sancar et al., 2004].
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Figure 2.21: Radiosensitivity depends on the cell cycle [Suntharalingam et al.,
2005].
Figure 2.22: Cell survival curves at various stages of the cell cycle.
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Following the ionising radiation, cells arrest at the checkpoints. Consequently,
the failure to achieve completion of the cell cycle events may lead to cell death.
2.1.5.5 Cell death
Apoptosis or programmed cell death is a series of morphological and biochem-
ical changes that take place in cells, which have been instructed to die. In
radiobiology, a cell is commonly defined as dead when it fails to produce a
colony of more than fifty descendant cells, this is more accurately called a loss
of proliferative capacity [Lawrence, 1971]. Investigation of radiation-induced
cell death in terms of a loss of proliferating capacity is used in this study.
2.2 Introduction to Nanotechnology and Nano-
medicine
The application of nanotechnology to medicine, also known as nanomedicine,
concerned with the use of nanomaterials with unique physicochemical proper-
ties, such as small size, large surface area (SA) and a high reactivity di↵erent
from bulk materials [Moreno-Vega et al., 2012]. It provides an innovative ap-
proach that can enhance the e↵ectiveness of radiotherapy [Allard et al., 2010].
Over recent years, ceramic nanoparticles have been widely used in biomedical
applications because of their biocompatibility with tissues and cells. Among
many nanomaterials studied for cancer diagnosis and therapy, the engineered
nanostructure particles (NSPs) used in this study were cerium oxide, which has
a potential as a radioprotectant, and tantalum pentoxide and bismuth oxide,
which both have potential as radiosensitisers.
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2.3 Principles of Chemo-radiotherapy
2.3.1 Introduction to Chemo-radiotherapy
Chemo-radiotherapy is a combination of chemotherapy and radiotherapy, widely
being researched for use in the treatment of cancer. Radiotherapy uses high-
energy X-rays to instigate tumour cell apoptosis via secondary electrons. The
drugs utilised in chemotherapy have specific mechanisms to inhibit tumour
cells from dividing, this ensuring that they stop growing or eventually die.
Thus, the combination of radiotherapy with chemotherapy represents an ex-
citing opportunity to give rise to a method to enhance the cancer cell killing
e↵ect.
When both chemotherapy and radiotherapy are administered concomitantly,
lower doses of one or both are often needed, thus reducing toxicity on healthy
cells [Hahn and Maity, 2009]. Moreover, the chemoradiation may help over-
come the radioresistance of tumour cells and sensitise them to the cytotoxic
e↵ects of ionising radiation. This is expected to enhance tumour control and
minimise the radiation toxicity of healthy tissues by allowing dose reduction
[Bischo↵ et al., 2009]. This is one of the main aims of this thesis, where it is
proposed to use the synergy of pharmacological drugs and radiations that will
either:
allow for the reduction of the required dose of both radiation and targeted
chemotherapy drugs without compromising the desired treatment outcome,
and/or
increase the lethal damage to the tumour target with equivalent or less
toxicity to the surrounding normal tissue.
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2.3.2 General Mechanism of Chemo-radiation Interac-
tion
DNA damage can be induced by chemotherapy and radiotherapy acting syn-
ergistically as ionising radiation induced DNA damage (e.g. SSB and DSB).
The addition of chemotherapy drugs (e.g. cisplatin that target DNA) can also
work in combination to make the damage induced by the radiation dose sig-
nificantly more di cult to repair.
There are several other specific mechanisms of chemotherapy and radiotherapy
such as platinum analogs, taxane-based, mitomycin-C-based, tirapazamine-
based, and temozolomide-based chemoradiotherapy. In this project, only anti-
metabolite-based chemo-radiotherapy is used. Consequently, only those are
described in more detail.
The hypothesis of the work described in this thesis is based around one of
the general mechanisms of chemotherapy in that it can inhibit post-radiation
damage repair. Since DNA synthesis and repair share common pathways, the
rationale for using thymidine antimetabolites (i.e MTX as DNA synthesis in-
hibitors) is that they act as the agents that a↵ect nucleoside and nucleotide
metabolism with radiation as a means of inducing more cytotoxic damage to
tumour cells when combined with halogenated pyrimidine analog (i.e BrUdR).
2.3.3 Chemotherapeutic Agents
Most anticancer drugs act by disrupting the function of DNA and are classed
as cytotoxic. Some act directly on the DNA whilst others (e.g. antimetabo-
lites) act indirectly by inhibiting the enzymes involved in DNA synthesis or
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its nucleotide building blocks [Hall and Giaccia, 2012; Patrick, 2005].
2.3.3.1 Antimetabolites
Antimetabolites can be defined as analogues of the metabolites required for cell
function and replication. They damage cells by interacting with enzymes and
interfering with their structure by any of its mode of actions to incorporate with
nucleic acids. This inhibits their normal function and induces apoptosis (cell
death process). They also compete for binding sites of the enzymes. In other
words, antimetabolites are drugs that interfere with normal cellular function,
particularly the DNA synthesis that is required for replication [Siu and Moore,
2005], with the added possibility of selectivity toward cancer cells due to their
faster division [Avendaño and Menéndez, 2008]. Some of the many clinically
useful metabolites are purine or pyrimidine analogs (i.e. 5-fluorouracil). These
metabolites inhibit the synthesis of DNA (and sometimes RNA) by either in-
hibiting the formation of the normal nucleotides or interacting with DNA to
prevent further new DNA strand extension, leading to an inhibition of the cell
division [Siu and Moore, 2005; Avendaño and Menéndez, 2008].
Among the many compounds known to inhibit the reactions of the DNA
biosynthesis pathway, only methotrexate (MTX) and 5-fluorouracil (5-FU) are
used in this project as these two drugs have been widely used as anticancer
drugs worldwide for more than 50 years. Thus, it was proposed to use both
MTX and 5-FU as competitive inhibitors of enzymes, dihydrofolate reductase
(DHFR) and thymidilate synthase (TS), respectively. This is described in
more detail below.
Methotrexate (MTX) is not a nucleoside analogue, it is an analogue of
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Figure 2.23: Chemical structure of the antifolate MTX [Hatse et al., 1999]
the vitamin folic acid (Figure 2.23). MTX is one of the anti folates that
are not nucleoside analogues and prevent the formation of reduced folates,
which is required for DNA synthesis. Reduced folate is required for transfer
of methyl groups in purines biosynthesis and in the conversion of deoxyuridine
monophosphate (dUMP) to deoxythymidine monophosphate (dTMP), which
is a reaction catalysed by thymidilate synthase (TS). In the latter reaction, re-
duced folate becomes oxidised and its generation is dependent on the enzyme
dihydrofolate reductase (DHFR).
DHFR is a critical enzyme that catalyses the reduction of dihydrofolate (FH2)
to tetrahydrofolate (FH4), which is essential for DNA synthesis. MTX (with
similar structure to FH2) is a competitive inhibitor of DHFR, a key enzyme
in the thymidilate cycle, which is resulting the FH4, is then not produced. A
result of this inhibition may be blocking of the DNA synthesis due there being
no available dTMP and/or purines, which can lead to cell death (by inhibiting
the de novo synthetic pathways) [Siu and Moore, 2005; Kamen and Dracht-
man, 2000; Tehei et al., 2006; Huennekens, 1994; Hatse et al., 1999].
5-Fluorouracil (5-FU) is halogenated pyrimidine analog, a drug that resem-
bles the pyrimidine bases uracil (RNA) and thymine (DNA) [Siu and Moore,
2005] (Figure 2.24) by inhibiting the TS. As mentioned above, TS catalyses
the conversion of dUMP to dTMP, in a reductive methylation that involves
the transfer of a carbon atom from 5,10-methylene tetrahydrofolate (CH2FH4)
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Figure 2.24: Chemical structure of the 5-fluorouracil [Hatse et al., 1999]
to the 5-position of the pyrimidine ring [Avendaño and Menéndez, 2008].
5-FU is converted in the body to the fluorinated analogue of 2-deoxyuridylic
acid monophosphate (FdUMP), which then combines with the enzyme and the
CH2FH4 to form a suicide substrate in situ and the reaction mechanism pro-
ceeding normally. The FH4 has formed a covalent bond to the uracil skeleton
via the methylene unit, which is usually transferred to uracil. At this stage,
things start to go wrong when a proton is usually lost from the 5-position of
uracil, but 5-FU has a fluorine (F) atom at that position instead of hydrogen
(H) atom. The fluorouracil remains covalently and irreversibly bound to the
active site as uracil. As a result, thymidine synthesis is now terminated, which
in turn stops the DNA synthesis [Patrick, 2005] and 5-FU could be incorpo-
rated in DNA. 5-fluorouracil is the main inhibitor of TS [Pinedo and Peters,
1988; Shewach and Lawrence, 2007].
Thus, MTX has an indirect e↵ect on thymidilate synthase by lowering the
amount of CH2FH4, whereas 5-FU acts to inhibit TS directly. These mecha-
nisms are illustrated in (Figure 2.25).
Moreover, an investigation to the parenteral 5-FU and folinic acid formulations
also presented in parallel to this study (termed Fluorodex) [Locke et al., 2009;
Stutchbury et al., 2010].
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Figure 2.25: Schematic diagram of mechanisms of methotrexate (MTX) and
5-fluorouracil (5-FU) on thymidilate cycle. DHFR= dihydrofolate reduc-
tase; TS= thymidilate synthase; FH4= tetrahydrofolate; FH2= dihydrofolate;
CH2FH4= 5,10-methylene tetrahydrofolate; dUMP= deoxyuridine monophos-
phate; dTMP= deoxythymidine monophosphate.
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2.3.4 Radiosensitiser Drugs
2.3.4.1 Halogenated pyrimidine
Numerous studies have shown that pyrimidine analogues, especially halogenated
deoxyuridine, that are incorporated into deoxyribonucleic acid (DNA) of divid-
ing cells act as radiosensitisers. Of these agents, iododeoxyuridine (IUdR) and
bromodeoxyuridine (BrUdR), which is incorporated into DNA as a thymidine
substitute, show good radiosensitising activity at non-toxic doses [Djordjevic
and Szybalski, 1960]. The halogen atom (i.e Br or I) replaces the hydrogen
at the 5-position on the pyrimidine ring of deoxyuridine. The Van der Waals
radii of bromine (Br) and iodine (I) are 1.95 Åand 2.15 Å, respectively, which
closely resembles the methyl group of the thymidine (2.0 Å). Therefore, they
are known as pyrimidine thymidine analogues [Djordjevic and Szybalski, 1960;
McGinn and Kinsella, 1993; Tubiana et al., 1990] (Figure 2.26). There is a
large literature on these compounds. Only the literature for BrUdR is relevant
for this thesis.
The 5-bromo-20-deoxyuridine or bromodeoxyuridine (BrUdR) (Figure 2.27) is
one of the most well-known radiosensitisers for use in radiotherapy treatment
of cancer. It has been studied in the lab and clinical setting for more than
50 years. BrUdR has been shown to enhance cytotoxicity when administered
concurrently with radiation [Shewach and Lawrence, 2007] by either increasing
DNA DSBs or inhibiting their repair [Iliakis and Kurtzman, 1989].
Figure 2.28 illustrates the main mechanism of cytotoxicity through which ra-
diosensitiser drugs (i.e BrUdR and IUdR) act as nucleoside analogues via in-
corporation into the DNA. Its e↵ect is to alter the deoxynucleotide pools (i.e
dATP, dTTP. dGTP, dCTP) and may contribute to radiosentisation [Shewach
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Figure 2.26: Chemical structure of thymidine and their analogs (BrUdR and
IUdR), with Van der Waals radii of atoms at 5-position represent in the circles
(modified from McGinn and Kinsella [1993]).
Figure 2.27: Chemical structure of bromodeoxyuridine (BrUdR).
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Figure 2.28: Schematic diagram of the target for radiosensitiser drugs.
dUMP= deoxyuridine monophosphate; dTMP= deoxythymidine monophos-
phate; TS= thymidilate synthase; dATP= deoxyadenosine triphosphate;
dTTP= deoxythymidine triphosphate; dGTP= deoxyguanosine triphosphate;
dCTP= deoxycytidine triphosphate.
and Lawrence, 2007] (Figure 2.28).
2.4 Enhancement of radiation e↵ect by high-Z
elements
As mentioned above, using photons in the kilo-electron voltage (keV) range
enhances the radiation dose enhancement mainly as a result of the additional
photoelectric interactions arising from the increased interaction cross section,
which are highly Z dependant, of the high-Z material.
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Furusawa et al. [1991] studied Auger enhancement by a bromine atom, which
was incorporated in phage DNA as bromodeoxyuridine and showed that en-
hancement of radiobiological e↵ects by bromine atom is caused by the K-shell
ionisation followed by Auger e↵ects. Shinohara et al. [1985] were the first to
report data on the enhanced of killing mammalian cells pre-labeled with 5-
bromodeoxyuridine for mammalian cells. Similar work was carried out done
by sensitising the mammalian cells with 5-bromodeoxyuridine [Larson et al.,
1989] and with 5-iododeoxyuridine [Laster et al., 1990, 1993]. It was also
demonstrated that a platinum-containing molecule acts as a radiosensitiser
when photons with energy close to that of the absorption edge of the inner
shell of platinum are used [Le Sech et al., 2000, 2001]. In the work of this
thesis, the enhanced radiosensitivity e↵ects of BrUdR to external X-ray irra-
diation were investigated, using the 9L rat gliosarcoma cells.
2.4.1 Auger E↵ects
2.4.1.1 Introduction
In 1925, a 26-year old French physicist, Pierre Victor Auger described a new
phenomenon that later became known as the Auger e↵ect. He was investigat-
ing the pattern of electron tracks produced by irradiation of a cloud chamber
with low-energy X-rays and noted the production of multiple electron tracks
([Kassis et al., 2004; Hofer, 2000]. He concluded that this event was caused by
electron transitions that are initiated when low energy X-ray photons impinge
on target atoms and eject inner shell electrons [Hofer, 2000]. The resulting va-
cancy leads to the emission of characteristics X-rays (a radiative process) and
low-energy Auger electrons (a non-radiative process – Auger process), in the
emission of Auger, Coster-Kronig, and super Coster-Kronig electrons [Hofer,
2000; Howell, 2008]. It was later shown that the Auger e↵ect occurs in many
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radionuclides that decay by electron capture (EC) or internal conversion (IC)
([Kassis et al., 2004; Hofer, 2000].
In the case of the photons utilised in this study, when their energy is higher
than the inner-shell binding energy of the target atom, an electron can absorb
the photons via a photoelectric e↵ect and thus a vacancy is produced. The
probability of photoelectric interaction depends upon both the photon energy
and the targeted element (as mentioned earlier). The ionisation of a specific
inner-shell state is e↵ectively induced by choosing an appropriate energy of
the incident X-rays, synchrotron radiation is the only light source that gives
access to intense monoenergetic photon sources. However, it should be noted
that Auger e↵ects are induced very frequently in X-ray irradiated samples even
though X-rays are not monochromatised [Kobayashi et al., 2010].
2.4.1.2 Biological e↵ect of radiation-induced Auger E↵ect
The biological significance of Auger electrons for therapeutic purposes was
neglected for many years because of their low energy, and consequent short
range, compared to the energy released from a decaying radionuclide [Hofer,
2000; Kassis, 2003]. Auger electrons travel a distance of 2 – 500 nm, which
results in a high-LET radiation that in the range of 2 – 25 keV/µm ([Kassis
et al., 2004; Sastry, 1992; Charlton et al., 1987]. Investigations and applica-
tions of the photoabsorption spectra at the X-rays energy level have failed
due to the polychromatic nature of X-rays from X-ray tubes [Kobayashi et al.,
2010]. This was the state of play until the founding meeting in 1975 that was
organised by Ludwig Feinendegen in Jülich, Germany that focused on the bi-
ological aspects of the Auger process [Howell, 2008].
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In this thesis, the radiobiological e↵ects of Auger electrons released as the con-
sequence of photoelectric e↵ect (induced by external X-ray beams) is mainly
investigated in the presence of chemotherapeutic drugs (MTX) and radiosensi-
tiser drugs containing a high-Z material (i.e. BrUdR) loaded and incorporated
into DNA to produce more lethal damage.
Experimental investigations into BrUdR were initiated in the 1960s but fell out
of favour in the late 1980s. The emphasis was on determining the optimum
concentration of the drugs used or designing a new radionuclide. However,
there were no studies that investigated optimising X-ray beam energies using
conventional X-rays machines or LINACs (i.e polychromatic). Beam energies





Nalgene R  cryogenic vials and Mr.Frosty freezing container were purchased
from Thermo Fisher Scientific, VIC, Australia. Unless otherwise noted, all
tissue culture plasticware were from Becton-Dickinson (BD FalconTM).
3.1.1 Cell Lines
The rat gliosarcoma (9L), human glioblastoma (U-87 MG), and Madin Darby
Canine Kidney (MDCK) cell lines were obtained from the European Collec-
tion of Cell Cultures (ECACC) distributed by Westmead Children Hospital
and Sigma-Aldrich, Australia. The human breast carcinoma (MCF-7) cell line
was obtained from the American Type Culture Collection (ATCC), kindly pro-
vided by A/Prof. Marie Ranson from IHMRI (Illawarra Health and Medical
Research Institute), Wollongong, Australia. Detailed information about the




Dimethylsulfoxide (DMSO) is the most commonly used cryoprotective agent,
which prevents ice crystal forming and the fragmenting of membranes [Macleod
and Langdon, 2004]. The freezing medium GibcoTM(90%medium; 10% DMSO)
were used for 9L cell line, whilst freezing mixtures of (95% medium; 5% DMSO)
were freshly made for U-87MG, MCF-7 and MDCK cell lines. The cell stocks
of all the cell lines is stored in liquid nitrogen at –196 C.
3.1.2 Cell Culture Reagents
Dulbeccos modified eagles medium (DMEM), foetal bovine serum (FBS), peni-
cillin/streptomycin (Pen Strep), trypsin-ethylenediaminetetraactic acid (Trypsin-
EDTA), phosphate bu↵er solution (PBS), and Hanks balanced salt solution
(HBSS) were purchased from GibcoTM(Invitrogen Life Technologies, NSW,
Australia).
3.1.3 Drugs and Other Chemicals
Methotrexate (MTX), 5-bromo-20-deoxyuridine (BrUdR), 5-fluorouracil (5-FU),
propidium iodide (PI), 20,70-Dichlorofluorescein diacetate (DCFD) and all other
reagents were purchased from Sigma–Aldrich (Sigma–Aldrich Chemicals, MO,




The nanomaterials CeO2 and Ta2O5 were synthesised by Dr Konstantinov,
a TNT member of Institute for Superconducting and Electronic Materials
(ISEM). All the nanoparticles were dried and sterilised at 121 C before ad-
dition to the cells.
3.1.4.1 Ceramic Nanoparticles
All the nanoparticles samples were synthesised at the ISEM. Cerium oxide
was synthesised using a spray-pyrolysis technique derived from previous work
[Briggs et al., 2013]. Tantalum pentoxide was synthesised using Ta(OEt)5 via
an ethoxide decomposition reaction with water, which is derived from Komi-
nami et al. [2001]. Bismuth oxide was synthesised from bismuth (III) nitrate
pentrhydrate – Bi (NO3)3 using two techniques: a precipitate method (in ar-
gon and air annealed) [Stewart et al., 2014] and a citrate gel method derived
from [Patil et al., 2005] and Anilkumar et al. [2005], respectively.
3.1.4.2 X-ray Di↵raction (XRD)
After the nanoparticles were synthesised, they were analysed using X-ray
di↵raction (XRD). The XRD analysis was performed using an automated
GBC R  eMMA X-ray Di↵ractometer (GBC, Vic, Australia). Phase identi-
fication was extracted by comparing the recorded di↵raction pattern with the
Inorganic Crystal Structure Database (ICSD). The average nanoparticle crys-







where K is the shape factor constant (K = 0.89),   is the X-ray beam wave-
length,   is the FWHM (full-width half-maximum) in radians and ✓B is the
Bragg angle.
3.1.4.3 Transmission Electron Microscopy (TEM)
The particle size and morphology of the nanoparticles were determined by high
resolution Transmission Electron Microscopy (TEM). TEM was performed us-
ing a JEOL 2011 high-resolution (HR) instrument.
3.1.4.4 Sonicator
The Branson Sonifier R  S-250D digital with double-step Micro-tip (Consonic
Pty Ltd., NSW, Australia) was used for sonication of nanoparticles.
3.1.5 X-rays Irradiated Machine
3.1.5.1 Linear accelerator (LINAC) machine
The Axesse Elekta LINAC with beam modulator (Elekta AB, Kungstensgatan,
Stockholm, Sweden) in the radiation oncology department at the Prince of
Wales Hospital (Randwick, NSW, Australia) was used for cellular irradiations
in the megavoltage (MV) energies range. X-ray energies of 6 and 10 MV were
used to irradiate the cells. The dose rate was 0.5 and 5 Gy/min for 10 MV and
5 Gy/min for 6 MV. All doses (1, 2, 3, 5 and 8 Gy) were delivered in single
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fractions at room temperature. The dose rate is altered by changing the beam
dose rate in the LINAC without removing the flattening filter.
3.1.5.2 Kilovoltage (kV) orthovoltage machine
The Nucletron Oldelft Therapax DXT 300 Series 3 Orthovoltage unit (Nu-
cletron B.V., Veenendaal, The Netherlands) in the radiation oncology depart-
ment at the Prince of Wales Hospital (POWH) (Randwick, NSW, Australia)
was used for cellular irradiations in the kilovoltage (kV) energies range. X-ray
energies at 50, 125, 150 and 250 kVp were used to irradiate the cells for the
same range of dose as MV above. Details of orthovoltage beams characteris-
tic (e.g. mA and half-value layer HVL) used at the POWH is summarised in
Table 3.1.
Table 3.1: Summary of orthovoltage beams used in this study at the POWH.
HVL 30 cm
Filter no. Energy mA FSD (cm) HVL 50 FSD (cm)
(kv) mm Al mm Cu mm Al
1 50 26 1.48 1.57
2 75 30 2.47 2.62
3 100 22 3.77 3.9
4 125 20 6.52 6.7
5 150 20 0.67
6 200 15 1.47
7 250 11 2.38
8 300 10 3.66
The mechanism for activation of high-Z materials requires an ionisation of one
of its atom (i.e for BrUdR, it requires an ionisation of the bromine atom).
This is the simplest and most important concept that underlies the under-
standing of what kind of radiation is required to give enough activation of
the drug in order to maximise the dose enhancement e↵ect. For instance, the
synchrotron experimentation by [Corde et al., 2004] confirmed that the iodine
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Figure 3.1: Ratio of the mass energy absorption coe cient of bromine to water
relative to photon energy (MeV).
atom is ionised most e ciently just above its K-edge, with the peak of absorp-
tion compared to water occurs in the spectrum around ⇠50 keV.
In this study, as in the case of BrUdR, the peak of absorption contrast rel-
ative to water in the spectrum around ⇠40keV is illustrated in Figure 3.1).
Briefly, the full mass-energy absorption coe cients ((µen/⇢)E) of bromine and
water were obtained from the National Institute of Standards and Technology
(NIST) and the ratio were then graphed as a function of energy (Figure 3.1).
Since the radiation photoactivation source used in this study is not monochro-
matic (i.e polychromatic), the optimum energy has to be carefully chosen. It
is by using the available beam filters and their associated HVL (Table 3.1),
the attenuation coe cient can be calculated. These were then interpolated to
those listed by John and Cunningham [1983] to obtain the e↵ective energies
for our radiation spectrum. As the rule of thumb, the mean e↵ective energy
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Figure 3.2: The ouput spectrum emitted from the orthovoltage X-ray unit at
50 kVp (filter 1) at the POWH.
delivered is about one-third of the maximum beam energy.
For instance, filter 4 (125 kVp) and filter 5 (150 kVp) was chosen as the op-
timal energy for both irradiation with BrUdR and the nanoparticles (cerium
and tantalum details in section 4.5), respectively. To confirm this, the output
spectra emitted from the orthovoltage machine was also generated by simula-
tion. The SpekCalc X-ray spectrum generator [Poludniowski et al., 2009] was
used to simulate the output spectra emitted from the X-ray unit of every filter
used (Figures 3.2 – 3.5).
3.1.6 Flow Cytometer
Flow cytometry is an invaluable technique that has been applied extensively to
many areas of radiation research at both the experimental and clinical level.
It is used as an investigational technique in molecular radiobiology to iden-
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Figure 3.3: The ouput spectrum emitted from the orthovoltage X-ray unit at
125 kVp (filter 4) at the POWH.
Figure 3.4: The ouput spectrum emitted from the orthovoltage X-ray unit at
150 kVp (filter 5) at the POWH.
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Figure 3.5: The ouput spectrum emitted from the orthovoltage X-ray unit at
250 kVp (filter 7) at the POWH.
tify and characterise the temporal response of cells to radiation damage such
as those involved with cell cycle kinetics and DNA damage sensing and re-
pair [Wilson and Marples, 2007]. It is a laser-based technology that is used
to measure the physical and biochemical characteristics of biological particles
[Radcli↵ and Jaroszeski, 1997]. Becton Dickinson fluorescence-activated cell
sorting (FACS) flow cytometer (BD LSR II; BD Biosciences, USA) at IHMRI,
Wollongong, Australia (Figure 3.6) was used for all flow cytometry analysis.
3.1.6.1 Overview of flow cytometric instrumentation
Flow cytometers scan single particles or cells in suspension [Dean and Ho↵man,
2007] as they flow one at a time through a flow chamber (Figure 3.7) past an
excitation light source [Radcli↵ and Jaroszeski, 1997]. Certain properties such
as size and internal complexity of the particles are measured [BD, 2000, 2007].
To do this, a flow cytometer needs a combined system of: fluidics, optics and
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Figure 3.6: Becton Dickinson fluorescence-activated cell sorting (FACS) flow
cytometer (BD LSR II; BD Biosciences, USA) at IHMRI, Wollongong, Aus-
tralia.
electronic systems [BD, 2000, 2007].
Fluidics system A fluidics system in a flow cytometer moves cells in the
fluid through a flow chamber (i.e. flow cell), past a light source (i.e. laser
beam) and then into a waste tank [BD, 2000]. Figure 3.7 illustrates that a
sheath stream is introduced to the flow chamber. Due to of its higher flow
rate (⇠ 10ml/min) than the sample (⇠ 100µl/min), it serves to compress the
sample particles in a stable stream and confine them through the center of the
flow chamber. This techniques is known as hydrodynamic focusing [Dean and
Ho↵man, 2007].
Optics system When a cell or particle passes through a focused laser beam,
laser light is scattered and emitted in all directions (360 ). Light that scatters
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Figure 3.7: Flow chamber of a flow cytometer (longitudinal cross-sectional
view) [Dean and Ho↵man, 2007]. In this work, FACS LSR II from BD [BD,
2007]
.
Figure 3.8: Forward scatter (FSC) and side scatter (SSC) [BD, 2000, 2007]
.
roughly in the forward direction is called forward scatter (FSC) and light that
is scattered roughly perpendicular (90 ) is called side scatter (SSC). Forward
scattered light is a result of di↵raction and indicates relative di↵erences in the
size of the cells or particles whereas side-scattered light, as a result of reflected
and refracted light, indicates relative di↵erences in the internal complexity or
granularity of the cells (Figure 3.8) [Radcli↵ and Jaroszeski, 1997; BD, 2000,
2007].
The optics systems consist of excitation and collection optics. Excitation op-
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tics include lasers as light source, filters and mirrors that route the laser light
to the fluidic stream and modify the spectral distribution of light scatter and
fluorescence directed to detectors.
Collection optics consist of detectors that collect and convert light signals into
electrical signals that can be processed by the electronic system [BD, 2000].
Two types of signal detectors are used: the photodiode and the photomul-
tiplier tube (PMT). The photodiode is used when the FSC signal is strong
and photomultipliers that are very sensitive to light, are used when the light
signal generated by SSC and fluorescence [Dean and Ho↵man, 2007; BD, 2000].
Electronic system After light scatter and fluorescence is converted to elec-
trical signals by the optical system, the resulting information is converted into
digital data before being interpreted and stored by the computer. A schematic
of the flow cytometry components is shown in (Figure 3.9).
Flow cytometry is particularly important for biological investigations because
it allows both qualitative and quantitative examinations of whole cells and cel-
lular constituents that have been labelled with dyes or monoclonal antibodies.
It has become a powerful tool for use in clinical research due to its capability to
process thousands of individual particles in a matter of seconds. In addition,
it also has the powerful ability to sort particles based on light scattering and
fluorescent emission characteristics [Radcli↵ and Jaroszeski, 1997; BD, 2000].
A more comprehensive review of the flow cytometer can be found in [Saphiro,
1988; Ormerod, 1999].
3.1. Materials 65
Figure 3.9: Schematic of flow cytometer systems
3.1.6.2 Fluorescence measurements
The stained nuclei were analysed for both DNA-PI and anti-BrUdR mouse
monoclonal antibody (Clone MoBU-1) conjugated with Alexa Fluor 488 fluo-
rescence on the FACS with excitation at 488 nm. The linear red fluorescence
intensity was measured with a long-pass filter at 620 nm for PI detection. The
log green fluorescence intensity was measured with a band-pass filter at 515
– 570 nm for the detection of Alexa Fluor 488 anti-BrUdR. A minimum of
10,000 single cell events was analysed for each sample in each experiment.
3.1.7 Confocal Microscope
Light and fluorescence microscopy images were obtained using a Leica con-
focal laser scanning microscope (Leica TCS SP5 Advcanced System – UV-
VIS-IR and X1-Port Access with SMD FCS and CO2 incubation chamber,
Germany) and the accompanying image manager software Leica Application
Suite Advanced Fluorescence (LAS AF, v.2.6.1–7314, Germany) at IHMRI,
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Figure 3.10: Leica confocal laser scanning microscope (Leica TCS SP5 Ad-
vcanced System – UV-VIS-IR and X1-Port Access with SMD FCS and CO2
incubation chamber, Germany at IHMRI.
Wollongong, Australia (Figure 3.10).
3.2 Cell Culture Methods
3.2.1 Subculture Cells
Cells were routinely maintained in the exponential growth phase in 75cm2 cell
culture flasks with a vented screw cap (Greiner Bio–one) in complete DMEM
containing L-Glutamine and supplemented with 10% (v/v) FBS and 1% (v/v)
Pen Strep) for 9L and MCF–7; and complete DMEM with sodium pyruvate
supplemented with 10% (v/v) FBS and 1% (v/v) Pen Strep for U87–MG. All
cells were maintained in a 37 C humidified 5% (v/v) CO2 cell culture incubator
(Heracell 150i). The cell concentration was maintained at 2–4⇥104 cells/cm2
and was routinely passaged upon reaching confluence for up to 30 passages.
Following removal of the media, the monolayer was washed with PBS (Ca2+
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and Mg2+ free), and the cell detached by incubating with 0.05% trypsin–EDTA
at 37 C for 2-3 mins. Cell lines were routinely tested for mycoplasma contam-
ination. All the cell culture experiments were carried out using cells in the
exponential growth phase at IHMRI, Wollongong, Australia. Details of the
procedure is provided in Appendix B.
3.2.2 Cell Counting
The most common way to determine the concentration of cells in a suspension
is by using the Neubauer haemocytometer. Typically, the procedure is carried
out after mixing an equal volume of the cell suspension with a solution of the
dye Trypan blue. Trypan blue is excluded by live cells (which appear clear) but
enters dead cells and stains them blue. So, with only the clear cells counted,
the result indicates live cells per ml. All the counting procedures mentioned in
this thesis were carried out using this technique. The details of procedure are
provided in Appendix C.
3.2.3 Cryopreservation – Freezing and Thawing
3.2.3.1 Freezing
Briefly, cells (in the exponential growth phase from 4 – 6 of T75cm2 flasks)
were washed and trypsinised as described above. A small aliquot of the cell
suspension is taken and counted. Cells were then pelleted by centrifugation
(e.g. 1500 rpm for 5 mins) and resuspended with the freezing medium to give
a final concentration of 2 – 4⇥106 cells/ml to each Nalgene R  cryogenic vial.
All cryogenic vials were then labelled (i.e cell name, passage number, date)
and placed in a Nalgene R  Mr.Frosty freezing container containing 250 mL
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isopropanol to freeze the cells at a cooling rate between 1– 3 C/min and kept
at –80 C in a freezer overnight. Then, all vials were transferred to a gas phase
liquid nitrogen permanent storage vessel. The details of procedure are pro-
vided in Appendix D.1.
Shortly after freezing (after 24 hour in liquid nitrogen vessel), one vial of master
stock was revived (to check the viability). The cells were then being expanded
to freeze more vials (i.e. as working stock). The working stock will then be
revived and is used until there are only 2 – 3 vials remaining. Then, when
the working stock is depleted, another vial of master stock is revived to create
another batch of working cell stocks. Details, including a schematic diagram
and table, are provided in the Appendix D.1.
3.2.3.2 Thawing
The cryogenic vial from the liquid nitrogen is placed in a 50 mL tube contain-
ing pre-warmed 70% ethanol. The tube was then rapidly warmed into a 37 C
water bath. Once thawed, the cells were transferred into a new sterile flask and
pre-warmed complete culture medium (i.e DMEM) was added. The medium
was added dropwise while gently swirling the flask in a circular motion to
slowly equilibrate the cells to the medium. At first, only few mLs were added
very slow (e.g. 1 drop per second and then speeded up). The cells were pipette
up and down gently and a small aliquot was taken and counted to check the
viability of the cells. The cells were then maintained in a 37 C humidified 5%
(v/v) CO2 cell culture incubator (Heracell 150i). Once the cells have attached
and had a chance to expel the DMSO, the media was removed and fresh media
added. After the cells reach ⇠ 90% confluent, they were washed and detached
as described above. The cell suspensions were then centrifuged (if required –
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as this will e↵ectively remove the DMSO from the cells) and the cell pellet
were resuspend in the media. Then, the cells are maintain and subculture as
necessary. The details of the procedure are provided in Appendix D.2.
3.3 Cell Growth Assay
3.3.1 9L cell line
Cells were plated in a 60-mm petri dish (growth area = 21.3 cm2) in com-
plete DMEM. Briefly, monolayers were washed and detached as above. Cell
suspensions were diluted in a DMEMmedium and were counted using a haemo-
cytometer. The final concentration of 5 ⇥104 cells in 5 ml was then plated into
each 60-mm petri dish. Cell numbers were counted daily (triplicate for each
day) for up to 10 days. Three independent experiments were performed. The
second and third experiments were done with higher cell seeding on day 0 (i.e.
2 ⇥105 cells) in 100-mm petri dish. The details of the procedure are provided
in Appendix E.1.
3.3.2 MCF–7 cell line
Cells were plated in a 100-mm petri dish (growth area = 58.95 cm2) either
in complete DMEM or RPMI-1640 supplemented with 5% (v/v) FBS and 1%
(v/v) Pen Strep. Briefly, monolayers were washed and detached as above. Cell
suspensions were diluted in a DMEM medium and were counted using a hemo-
cytometer. The final concentration of 2 ⇥105 cells in 10 ml was plated into
each 100-mm petri dish. Cell numbers were counted daily (triplicate for each
day) for 7 days. The details of this procedure are provided in Appendix E.2.
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3.3.3 U–87MG cell line
Cells were plated in a 60-mm petri dish (growth area = 21.3 cm2) in com-
plete DMEM. Briefly, monolayers were washed and detached as above. Cell
suspensions were diluted in a DMEM medium and were counted using a hemo-
cytometer. The final concentration of 1.5 ⇥105 cells in 5 ml was plated into
each 60-mm petri dish. Cell numbers were counted daily (triplicate for each
day) for 10 days. The details of this procedure are provided in Appendix E.3.
3.3.4 MDCK cell line
Cells were plated in a 100-mm petri dish (growth area = 58.95 cm2) in com-
plete DMEM. Briefly, monolayers were washed and detached as above. Cell
suspensions were diluted in a DMEM medium and were counted using a hemo-
cytometer. The final concentration of 2 ⇥105 cells in 10 ml was plated into
each 100-mm petri dish. Cell numbers were counted daily (triplicate for each
day) for 7 days. Extra plates and flasks were also used. The details of this
procedure are provided in Appendix E.4.
3.4 Cloning E ciency of Plating
A clonogenic survival assay (see Section 3.8) with di↵erent densities of cells
plated was performed to test the cloning e ciency. Fourteen densities of 200
cells/plate, 500 cells/plate, 1000 cells/plate, 1500 cells/plate, 2000 cells/plate,
2500 cells/plate, 3000 cells/plate, 4000 cells/plate, 5000 cells/plate, 6000 cells/plate,
7000 cells/plate, 8000 cells/plate, 9000 cells/plate, and 10,000 cells/plate were
performed using 100-mm petri dishes for each cell line in 10 ml of their corre-
sponding complete media and were incubated for 15 doubling times.
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3.5 Drugs Treatment and Cytotoxicity
Stock solutions of methotrexate (MTX), 5-fluorouracil (5-FU) and 5-bromo-20-
deoxyuridine (BrUdR) were prepared in Hanks Balanced Salt Solution (HBSS)
and stored at –20 C. Fluorodex was prepared using the method derived from
previous work (Locke et al 2009). Exponentially growing culture of 9L cells
were seeded in vented T12.5 cm2 tissue culture flasks in complete DMEM at
a density of 8–10⇥104 cells per flask. Cells were allowed to attach and divide
for 48 hours. Then, the medium was replaced and cells were incubated with
0.01– 0.1 µM MTX/5-FU and/or 1–10 µM BrUdR. After a two doubling times
incubation period with the drugs, the cytotoxic e↵ect of the drugs was deter-
mined by clonogenic assay (refer to section 3.8). The number of cells plated
was chosen based on the count of toxicity on cells (with reference of the cor-
responding controls for each cell line). Details of the procedure are provided
in Appendix F.
3.6 Nanoparticles Treatment and Cytotoxic-
ity
The nanoparticles were freshly prepared and dispersed in PBS (Ca2+ and
Mg2+) to solubilise them. Sonication and vortex mixing was used to minimise
the size of nano particle aggregates and increase the homogeneity of dispersion
prior to exposure.The set up for sonication experiment is shown in (Figure
3.11). A concentration of 50 µg/ml was applied to the cells for subsequent
analysis. Details of the procedure are provided in Appendix G.
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Figure 3.11: Set up of sonication procedure using the Branson Sonifier R  S-
250D digital with double-stepMicro-tip (Consonic Pty Ltd., NSW, Australia).
3.7 Cellular Irradiation Methods
3.7.1 Chemotherapy Drugs Combination
All experiments were carried out with confluent cultures grown as monolayer
in 12.5cm2 cell culture flasks with a vented screw cap (BD FalconTM). For
the control (untreated cells or radiation-treated cells only), it contain 5 mL
of DMEM medium and 30 mL of Hanks balanced salt solution (HBSS). For
the drug-treated cells (following a two doubling times incubation period with
drugs), just prior to irradiation, drugs-containing medium was added to make
up the total of 35 ml (same conditions as controls above with concentration of
drugs being adjusted). Unirradiated control samples were kept at room tem-
perature in the control room while the other samples were irradiated in the
treatment room. The complete procedures for irradiated cells in the absence
of drugs (i.e the experimental on dose rate) and the irradiated cells combined
with drugs (with its correspond control) are provide in Appendix H.1 and Ap-
pendix H.2, respectively.
3.7. Cellular Irradiation Methods 73
Figure 3.12: Schematic diagram of experimental setup for cellular irradiation
(MV with or without drugs).
3.7.1.1 Megavoltage irradiations
The cell flasks were placed vertically facing the beam and were positioned at
a depth of 2.2 cm and 1.7 in solid water (water-equivalent material) to match
the Dmax depth of the 10 MV and 6 MV photon field, respectively. An addi-
tional thickness of 10 cm of solid water was placed behind the flask to assure
adequate scattering conditions. To maintain electronic equilibrium conditions
within the flasks during the irradiation, the flask was also surrounded by solid
water slabs. The irradiation field size used for all experiments was 10.4 ⇥ 10.4
cm2 and the source-to-surface distance (SSD) was 100 cm. Figure 3.12 shows
a schematic diagram of the setup for cellular irradiation – MV X-rays for com-
bination with and without chemotherapy drugs (the dose rate experimental on
LINAC).
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Figure 3.13: Photograph of experimental setup for cellular irradiation (with
or without drugs).
3.7.1.2 Kilovoltage irradiations
The irradiation field size used for all experiments was 6 ⇥ 8 cm2 at the source-
to-surface distance (SSD) of 50 cm, with the tissue culture flasks positioned
as described previously (irradiated in a vertical orientation facing the beam
directly) with solid water placed both behind and around the sides of the
flasks, primarily to maintain adequate backscattering e↵ects and to stabilise
electronic equilibrium. Figure 3.13 shows the real setup for cellular irradiation
combined with chemotherapy drugs.
3.7.2 Nanoparticles Combination
The confluent cell cultures were irradiated in non-vented T12.5 cm2 tissue cul-
ture flasks (BD FalconTM) following a 1-day incubation period with nanopar-
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Figure 3.14: Photograph of experimental setup for cellular irradiation (MV
with or without nanoparticles).
ticles at a concentration of 50 µg/ml. The complete procedure is provided in
Appendix H.3.
3.7.2.1 Megavoltage irradiations
Prior to irradiation, all the flasks were filled completely with HBSS to ensure
no air bubbles were present inside the flask. Tissue culture flasks were irradi-
ated in a horizontal orientation with solid water placed both underneath and
around the sides of the flasks, primarily to maintain adequate backscattering
e↵ects and to stabilise electronic equilibrium (Figure 3.14).
3.7.2.2 Kilovoltage irradiations
Kilovoltage irradiation was performed using a 6 mm depth of medium in an
attempt to maximise the accuracy of the dose delivered to the cell monolayer.
Only beam energies of 150 kVp were explored. Tissue culture flasks were irra-
diated in a horizontal orientation with solid water placed both underneath and
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around the sides of the flasks, primarily to maintain adequate backscattering
e↵ects and to stabilise electronic equilibrium.
3.8 Clonogenic Survival Assay
In 1956, Puck and Marcus were the first to describe a cell culture technique
for mammalian cells, which were plated in cultured dishes with a suitable
medium. They determined the first Xray radiation dose survival curve for ir-
radiated HeLa cells in culture [Puck and Marcus, 1956]. Subsequently, many
studies have performed clonogenic assays or colony formation assay as the
method of choice to determine cell reproductive death after treatment with
ionising radiation or to determine the e↵ectiveness of other cytotoxic agents
[Munshi et al., 2005; Franken et al., 2006; Rafehi et al., 2011]. It is an in vitro
cell survival assay based on the ability of a single cell to grow into a colony
consisting of at least 50 cells. It is commonly regarded as the gold standard
cellular sensitivity assay [Plumb, 2004].
In this project, both the control and irradiated/treated cells were plated im-
mediately after the irradiation experiments. The medium was removed and
the confluent cells were washed gently with DPBS (Ca2+/Mg2+ free), then de-
tached using Trypsin-EDTA. The disassociated cells were counted with a hemo-
cytometer and seeded at low densities to achieve approximately 100 colonies
after fifteen doubling times into 100-mm tissue culture dishes (BD FalconTM)
containing 10 mL of complete cell growth medium (i.e. DMEM containing L-
Glutamine and supplemented with 10% (v/v) FBS and 1% (v/v) PenStrep).
Depending on the prescribed dose, each experiment involved a minimum of
three cells densities with triplicate dishes for each density (Figure 3.15). The
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Figure 3.15: Example of photograph of cells plated immediately after the
irradiation (approximately of 120 plates for each set of single experiment).
The assays of all irradiations treatment conditions (with or without drugs/NPs
treated) were performed at least three times independently, unless otherwise
specified.
numbers of cells plated per petri dish were determined by preliminary exper-
iments designed in order to determine the radio-sensitivity of the cell lines.
The cells in petri dishes were then incubated to allow colonies to form in a
37 C humidified 5% (v/v) CO2 cell culture incubator (Heracell 150i). The
details of this procedure are provided in figure H.1 (Appendix H). We believe
our protocol to be free of major flaws and that clonogenic assay is the most
robust technique for biological endpoint measurement after irradiation.
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Figure 3.16: Photograph of fix and staining the cells.
3.8.1 Fixing and Staining
After fifteen doubling times, the colonies were fixed and stained with a mixture
solution of 25% (v/v) crystal violet and 75% (v/v) ethanol for five minutes,
washed, and air-dried (Figure 3.16). Only the numbers of colonies containing
more than 50 cells were counted, as observed by microscope (Figure 3.17).
3.9 Flow Cytometric Detection
3.9.1 Propidium Iodide (PI) Staining
Propidium Iodide (PI) is the most commonly used dye for DNA cell cycle anal-
ysis by flow cytometry. This technique was also used as in vitro chemosensi-
tivity test to detect DNA damage induced by anticancer drugs [Iwadate and
Fujimoto, 1997]. Briefly, cells were harvested by trypsinisation as above and
centrifuged at 1500 rpm for 5 min at 4 C and then washed once with cold
phosphate bu↵er solution (PBS) which is Ca2+/Mg2+ free. Then, resuspend
with PBS at cell density of 1 ⇥106 cells/mL and transferred to labelled FAC-
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Figure 3.17: Example of photograph of the stained plates.
Stubes. PI of 1 mg/mL was added to give a final concentration of 10 µg/mL
just before the analysis is run on a flow cytometer.
3.9.2 Cell Cycle Analysis
Measurements of the cell cycle distribution were performed by flow cytometric
analysis using propidium iodide (PI) staining. The method used was derived
from previous work [Vine et al., 2007]. Cells (2 ⇥106) were centrifuged at
1500 rpm for 5 min at 4 C and washed twice with cold phosphate bu↵er solu-
tion (PBS) pH 7.4 (Ca2+/Mg2+ free) then finally fixed by drop wise addition
of 1 mL ice-cold ethanol (70%) and stored at –20 C for up to 7 days before
DNA analysis. The ethanol was then removed via a centrifuge process, washed
twice with cold PBS. The cells were then stained with a solution containing 40
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µg/mL PI, 100 µg/mL RNase A, and PBS (pH 7.4) at 37 C for 1 hour. The
stained nuclei were analysed for DNA-PI fluorescence using a FACS flow cy-
tometer. A minimum of 10,000 single cell events was analysed for each sample
in each experiment and at least three independent experiments was performed.
Details of this procedure are provided in Appendix I.1.
3.9.3 Detection of Forward and Side Scatter (for Nanopar-
ticles)
After exposure to nanoparticles for 24 h, cells were harvested by trypsinisation,
centrifuged at 1500 rpm for 5 min at 4 C and washed twice with cold phosphate
bu↵er solution (PBS) with Ca2+/Mg2+ free. Flow cytometric measurements
were performed and a minimum of 10,000 cells were analysed for each sample.
Cell doublets and aggregates were gated out using a two-parameter histogram
of FL2-Area versus FL2-Height. The decrease in size of forward scatter (FSC)
and the increase of side scatter (SSC) associated with the granularity were
evaluated.
3.9.4 Immunofluorescence Staining of BrUdR)
Immunofluorescence staining is the staining of cells with antibodies and other
specific ligands directly or indirectly with fluorescent molecule [Radbruch,
1992] to detect the presence of antigen (antibody-generating substance) on or
in a cell by the fluorescence emitted by the bounded antibody. Direct staining
is by using antibody-fluorescent conjugated directly whereas indirect staining
is using unconjugated antibodies (primary antibody) and then detected using
secondary antibody that fluorescent-conjugated (Figure 3.18). In this project,
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Figure 3.18: Direct (A) vs. indirect (B) immunofluorescence staining.
direct staining with antibodies conjugated to fluorescent is used (i.e. anti-
BrUdR antibodies conjugated to Alexa Fluor 488). Therefore, the detection of
anti-BrUdR antibody binding level by flow cytometry showed to be correlated
with the number of Br uptake into cells.
3.9.4.1 Detection of BrUdR & total DNA content simultaneously
Cells that had incorporated BrUdR during drug the incubation procedure were
detected by fluorescently labelled anti-BrUdR antibodies. In this study, the
3.10. Confocal Microscopy Analysis 82
anti-BrdU mouse monoclonal antibody (Clone MoBU-1) that is highly specific
for BrdU incorporated into DNA was used. The clone MoBU-1 conjugated
with Alexa Fluor 488 was purchased from Molecular Probe (Invitrogen Life
Technologies, NSW, Australia). The assay was carried out using an acid de-
naturation method as per the manufacturers references with minor modifica-
tions.
Briefly, cells were incubated with 10 µM BrUdR as described previously, har-
vested and fixed at least overnight after the addition of 1mL of ice-cold 70%
ethanol as above. The cells were washed twice with cold PBS and then treated
with 4M HCl (Sigma) for 20 min at room temperature. After this, the cells
were washed with a phosphate/acid bu↵er at pH 7.4 and were washed a sec-
ond time with antibody diluting bu↵er (PBS with Triton X-100 and bovine
serum albumin (Sigma). After washing, the cells were then incubated with
the clone MoBU-1 antibody for 30 min, followed by antibody diluting bu↵er
washing. The pelleted cells were then counterstained with PI staining solution
(10 µg/ml PI, 100µ/ml RNase A, and PBS pH 7.4) for 30 min at room tem-
perature. The stained nuclei were then analysed using flow cytometer. Details
of this procedure are provided in Appendix I.2.
3.10 Confocal Microscopy Analysis
3.10.1 Detection of Intracellular Reactive Oxygen Species
(ROS)
The formation of ROS in 9L cells following treatment by nanoparticles was
assessed using confocal laser scanning microscopy. Briefly, 1⇥105 cells were
seeded onto Nunc TMLab-TekTMII Chamber SlideTMSystem 4 wells (growth
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Figure 3.19: Cells grown onto TMLab-TekTMII Chamber SlideTMSystem 4 wells
(growth area = 1.8cm2) (Thermo-Scientific).
area = 1.8cm2) (Thermo-Scientific) (3.19) in fresh culture medium (complete
medium) containing nanoparticles. Only tantalum pentoxide (Ta2O5) nanopar-
ticles have been tested, with a concentration of 50 µg/ml. After 24 hours of in-
cubation, 10 µg/ml of propidium iodide (PI) and 10µM of 20,70-Dichlorofluorescein
diacetate (DCFD) dye were added. Stained cells were then visualised imme-
diately by confocal microscopy. Confocal laser scanning microscopy were ac-
quired using a Leica TCS SP system with a water immersion objective lens.
As DCFD is very light sensitive, the procedures were performed in the dark.
3.10.2 Immunofluorescence Staining of BrUdR
The immunofluorescence staining procedure was carried out in a similar method
as described for flow cytometry (section 3.9). Briefly, 7.5⇥104 cells were seeded
onto NuncTMLab-TekTMII Chamber SlideTMSystem 4 wells (growth area =
1.8cm2) (Thermo-Scientific) (Figure 3.19). After an incubation period with
drugs (MTX or BrUdR) or without drugs (negative control) corresponding
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to 15 doubling times, cells were fixed with 70% ethanol at 4 C for 30 mins,
washed twice with cold PBS and treated with 4M HCl for 20 mins at room
temperature. Cells were then washed with phosphate/acid bu↵er (pH 7.4) and
washed three times with an antibody diluting bu↵er containing Triton X-100
and bovine serum albumin. The cells were then incubated with MoBU-1 anti-
body for 30 mins, followed by antibody diluting bu↵er washing. The cells were
then counterstained with PI staining solution (10 µg/ml PI, 100µ/ml RNase
A, and PBS pH 7.4) for 30 mins at room temperature. Stained cells were then
visualised by confocal microscopy. Confocal laser scanning microscopy were
acquired using a Leica TCS SP system with an oil immersion objective lens.
3.11 Data Analysis and Statistics
3.11.1 Cells Growth Analysis
The exponential growth curves for all the cells were plotted as the number of
cells against time, which is based on the equation:
N = N0 exp( t), (3.2)
where N = the concentration of cells at time, t, N0 = the initial concentration
of the cells, and   is the growth constant. The doubling time, t2, is the time
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3.11.2 Plating E ciency
The plating e ciency (PE) was calculated as the number of surviving colonies
divided by the number of cells seeded:
PE =
Number of colonies counted
Number of cells seeded
(3.4)
3.11.3 Cell Survival Analysis
The number of colonies that arise after irradiation, which is expressed in terms





where SF (D) is the cell survival fraction at dose D (Gy), PE (D) is the plat-
ing e ciency at the dose (irradiated cells), and PE (0) is the plating e ciency
at zero dose (unirradiated cells or control). The values of PE (D) and PE
(0) are the average over the replicate samples for each dose. The radiation
dose-survival curves were generated by plotting the SF as a function of the
dose on a semi-logarithmic scale. The radiation dose survival curves were fit-
ted by a linear quadratic function (LQ model) (Eq. 2.6) used to describe in
vitro radio-sensitivity [Fertil and Malaise, 1981, 1985]. ↵ and   parameters
were determined in order to quantify the radio-sensitivity [Curtis, 1986]. A
schematic diagram of the overall procedure is illustrated in Figure 3.20, where
the clonogenic assay (Section 3.8) was initiated. Details of the procedures are
provided in Appendix H.
3.11. Data Analysis and Statistics 86
Figure 3.20: Schematic diagram of cell culture technique (i.e clonogenic assay)
to produce a cell survival curve.
3.11.4 Flow Cytometric Data
Cell doublets and aggregates were usually gated out using a two-parameter
histogram of FL2-Area versus FL2-Height. In this study, the FSC-A vs SSC-A
gate was su cient. Figure 3.21a is a two-dimensional dot plot of FSC vs. SSC,
show the bulk of the cells as the dense population of dots and each dot repre-
sents one acquired event. The intensity of fluorescence (i.e. red fluorescence in
this case as PI used) is displayed in a histogram plot (Figure 3.21b). In figure
3.21c, a gate has been drawn around the dense cell population of interest on
the plot to exclude cell doublets and debris from analysis, which give a better
histogram plot shown in Figure 3.21d.
The resulting DNA distribution was then analysed on the basis of histograms
using FlowJo software Mac version (V9.6.2, Tree Star Inc., USA) for the pro-
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portion of cells in G0/G1, S and G2/M phases of the cell cycle. Figure 3.22
show a typical cell cycle of each phase by flow cytometry, with G0/G1 phase
and G2/M phase represents as diploid (2N) and tetrapoid (4N) DNA content,
respectively (where N as a single complement of chromosomes, the haploid
content). Therefore, by fluorescence labelling of the nuclei cells with PI, the
population of each phase cells can be determined by analysing its fluorescence
properties. The G0/G1 phase (2N) with one copy of DNA will have 1X fluo-
rescence intensity whereas the G2/M phase (4N) with two copies of DNA will
have 2X intensity. For the S-phase, the fluorescence values are between 1X
and 2X as they are synthesising DNA. All data were stored by the computer
system in a flow cytometer standard (FCS) format.
3.11.5 S-phase Fraction
The S-phase fraction (SPF) was calculated as the number of S-phase fraction






The cell growth curves are fitted using equation (3.2), weights in the fit by the
standard deviation at each point. The plating e ciencies (PEs) for each irra-
diation were calculated and were normalised to 100% survival controls at zero
dose (unirradiated cells). PEs for each irradiation combined with drugs, the
data were normalised to 100% survival controls of unirradiated drugs-treated
cells.
The cell survivals are then given as the mean values from the pooled data of
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(a) (b)
(c) (d)
Figure 3.21: A representative typical data analysed on BD LSR II flow cy-
tometer and an illustration of gating using FlowJo software (from 9L cells
stained with PI). (a) Dot plot (or cytogram) which showing forward scatter
(FSC) versus side-scatter (SSC). (b) Histogram plot which showing positive
population of cells (ungated). (c) Dot plot, which was gated shown as 74%
cells (singlets). (d) Histogram which showing gated on singlet cells only.
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Figure 3.22: A schematic diagram of cell cycle, showing flow cytometric com-
ponents of each phase (www.phoenixflow.com).
at least six-replicate samples (each triplicate from a minimum of three inde-
pendent experiments, unless specified otherwise) for each data point, with the
experimental uncertainty given as one standard deviation (mean ± SD). The
LQ model was fitted to cell survival data using IGOR Pro software (V.6.21,
WaveMetrics, Inc. Oregon, USA). The fit of the data is weighted by the re-
ported error at each dose in the determination of the radiobiological constants
of the LQ model (non-linear least squares algorithm). FACS plots and his-
tograms are representative of at least two independent experiments.
3.12 Sensitisation Defined
3.12.1 Sensitisation Enhancement Ratio (SER)
There are two major sensitisation enhancement ratios (SER) defined in the
literature: horizontal and vertical. For the horizontal ratio, the values are
given as the ratio of the dose required to kill a given surviving percentage in
the control group to the dose required in the treated group (e.g. SER10.). For
vertical ratios, the SER is defined as the ratio of the surviving fraction in the
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control to the surviving fraction in the treated group in particular dose (e.g.
SER2Gy.). Researchers often choose 2 Gy because of its practical value when
used as prescribed dose (per fraction) in fractionation RT. In this study, SER10
is used as a way to measure the dose-enhancement by di↵erent energies (e.g.
kVp vs. MV).
3.12.2 Protection Enhancement Ratio (PER)
For cerium oxide nanoparticles in this study, we defined a protection enhance-
ment ratio, PER10, as the ratio of the dose required to protect 10% surviving
fraction in the control group to the dose required in the treated group.
Chapter 4
Results & Discussions
4.1 Cell Line Characteristics and Protocols
This thesis is part of the foundation research and development associated with
the recently formed Targeted Nano-Therapy (TNT) team at the University
of Wollongong. The TNT team is made up of collaborating members from
the Centre for Medical Radiation Physics (CMRP), the Centre for Medical
Bioscience (CMB), and the Institute for Superconducting and Electronic Ma-
terials (ISEM) of the University of Wollongong. The initial research, carried
out at the Illawarra Health and Medical Research Institute (IHMRI), centred
on the establishment of a variety of cell lines and cell handling protocols.
This chapter examines the exponential growth of all the cell lines used in this
thesis: 9L, MCF-7, U87-MG, and MDCK. The cell growth analysis of MCF-7,
U87-MG, and MDCK has also been performed as groundwork analysis only.
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4.1.1 9L Cell Line
The 9L is an adherent, fibroblast-like, radioresistant rat gliosarcoma cell line
derived from a N-nitrosomethylurea-induced tumor. The mean population
doubling time of 9L cells over a series of three experiments was approximately
32 – 34 hours (Figure 4.1). This doubling time is comparable to reported dou-
bling times of 1.3 days [Ghulam Muhammad et al., 2009]. The 9L cells are also
similar to some human high-grade glioma cells that are relatively resistant to
X-rays irradiation [Malaise et al., 1987]. As is generally true for most glioma
cell lines, the 9L cell line is aggressive and less radio-sensitive than other rat
tumour cell lines [Henderson et al., 1981; Bencokova et al., 2008]. It is the
best and most widely used of all rat brain tumour models for research [Barth,
1998] as well as a preclinical model used in brain radiotherapy [Vinchon-Petit
et al., 2010] and has been utilised in such experiments for more than 30 years
[Kimler, 1994].
4.1.1.1 Cell Age E↵ect on 9L Cells
An additional preliminary cell growth assay of 9L cells was performed to check
whether there is an e↵ect on cell age (Figure 4.2). 9L cells on passage 54
(new) were compared to cells on passage 89 (old). The doubling time for the
old passage is shorter (26 hours) than the newer passage (32 – 34 hour). From
this result, it was recommend to use cells for up to 30 passages.
4.1.2 MCF–7 Cell Line
MCF-7 is an adherent, epithelial-like, radiosensitive breast adenocarcinoma
cell line established from a 69-year-old female. There is no significant di↵er-
ent in growth of MCF-7 between using the DMEM (27 hours) or RPMI-1640
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Figure 4.1: Analysis of exponential growth of 9L cells (passage 47). The assay
was performed three times, and a representative result is shown. Experimental
points are shown, along with exponential fit describe in methods section (Eq
3.2). Bars are ± one standard deviation.
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Figure 4.2: Analysis of exponential growth of 9L cells passage 54 (new) vs.
passage 89 (old). Experimental points are shown, along with exponential fit
describe in methods section (Eq 3.2). Bars are ± one standard deviation (error
bars are too small).
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Figure 4.3: Analysis of exponential growth of MCF-7 cells in DMEM vs.
RPMI-1640. Experimental points are shown, along with exponential fit de-
scribe in methods section (Eq 3.2). Bars are ± one standard deviation.
(26 hours) media (Figure 4.3). Thus, in order to keep the same experimental
conditions for all the cell line used in this study, DMEM medium is chosen for
MCF-7. The mean population doubling time of MCF-7 cells over a series of
two experiments was approximately 25 – 27 hours (Figure 4.3). This doubling
time is comparable to reported doubling times of 24 hour (ATCC - Ameri-
can Type Culture Collection). The MCF-7 cell line represents a well-adopted
pre-clinical model of breast tumour tissue. It has provided the basis of many
breast cancer biology studies [Tutt and Yarnold, 2006]. These cells are rela-
tively more radio-sensitive [Matthews et al., 1989] than 9L cells.
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Figure 4.4: Analysis of exponential growth of U-87MG cells. Experimental
points are shown, along with exponential fit describe in methods section (Eq
3.2). Bars are ± one standard deviation.
4.1.3 U–87 MG Cell Line
The analysis of exponential growth for U-87 MG cells was performed as ground-
work analysis. The mean population doubling time of U-87 MG cells was ap-
proximately 36 – 38 hours (Figure 4.4). This doubling time is comparable to
the reported doubling times of 34 hours (ATCC). Glioblastoma cells were re-
ported as very highly aggressive cells and highly vascularised tumours [Jensen,
1998]. Therefore, the U87-MG glioblastoma cells were chosen as a highly ra-
dioresistant cell line [Leith et al., 1994; Williams et al., 2008] to be comparable
with the radioresistant 9L cells for future work.
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4.1.4 MDCK Cell Line
As it is generally di cult to maintain primary culture, we chose a continuous
non-malignant cell line that is easy to maintain (i.e. the MDCK – Madin Darby
Canine Kidney) cells. The MDCK cell line is the most well studied epithelial
cell [Simons and Virta, 2006]. It is derived from a normal dog kidney [Madin
and Darby, 1958; Gaush et al., 1966]. MDCK cells were chosen to mimic the
model for glioma (i.e. 9L), which is used for the preliminary nanoparticles work
presented in this study. MDCK was chosen as a model for permeation exper-
iments on blood brain barrier (BBB) [Veronesi, 1996; Garberg et al., 2005;
Hombach and Bernkop-Schnurch, 2009]. The mean population doubling time
of MDCK cells was approximately 19 hours (Figure 4.5). This doubling time
is comparable to reported doubling times of 21 hours (ATCC).
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Figure 4.5: Analysis of exponential growth of MDCK cells. Experimental
points are shown, along with exponential fit describe in methods section (Eq
3.2). Bars are ± one standard deviation.
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Figure 4.6: Photograph of colonies of unirradiated MCF-7 cells. Plating e -
ciency of cells densities of 200, 500, 1000 and 1500cells/plate are shown.
4.2 Cloning E ciency of Plating
Di↵erent cell lines have di↵erent plating e ciency [Franken et al., 2006]. Un-
der our experimental conditions, the range of plating e ciencies (Figure 4.6)
at low density for 9L and MCF-7 was approximately 8–10% and 50–70%, re-
spectively. The plating e ciency for U87-MG and MDCK has also been per-
formed as groundwork analysis. The range of plating e ciencies at low density
for U87-MG and MDCK was approximately 6–8% and 15–20%, respectively
(Figure 4.7).
A clonogenic assay was also performed to investigate whether there is an e↵ect
on cells while travelling to the POWH for irradiation experiment. Two sam-
ples of unirradiated cells, both 9L and MCF-7 (not travelling), were tested as
well as with or without filter cap for the 9L cells. There were no di↵erences
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Figure 4.7: Plating e ciency of 9L, MCF-7, U-87 MG, and MDCK cells. Bars
are ± one standard deviation.
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observed in any of the treatments (data not shown). This suggests that the
traveling period for the irradiation experiment (approximately 3 hours) has no
additional e↵ect on the cells.
For the irradiation experiment, there are always two controls used in each
treatment conditions. One sample of each control was plated immediately
whereas another was plated at the end (i.e. after all the remaining samples
are plated) in order to anticipate the e↵ect of timing on the last sample being
plated.
4.2.1 Conclusions
The cell proliferation rate was determined by calculating the doubling time of
each cell line. For our experimental conditions, it showed that 9L, MCF-7,
U-87 MG, and MDCK cells grow exponentially with doubling times of 32 – 34
hours, 24 – 27 hours, 36 – 38 hours, and 19 – 21 hours, respectively. These
doubling times are consistent with literature values, which are 1.3 days for
9L [Ghulam Muhammad et al., 2009], 24 hours for MCF-7 (ATCC), 34 hour
for U-87 MG (ATCC), and 21 hours for MDCK (ATCC). Thus, the observed
exponential growth of cells proved validity of the tissue culture technique used
in this project.
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4.3 Cytotoxicity Test
This section is concerned with the toxicity assessment of both the drugs and
the nanoparticles on cells. The first part of this section describes the cyto-
toxicity of drugs and the reasons how the optimum concentration used in this
study was chosen. The second part describes the cytotoxicity of the ceramic
nanoparticles (cerium oxide – CeO2, tantalum pentoxide – Ta2O5, and bis-
muth oxide – Bi2O3) on 9L cells and only bismuth on the non-malignant cells.
Finally, the last part describes the cytotoxicity test of a new pro-drug of 5-
fluorouracil (fluorodex).
4.3.1 Drugs Cytotoxicity Test on 9L Cells
The present study involved two kinds of cytoxicity tests. The toxicity of the
drugs (MTX, 5-FU, and/or combination with BrUdR) was first investigated
over a period of two doubling times by counting the viable cells using a haemo-
cytometer. This first investigation (i.e. cell viability assay) was required in
order to determine the cell density required for the second cytotoxicity test, i.e
cell clonogenic assay. The number of cells plated in the second investigation
was based on the percentage toxicity rate in the initial investigation (a detailed
procedure is given in Appendix F1 of the thesis).
In the second investigation the toxicity of the drugs was assessed over fifteen
doubling times using clonogenic assay. Only the cytotoxicity on 9L cells is
presented in this study. There was no significant decrease in the number of
viable cells following exposure to drugs at a concentration of 0.01 µM for either
MTX or 5-FU alone or when either of these was combined with BrUdR (at
a concentration of either 1 or 10 µM). Under these conditions both of these
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doses of BrUdR can be considered non-toxic. Only when the dose of MTX was
(i.e. 0.1 µM), both alone and combined with 1 µM BrUdR, was significant
toxicity indicated by a decrease in the number of viable cells to less than 20%.
These results are summarised in Table 4.1.
Table 4.1: Cell viability of control (untreated cells) of 9L cells and of treated
cells with drugs for two doubling times








MTX 0.01µM; BrUdR 1µM 63.5
MTX 0.01µM; BrUdR 10µM 67.5
MTX 0.1µM; BrUdR 1µM 19.0
MTX 0.1µM; BrUdR 10µM 50.8
5-FU 0.01µM; BrUdR 1µM 54.7
5-FU 0.01µM; BrUdR 10µM 79.4
5-FU 0.1µM; BrUdR 1µM 54.7
5-FU 0.1µM; BrUdR 10µM 59.5
An interesting observation in the cell viability test results is that when either
MTX or 5-FU is combined with a higher dose of 10 µM BrUdR, there is an
increase in the number of viable cells compared to when they are combined
with a lower dose (1µM BrUdR). These results not only suggest that BrUdR is
non-toxic but also support the general mechanism of BrUdR. When the DNA
synthesis of cells is blocked by MTX or 5-FU, the cells can mistakenly uptake
and incorporate the BrUdR into the newly formed DNA chains.
Cells cultured for two doubling times when exposed to a low dose of MTX (0.01
µM) alone or combined with either low or high doses of BrUdR show about
a 40% decrease in the clonogenic survival fraction. In the case of a higher
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dose of MTX alone (0.1 µM) or combined with either a low or high dose of
BrUdR, the clonogenic surviving fraction of cells was significantly decreased.
Cells cultured for two doubling times when exposed to a low or high (0.01 µM
and 0.1 µM) dose of 5-FU alone or combined with 1µM BrUdR did not show
any significant decrease in survival. Only when the 5-FU was combined with
10 µM BrUdR, did the surviving fraction decrease by 40%. These results are
presented in figure 4.8.
The high dose of MTX (i.e. 0.1 µM) can therefore be considered to be toxic
since the results in Table 4.1 and Figure 4.8 are consistent.This is clearly indi-
cated by the significant decrease in the number of viable cells and cell survival
fraction. Interestingly, this is not the case for 5-FU. The cells grown in 0.1 µM
5-FU showed an increased in clonogenic survival cell compared to the control
(Figure 4.8). These results in Figure4.8 are also in a good agreement with
Wakisaka [1979]. The latter author found the optimum range of MTX and
BrUdR concentration for a synergistic e↵ect was 0.01 to 0.02 µM and 0.3 to
30 µM, respectively tested on L5 mouse fibroblast cells [Wakisaka, 1979].
4.3.2 Ceramic Nanoparticles Cytotoxicity on 9L Cells
The nanoparticles are tested for biocompatibility, as they are expected to in-
teract with biological systems. The current understanding of the mechanisms
which determine the level of such interaction is limited. As described previ-
ously, a concentration of 50 µg/ml of each ceramic nanoparticles (CeO2, Ta2O5,
and Bi2O3) was tested on 9L cells for a 1-day incubation. Biocompatibility
testing on MDCK cells was carried out, but for Bi2O3 only.
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Figure 4.9: The surviving fraction of 9L cells exposed to cerium oxide (CeO2)
and tantalum pentoxide (Ta2O5) nanoparticles following a 24 hour exposure at
a concentration of 50 µg/ml. The toxicity was measured using the clonogenic
survival assay. Bars are ± one standard deviation.
4.3.2.1 Cerium Oxide (CeO2)
The toxicity of CeO2 nanoparticles to 9L cells is shown in Figure 4.9. There
is no significant toxic e↵ect on the survival fraction of 9L cells (Figure 4.9) at
a nanoparticle concentration of 50 µg/ml, this is consistent with the literature
[Colon et al., 2009; Tarnuzzer et al., 2005; Xia et al., 2008].
4.3.2.2 Tantalum Pentoxide (Ta2O5)
Tantalum is a known biocompatible material that has been used in orthopaedic
surgery [Zardiackas et al., 2001]. Given the high atomic number of tantalum,
the TNT group decided to develop a ceramic nano structured material based
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on the hypothesis that one could exploit both its biocompatibility and the
high-Z (Z = 73) nature of this element to produce an e↵ective radiosensitiser.
Tantalum pentoxide (Ta2O5) is one of the many unexplored ceramic nanoma-
terials that contain potentially desirable characteristics as high-Z material to
be used as radiosensitiser. The toxicity of the synthesised Ta2O5 nanoparticles
to 9L cells is shown in Figure 4.9. There is no significant toxic e↵ect on the
clonogenic survival fraction of 9L cells (Figure 4.9). This is unsurprising as
tantalum is a known biocompatible material that has been used in orthopaedic
surgery [Zardiackas et al., 2001] and consequently is non-toxic to healthy cells.
4.3.2.3 Bismuth Oxide (Bi2O3)
The toxicity of the synthesised Bi2O3 nanoparticles to 9L cells and MDCK cells
are shown in (Figure 4.10). A toxic e↵ect was observed for Bi2O3 nanoparticles
synthesised by precipitation in air on the clonogenic survival fraction of both
9L and MDCK cells at a concentration of 50 µg/ml (Figure 4.10). However,
there was no significant toxic e↵ect on the clonogenic survival fraction of both
9L and MDCK cells at a concentration of 50 µg/ml.when exposed to Bi2O3
synthesised by precipitation in argon. This result suggests that the presence
of the argon environment in the manufacturing process appears to passivate
the surface of the nanoparticles. Therefore, only the Bi2O3 synthesised by
precipitation in an argon environment was used in further experiments.
This biocompatibility result shown by the Bi2O3 synthesised by precipitation
in argon supports the use of many other bismuth compounds (e.g. bismuth
subsalicylate and bismuth oxychloride) that are widely used in medicines and
other biological application [Von Recklinghausen et al., 2008; Tripathi et al.,
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Figure 4.10: Comparison of cytotoxicity tests of Bi2O3 (air vs. argon tech-
niques) as the number of clonogenic survival of unirradiated 9L and MDCK
cells at the concentration of 50 µg/ml. Bars are ± one standard deviation.
2011; Lambert and Midolo, 1997; Fugiwara et al., 2005].
4.3.3 Fluorodex Cytotoxicity Test on 9L Cells
5-FU is an anticancer drug that has widely used for more than 50 years. How-
ever, the major drawbacks of its use in a clinical setting is in the administration
of these drugs, which includes phlebitis, thromboembolic events and catheter
blockages. Fluorodex is the clinical term used for pH neutral parenteral 5-FU
and folinic acid formulations that are improved injectable forms of 5-FU that
may reduce the occurrence of these limitations [Locke et al., 2009; Stutchbury
et al., 2010]. The toxicity e↵ect of Fluorodex on 9L cells is shown in Figure
4.11, which show that it is more toxic compared to 5-FU alone as well as with
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Figure 4.11: Comparison of cytotoxicity test of 5-FU (to allow for comparison)
and fluorodex on 9L cells at the concentration of 0.01 – 0.1 µM of fluorodex
and the combination with 10 µM BrUdR. Bars are ± one standard deviation.
the combination with 10 µM BrUdR (Figure 4.11).
Interestingly, the MDCK cells grown in fluorodex at all concentrations showed
an increased clonogenic survival of MDCK cells compared to the control cells
(untreated) (Figure 4.12).
4.3.4 Conclusions
By taking into account the toxicity e↵ect of the anti-cancer drugs alone, op-
timum drug doses of 0.01 µM was chosen for MTX and 5-FU. The optimum
concentration of 10 µM is chosen for BrUdR since there was either no or only
a slight toxicity observed in this case with or without the combination of the
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Figure 4.12: Comparison of cytotoxicity test of fluorodex on MDCK cells at
the concentration of 0.005 – 0.05 µM. Bars are ± one standard deviation.
anticancer drugs. In other words, the optimum drugs doses within a medium
range of toxicity were chosen as when they are combined with radiation, the
experiments did not lead to an over killing of the cells (i.e. cell survival vi-
ability was still countable). It appears that the e↵ect of exposure to either
BrUdR or MTX alone on unirradiated cells has an inhibitory e↵ect on the cell
proliferation to a similar extent.
For the biocompatible nanostructured particle work, all of the new engineered
nanomaterials: CeO2, Ta2O5, and Bi2O3 (except when synthesised by precipi-
tation in air) showed an excellent biocompatibility at the concentration tested.
Furthermore, they are potentially suitable as high-Z agents to study the inter-
action of such materials with biological systems.
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The results of the toxicity experiments indicate that there is significant poten-
tial for future research e↵ort directed towards investigating the use of 5-FU in
combination with BrUdR as well as Fluorodex in combination with radiations.
Especially with Fluorodex, since it exhibits toxicity e↵ect on cancerous cells
(9L) but not on non-malignant cells (MDCK).
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4.4 Experimental Dose Rate of LINAC
The aim of this section is to establish conditions for the optimal enhancement
of megavoltage (MV) X-ray radiation upon the survival curves. We do this by
investigating the e↵ect of the dose rate delivered by the LINAC. This investi-
gation is carried out prior to the main projects, which investigate the use of
pharmaceutical agents and the parallel studies using nanoparticles.
Research investigating the biological e↵ect of di↵ering dose-rates for 10 MV
X-ray irradiation delivered from a LINAC is highly significant in predicting
outcomes of new generation of intensity modulation radiation therapy (IMRT),
which is commercially available using technology that enable the delivery X-
rays with high dose-rates. To our best knowledge, this is the first time that
the biological e↵ectiveness of 10 MV X-ray radiation doses on 9L and MCF-7
cell lines has been investigated. The significance in the findings of this study
are discussed with regard to observations on the radio-sensitivity of the 9L
and MCF-7 cells, concepts of radiobiology, and potential implications for new
methods of dose delivery of IMRT.
4.4.1 Background
Radiation therapy (RT) is an important modality for many cancer treatments,
with over 50% of cancer patients receiving some form of RT as part of their
cancer management plan. The ongoing challenge in RT treatment is the con-
trolled delivery of a lethal dose to the tumour whilst minimising damage to
the surrounding normal tissue. Modern radiotherapy techniques such as inten-
sity modulation radiation therapy (IMRT), intensity modulated arc therapy
(IMAT) or volumetric-modulated arc therapy (VMAT), and stereotactic ra-
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diotherapy (SRT)[Tubiana and Eschwege, 2000; Benedict et al., 2001; Siochi,
1999] have improved local tumour control through better precision of the de-
livered radiation dose. These technologies consequently often deliver more
complex treatment fields than conventional techniques.
Clinically, IMRT has become an important modality and it has been widely
used in radiotherapy for over 15 years. The capabilities of IMRT have been
extensively described in the literature in terms of physical advantages, such
as target coverage conformity, better dose uniformity, and sparing the adja-
cent normal tissue, which make IMRT technique superior compared to conven-
tional or three-dimensional conformal external radiotherapy (3D-CRT) [Group,
2001; Cheung, 2006]. However, in IMRT an increased number of monitor units
(MUs) is required and thus IMRT (beam-on time) generally involves a longer
dose delivery time than conventional RT. The radiobiological advantages of
IMRT have been extensively debated in the literature [Wang et al., 2003; Mu
et al., 2003; Moiseenko et al., 2007; Fowler et al., 2004; Srensen et al., 2011;
Lohse et al., 2011]. The suspicion that IMRT could possibly decrease tumour
control due to the increase of the overall treatment time does not have any
clinical evidence and this would be o↵set by the advantages linked to the bet-
ter conformation of physical doses to the target volumes and therefore better
sparing of critical organs.
Improvement in clinical outcomes can be achieved by reducing patient intra
fraction movements. Recent technical developments have therefore focused on
increasing the clinical dose rates to minimise the e↵ect of such movements.
Increasing the dose rate also has the added benefit of reducing the overall pa-
tient treatment time, thus allowing an increase in patient throughput. One
recent development is the removal of flattening filters in the linear accelerator
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heads (flattening filter free (FFF) linac configuration), which has proven to
be particularly beneficial for IMRT and SRT [Fu et al., 2004; Stathakis et al.,
2009; Kragl et al., 2009]. The absence of the flattening filter, leading to a sig-
nificant decrease in the number of MUs for a given photon treatment delivery,
has been reported in the literature for both Varian (energies 6 MV and 18 MV)
[Stathakis et al., 2009] and Elekta (energies 6 MV and 10 MV) [Kragl et al.,
2009] clinical LINACs. It is thus important to, and would be hazardous not
to, investigate the biological e↵ectiveness of physical radiation doses delivered
with di↵ering dose rates.
Recently published radiobiological data has emphasised the radiobiological ef-
fect of a high instantaneous dose rate and indicated that there is no e↵ect of the
instantaneous dose rate of FFF LINACs on clonogenic cell survival [Srensen
et al., 2011]. Other data however, showed that the radiobiological e↵ect of the
FFF beam is dependent on dose per pulse and suggested that it might become
a crucial factor that influences the cancer cell survival [Lohse et al., 2011].
Ling et al. [1995] reviewed the dose rate e↵ect in external beam radiotherapy
and concluded that it is the overall beam-on time that determines tumour
cell survival, not the average dose-rate of the LINAC nor the instantaneous
dose-rates within LINAC pulses. In this work, we are primarily focused on
the overall time of irradiation and its influence on the survival of two cell lines
with significantly di↵erent radiosensitivities.
Dose-rate sparing is usually known to involve a decreased biological response
to radiation exposure at a low dose rate compared to a high dose rate, as theo-
retically predicted by Lajtha and Oliver [1961]. To the contrary, Mitchell and
Bedford [1977] and Mitchell et al. [1979] first identified the decrease in survival
of HeLa cells irradiated at a low dose rate of 37 cGy/h compared with a high
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dose rate of 1.54 Gy/h; this was referred to as the inverse dose-rate e↵ect.
Similar studies by Furre et al. [1999] also observed an inverse dose-rate e↵ect
on NHIK 3025 cells. These data suggest that for some cell lines, a monotonic
increase in dose-rate does not produce a similar increase in cell killing. More-
over, in some specific cell lines increasing the dose rate actually decreases the
cell killing e↵ectiveness.
4.4.2 Results
RT is rapidly evolving toward the adoption of equipment delivering higher dose
rates. The safe adoption of these latest technologies in clinical practice neces-
sitates a thoughtful evaluation of all the relevant parameters. However, the
radiobiological advantages of the use of higher dose rates has been the subject
of much recent debate in the literature. In this work, the results of in vitro
experiments in which the biological e↵ect of di↵ering dose-rates for 10 MV
X-ray irradiation delivery from a LINAC has been assessed by colony forming
assay. The dose is delivered using clinical dose rates of 0.5 Gy/min compared
to a 10-fold higher dose rate of 5 Gy/min. 9L and MCF-7 cell lines were used
because they represent a good pre-clinical model of brain and breast tumour
tissues respectively. Their intrinsic radio-sensitivity is di↵erent, the 9L being
considered to be more radiation resistant than the MCF-7.
Clonogenic assay was used to determine cell reproductive death after treat-
ment with ionising radiation as first described by Puck and Marcus [1956]. In
the present study, this assay was performed to measure the capability of each
cell line to proliferate and produce colonies after the irradiation, which can be
modelled by a linear-quadratic function of radiation dose.
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4.4.2.1 Determination of the dose-rate e↵ect of the MV X-ray beams
on clonogenic cell survival
The results for the 10 MV X-rays irradiation experiment at a dose-rate of 0.5
Gy/min compared to 5 Gy/min on 9L and MCF-7 cells are shown in Figure
4.13 and Figure 4.14, respectively. The reduction of dose-rate appears to have
no e↵ect on the clonogenic survival of 9L cells (Figure 4.13). However, with
MCF-7 cells, the lower dose-rate irradiation results in a decreased clonogenic
survival (Figure 4.14). Analysis of the data using the LQ model is shown in
Table 4.2 and reveals that the ↵ value for MCF-7 cells irradiated at 0.5 Gy/min
(0.83±0.01Gy 1) is larger than the corresponding value when irradiated at 5
Gy/min (0.47±0.03Gy 1). Hence, a change in the e cacy of treatments was
found, as measured quantitatively by a significant reduction of 20% in the nec-
essary absorbed radiation dose in order to achieve the same 10% cell-surviving
fraction.
Since there is no dose-rate e↵ect observed on clonogenic survival of 9L cells
(Figure 4.13), the high dose-rate of 5 Gy/min is chosen for all the megavoltage
irradiation experiments used in combination with the drugs/nanoparticles in
this study (i.e. including the 6 MV).
4.4.2.2 To explore the general applicability of the high-dose rate
MV X-ray induce enhancement of clonogenic killing to can-
cer cells
The cell survival curves of the 9L and MCF-7 cells after irradiation with 10
MV X-rays at a dose-rate of 5 Gy/min are plotted on the same graph to allow
comparison of the relative radio-sensitivities of the two cell lines (Figure 4.15).
From the graph it can be seen that 9L cells are about 2.2 times more resistant
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Figure 4.13: Radiation survival curves of 9L cells irradiated at dose rate of 0.5
Gy/min vs. dose rate 5 Gy/min. The data were fitted to the linear quadratic
model. Each data point represents the means ± standard deviation of three
independent experiments.
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Figure 4.14: Survival curves of MCF-7 cells irradiated at dose rate of 0.5
Gy/min vs. dose rate 5 Gy/min. The data were fitted to the linear quadratic
model. Each data point represents the means ± standard deviation of three
independent experiments. 8 Gy data point is not included as they are too
sensitive – number of colonies obtained were less than 50.
4.4. Experimental Dose Rate of LINAC 119
than MCF-7 cells. The 10% survival doses (D10) in 9L and MCF-7 are 8 Gy
and 3.7 Gy, respectively. The data point of 8 Gy is not included in MCF-7 as
the cells are too sensitive (number of colonies counted were less than 50). It
is not possible to increase the number of cell density for the clonogenic assay
in order to get more than 50 colonies due to the limited size of the flask used
(T12.5 cm2).
Table 4.2 presents the radiobiological parameters and indicates that the 9L
cell line, with ↵= 0.20±0.06 Gy 1 and  = 0.013±0.008 Gy 2, is more radio-
resistant than MCF-7, with ↵= 0.470.03 Gy 1 and  = 0.04±0.007 Gy 2.
These findings are consistent with values published in the literature, which
are ↵= 0.24 Gy 1;  = 0.029 Gy 2 for glioblastomas and ↵= 0.45 Gy 1 and
 = 0.039 Gy 2 for adenocarcinoma [Malaise et al., 1987].
Table 4.2: Summary of cell survival parameters








9L 0.5 0.13± 0.04 0.021± 0.007
5 0.20± 0.06 0.013± 0.008
MCF-7 0.5 0.84± 0.02 0.00
5 0.47± 0.03 0.040± 0.007
4.4.2.3 Cell cycle analysis
In an e↵ort to evaluate whether the observed inverse dose-rate e↵ect is linked to
the proportion of cells in radio-resistant and sensitive phases of the cell cycle, a
FACS analysis was performed. Under asynchronous confluent conditions, the
percentages of cells in G0/G1, S, and G2/M in both cell lines are summarised
in Table 4.3. In the case of the 9L cell line, 64.2% of the population is in
the G0/G1 phase, while MCF-7 has only 58.7%. The percentage of cells in
the S-phase in 9L and MCF-7 is 12.6% and 13.2%, respectively. The percent-
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Figure 4.15: Survival curves of 9L and MCF-7 irradiated at a dose-rate of 5
Gy/min. The data were fitted to the LQ model. Each data point represents
the means ± standard deviation of three independent experiments. 8 Gy data
point is not included in MCF-7 as the cells are too sensitive – number of
colonies obtained were less than 50
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age of 9L cells in G2/M is 23.2%, in contrast to 28.1% of MCF-7 cells in G2/M.
Table 4.3: Summary of cell cycle distribution of unirradiated confluent cell
populations
Cell line G0/G1 (%) S (%) G2/M (%)
9L 64.2 12.6 23.2
MCF-7 58.7 13.2 28.1
4.4.3 Discussions
As is generally true for most glioma cell lines, the 9L cell line is aggressive
and less radio-sensitive than other rat tumour cell lines [Henderson et al.,
1981; Bencokova et al., 2008]. It is the best and most widely used of all rat
brain tumor models for research [Barth, 1998] as well as for preclinical model
used in brain radiotherapy [Vinchon-Petit et al., 2010], it has been utilised in
such experiments for more than 30 years [Kimler, 1994]. The MCF-7 cell line
represents a well adopted pre-clinical model of breast tumour tissue. It has
provided the basis of many breast cancer biology studies [Tutt and Yarnold,
2006] and are relatively more radio-sensitive than the other breast cancer cell
line [Matthews et al., 1989].
No di↵erences in the survival curves of the 9L cell line were observed at dose
rates of 0.5 Gy/min and 5 Gy/min (Figure 4.13). Interestingly, an inverse dose
rate e↵ect was observed for the MCF-7 cells (Figure 4.14), where the lower dose
rate of 0.5 Gy/min induced an increased cell killing compared to that for the
5 Gy/min dose rate. The inverse dose rate e↵ect is complemented with a
linearisation of the cell survival curve when the lower dose rate experiment
at 0.5 Gy/min is performed. The results observed above suggest that the
optimum dose rate radiotherapy can be significantly di↵erent depending on
the tumour cells type.
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Several studies have shown that by decreasing the radiation dose rate, recov-
ery processes are allowed to take place during irradiation (i.e. within the first
few hours). This usually leads to a reduced biological e↵ect Steel [1989]; Hall
[1972]. This traditional key characteristic of the dose-rate e↵ect appears to be
inversed in this study.
The mechanisms underlying the cause of the inverse nature of the dose-rate
e↵ect are not well understood. Possible explanations for this finding could be
that the e↵ect is dependent on the intrinsic radio-sensitivity that varies along
the cell cycle [Ling et al., 1995] at the time of irradiation, the cell type [Fertil
and Malaise, 1981], the doubling time [Mitchell et al., 1979], cell age [Biade
et al., 1997] and, more clinically, the histology type [Ramsay et al., 1992].
Numerous studies have shown that the X-ray induced deficiency in DNA
synthesis depends on the cell cycle phase of cells at the time of irradiation
[Denekamp, 1986; Gri ths and Tolmach, 1975; Rowley and Leeper, 1985]. In
this study, while the mechanism of the change in the e cacy of treatments by
20% is unclear, these positive data support further exploration to investigate
the dose-rate e↵ect on the biological e↵ectiveness of megavoltage X-ray radia-
tion doses.
Radiation sensitivity, expressed as loss of reproductive ability, depends on
the cell cycle phase in which the cells are exposed. The variation in the cell
cycle response to ionising radiation is believed to be due to the intrinsic radio-
sensitivity of some human tumour cells [Biade et al., 1997]. A lower dose
rate would then be expected to be more e↵ective if a phase of the cell cycle
(i.e. G2/M-phase) was correlated with the radio-sensitivity [Knox et al., 1993;
Marples, 2004; Wilson, 2004].
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Numerous studies have found that plateau-phase cultures are generally more
radio-sensitive than exponentially growing cells. On the contrary, some studies
have observed the development of radio-resistance in plateau phase with V79
cells [Durand and Sutherland, 1973] and 9L cells [Mendonca et al., 1989; Kim-
ler and Henderson, 1982]. This condition is minimised in this study since all
experiments were carried out with confluent cultures, where the cell number
remained constant throughout the irradiation.
Flow cytometry experiments were used to evaluate whether the observed in-
verse dose-rate e↵ect is linked to the di↵erences in the intrinsic radiosensitivity
between these two cell lines. FACS analysis was performed to analyse the cell
cycle distribution and DNA content, this indicated that the proportion of cells
in the same phase were similar for the two di↵erent cell lines studies. Cells
are most radiosensitive in phases G2/M, have intermediate radiosensitivity in
G0/G1 and are most radio-resistant in the S-phase [Tubiana et al., 1990]. It is
reasonable then to consider that in vitro radiosensitivity of a cell line may be
influenced by the proportion of cells in the di↵erent phases of the cell cycle.
However, our flow cytometry results indicate that the cells phase distribution
may not play an important role in the observed di↵erences in the radiation
sensitivities of the two cell lines.
This study has potential implications for external radiation delivery tech-
niques, where the dose-rate is greatly increased. It is hypothesised that in
vitro cellular radio-sensitivity is correlated with in vivo tissue response [Dea-
con et al., 1984]. For instance, the ↵ parameter predicts best for intrinsic
radio-sensitivity of tumour cells irradiated at a dose of 2 Gy (SF2) [Fertil and
Malaise, 1981; Malaise et al., 1987].
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The clinical implementation of di↵erent dose-response parameters on biolog-
ically optimised IMRT in breast cancer has been studied by Ferreira et al.
[2008], their results suggest that it can only be maximised by predicting the
individual patient radio-sensitivity. Our studies support that individualised
radiation therapy may significantly increase the benefits for patients with ex-
treme radio-sensitivity or radio-resistance.
Since no single molecular factor has been identified which is common to all the
cancer cell lines that can explain their radiation sensitivity to radiation dose-
rate, an improved understanding of the intrinsic radio-sensitivity and damage
repair mechanisms should lead to personalised enhanced cancer RT treatments.
The results presented in this study may contribute to clinically significant ra-
diobiological e↵ects as the lower dose-rate induced an increased cell killing in
MCF-7 cells. It suggests that some patients with breast cancer would not
benefit from the latest technological advances and would require dose delivery
with a lower dose rate (rather than a higher) for a better treatment outcome.
The various external beam conformal RT techniques such as 3D-CRT, IMRT,
and VMAT have been reviewed for partial breast irradiation (PBI) treatment
[Njeh et al., 2012] and for malignant glioma of the brain [Wagner et al., 2009].
Furthermore, there are many interesting papers in the literature showing that
VMAT, which enables the delivery of higher e↵ective clinical dose-rates, can
be the most e cient treatment option in terms of plan quality and treatment
time (better conformal dose distributions with fewer MUs).
Although VMAT o↵ers the potential to provide improved target coverage and
should be favored because of the shorter treatment time compared to conven-
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tional RT techniques, in vitro experimental evidence specific to VMAT and its
optimisation with the biological response of the tumour is lacking. Therefore,
there is a need for a definitive radiobiological and clinical aspect for VMAT
patient selection. Our data demonstrated that for certain types of cancer cell
lines, a higher e↵ective dose rate can lead to a decreased radiobiological re-
sponse and therefore a less favourable treatment outcome. Hence, even for
radiosensitive patients, the simple treatment technique (i.e 3D-CRT) is su -
cient to maximise the outcome.
It is worth restating that only two dose rates were used in these experiments.
Namely, a low dose rate of 0.5 Gy/min and a dose rate of 5 Gy/min, the latter
is used clinically for external-beam radiotherapy. The radiobiological e↵ect of
the chosen dose rates may di↵er with alternative higher- or lower- dose rate
irradiation. The most important feature of the data presented here is the sig-
nificant di↵erence in response to low dose rate (0.5 Gy/min) irradiation for
the two cell lines. This finding is supportive of the hypothesis that dose rate
e↵ects contribute to clinically significant radiobiological e↵ects.
To investigate whether the results presented here are applicable to other types
of cells with similar radiobiological characteristics (radioresistant or radiosen-
sitive), a variety of dose rates needs to be studied. Furthermore, to confirm
if the proposed relationship between the intrinsic radiosensitivity parameters
and dose rate e↵ects is valid a variety of tumour types should be studied.
4.4.4 Conclusions
The data presented in this study have focused on cell survival following the
delivery of 10 MV X-rays radiation doses at a dose-rate of 0.5 Gy/min com-
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pared to a 10-fold higher dose-rate of 5 Gy/min. To date, there has been no
published literature on any change in the biological e↵ectiveness of 10 MV
X-ray radiation doses in 9L and MCF-7 cell lines with dose-rate. The in vitro
experiments presented in this study show that the lower dose rate induced a
larger e↵ect in cell killing in the MCF-7 cell line.
This observation emphasises the importance of taking into account not only the
physical dose but also the radiobiological responses when planning a particular
cancer treatment and may help clinicians to individualise patient treatment
decisions so as to maximise the e cacy of treatment and hence the clinical
outcome of the RT treatment. The results of this study may provide important
information to predict whether all cancer patients or perhaps only those with
particular tumour types, since we have demonstrated a variation in radio-
sensitivity, will benefit from the new advances in the technologies of RT that
enable the delivery of X-rays with high dose-rates.
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4.5 Utilisation of Nanoparticles
In the following section, there is no attempt to deal with this topic in any
more than a superficial manner. The main objective of this parallel project
was to investigate the possibility of using new modern engineered materials
(i.e. ceramic nanoparticles) for the same function as high-Z elements, either
as radiosensitiser or radioprotectant agents. The investigation of the ceramic
nanoparticle involved the synthesis of the particles, phase and structure charac-
terisation using X-ray di↵raction (XRD) and transmission electron microscopy
(TEM), internalisation and testing cytotoxicity (section 4.3) on both cancer
cells (9L) and non-malignant cells (MDCK) as well as exploring the e↵ect on
di↵erent energies of the X-rays beam. There are three ceramic nanoparticles
currently under investigation by the TNT team: cerium oxide (CeO2), tanta-
lum pentoxide (Ta2O5), and bismuth oxide (Bi2O3).
4.5.1 Introduction
Nanomaterials, commonly called as nanoparticles, are very attractive for both
basic science and technologies (i.e. nanotechnology). With the rapid growth
of nanotechnology, engineered nanomaterials are providing new opportunities
that can improve therapeutic ratio in medical field such as by targeting cancer
cells and limiting cytotoxicity to healthy normal tissue. An example of this
is in indirect radiation therapy (IRT) (Figure 4.16), which inactivates cancer
cells by secondary radiation products evolving from incorporated target mate-
rial inside the body upon specific absorption of an external radiation therapy
beam (one of the possible methods, known as photon activation therapy – PAT
is defined later in detail in section 4.6).
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Figure 4.16: Schematic representation of high-Z secondary radiation mecha-
nism (also known as indirect radiation therapy, IRT) [Nawroth et al., 2008]
.
4.5.2 Results – Cerium Oxide (CeO
2
)
4.5.2.1 Phase and structural characterisation of CeO2
The biochemical e↵ects of nanoparticles are dependent on their structural and
physical characteristics. Characteristics of particular interest include phase
composition, structure and crystallite size.
Figure 4.17A shows first order di↵raction peaks that have been labeled by
correlating recorded data against the ICSD (PDF card no. 01-089-8436). The
cerium oxide nanoparticles phase is confirmed to exist as CeO2. This phase
is known to provide protection against radiation [Madero-Visbal et al., 2012;
Colon et al., 2009; Rzigalinski et al., 2003; Tarnuzzer et al., 2005]. The CeO2
NP sample has a simple cubic crystalline structure with a single lattice pa-
rameter, a = 5.4112 Å. The average crystallite size can be extracted from the
XRD peaks using Scherrers equation [Patterson, 1939] (Eq. 3.1).
The average crystallite size was calculated to lay in the range of 6 – 8 nm,
which is consistent with the crystallite sizes observed in the TEM image (Fig-
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Figure 4.17: (A) XRD spectrum and (B) high resolution TEM of the CeO2
NP sample synthesised by spray pyrolysis with size between 6-8 nm. Data
was acquired using an automated GBC R eMMA X-ray Di↵ractometer. X-ray
di↵raction peaks were assigned Miller indices in correlation with the ICSD
Briggs et al. [2013].
ure 4.17B). This shows clear lattice fringes with a fringe spacing (d) of 3.15 Å,
which corresponds to the distance between the 111 lattice planes of CeO2.
4.5.2.2 Internalisation determination of CeO2
The internalisation or cellular uptake of the CeO2 nanoparticles was analysed
using flow cytometry (Figure 4.18). The flow cytometry analysis of side scat-
ter (SSC), a parameter that indicates the internal complexity or granularity of
the cells, showed that nanoparticle internalisation correlates with an increase
in cell side scatter [Celardo et al., 2011]. The CeO2 NPs a↵ected the cell side
scatter, evidenced by the increase of sparseness on the dot plots (Figure 4.18)
and the increase of SSC mean value of 393 to 734.
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Figure 4.18: Flow cytometric analysis of forward scatter (FSC) and side scatter
(SSC) of 9L cells incubated for 24 hours with 50 µg/ml cerium oxide (CeO2)
(right) and its control of untreated cells (left).
4.5.2.3 E cacy of CeO2 nanoparticles – influence of di↵erent X-ray
beams
As mentioned earlier in section 3.1.5.2, based on the atomic number of CeO2 Z
= 54, 150 kVp X-rays energy is believed to maximise the probability of inter-
action between X-ray and the high-Z atoms of CeO2. The peak of absorption
of CeO2 contrast relative to water in the spectrum around 50 keV is illustrated
in Figure 4.19 and it matches with the 150 kVp spectrum output defined in
section 3.1.5.2 (Figure 3.4) with the e↵ective energy of 65 keV.
Consequently, 9L cells were exposed to a range of doses up to 8 Gy using
the 150 kVp, 6 MV, and 10 MV X-ray beam to probe the e↵ectiveness of
CeO2 NPs. Clonogenic assays were then performed to obtain radiation sur-
vival curves. The results show that the 9L cell line has a response that varies
with treatment beam energy (Figures 4.20 – 4.22).
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Figure 4.19: Ratio of the mass energy absorption coe cient of CeO2 to water
relative to photon energy (MeV) [Briggs, 2011].
150 kVp irradiation The survival curves of 9L cells following irradiation
with 150 kVp alone and radiation combined with CeO2 NPs (50 µg/ml for 24
hours) are presented in Figure 4.20. This shows that CeO2 NPs had a radiation
enhancement e↵ect on cells, instead of providing protection against radiation.
A comparison of the 10% surviving fraction of cells in the presence and absence
of CeO2 NPs induced a sensitisation enhancement ratio (SER10) of 1.02. This
is also reflected in the ↵ value (±SD) for 9L cells irradiated with CeO2 NPs
(0.302±0.042 Gy 1) being higher than that of irradiated cells without CeO2
NPs (controls) (0.212±0.025 Gy 1) at 150 kVp (Table 4.4).
6 MV photon beam Irradiation The survival curves of 9L cells following
irradiation with 6 MV alone and radiation combined with CeO2 NPs (50 µg/ml
for 24 hours) are presented in Figure 4.21. This shows that CeO2 exhibits ra-
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Figure 4.20: Radiation dose-survival curves of confluent cultures of 9L cells
after irradiation with 150 kVp photon beam at a dose rate of approximately
75 MU/min, with or without 50 µg/ml cerium oxide (CeO2) treatment for 24
hours using T12.5 cm2 flask with a 6 mm depth of medium. Each data point
represents the means ± standard deviation of three independent experiments.
Experimental results modified from Briggs et al. [2013].
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diation protection. Instead of (SER10), a comparison of the 10% surviving
fraction of cells in the presence and absence of CeO2 NPs induced a protection
enhancement ratio (PER10) of 1.07. This is also reflected in the lower ↵ value
(±SD) for 9L cells irradiated with CeO2 NPs (0.193±0.015 Gy 1) compared
to irradiated cells without CeO2 NPs (controls) (0.220±0.021 Gy 1) at 6 MV
Table 4.4. This confirms the radioprotective ability of CeO2 NPs.
Table 4.4: Values of the linear-quadratic model parameters ↵ and   from 9L
cells treated with ionising radiation only and combined CeO2 NP plus radiation
survival curves at energies 150 kVp, 6 MV, and 10 MV. XIR = radiation only;
CeO2 NP = cerium oxide nanoparticles (50µg/ml).
Energies Treatment ↵ (Gy) 1   (Gy) 2
150 kVp XIR 0.212± 0.025 0.009± 0.004
CeO2 NP 0.302± 0.042 0.000± 0.007
6MV XIR 0.220± 0.021 0.021± 0.003
CeO2 NP 0.193± 0.015 0.016± 0.003
10MV XIR 0.200± 0.060 0.0013± 0.008
CeO2 NP 0.060± 0.040 0.019± 0.005
10 MV photon beam irradiation The survival curves of 9L cells follow-
ing irradiation with 10 MV alone and radiation combined with CeO2 NPs (50
µg/ml for 24 hours) are presented in Figure 4.22. This shows that when ir-
radiated with 10 MV, CeO2 provides a protective e↵ect to 9L cells. This is
evidenced by the higher surviving fraction of 9L cells at all doses in the pres-
ence of CeO2 NPs compared to the irradiated controls only (Figure 4.22). A
PER10 value of 1.23 is achieved during the 10 MV treatment, again confirming
the radioprotective ability of CeO2 NPs. This is also reflected in the lower ↵
value (±SD) for 9L cells irradiated with CeO2 NPs (0.060±0.040 Gy 1) com-
pared to irradiated cells without CeO2 NPs (controls) (0.200±0.060 Gy 1) at
10 MV (Table 4.4). Table 4.4 summarises the LQ parameters of 9L cells ob-
tained following analyses of the radiation dose-survival curves for irradiation
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Figure 4.21: Radiation dose-survival curves of confluent cultures of 9L cells
after irradiation with a 6 MV photon beam at a dose rate of 5 Gy/min, with
or without 50 µg/ml cerium oxide (CeO2) treatment for 24 hours using T12.5
cm2 flask filled with HBSS. Each data point represents the means ± standard
deviation of three independent experiments. Experimental results modified
from Briggs [2011].
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alone and following combined irradiation and CeO2 NPs at energies of 150
kVp, 6 MV, and 10 MV.





4.5.3.1 Phase and structural characterisation of Ta2O5
The XRD pattern for tantalum pentoxide nanoparticles, with the crystal planes
of reflection corresponding to each peak, is shown in (Figure 4.23A). The peak
analysis of the resulting di↵raction pattern established the presence of a single
beta Ta2O5 phase, orthorhombic in nature with parameters a= 6.20 Å, b=3.66
Å, and c=3.89 Å(PDF card no. 01-089-2843).
The average crystallite size was calculated to be 56 nm, consistent with the
crystallite sizes observed in the TEM image (Figure 4.23B). This revealed that
the average crystallite size observed is relatively large compared to the cerium
oxide nanoparticles (6 – 8 nm as in section 4.5.2).
4.5.3.2 Internalisation determination of Ta2O5
The internalisation or the cellular uptake of Ta2O5 NPs were analysed using
flow cytometry (Figure 4.24). Unlike CeO2, this showed that the Ta2O5 NPs
did not a↵ect cell side scatter, as evidenced by only a slight increase in the
mean SSC value from 451 to 499. This is consistent with the TEM image (Fig-
ure 4.23B) that the majority of the Ta2O5 NPs aggregates are too big to be
internalised within the cells. The slight increase in SSC observed was probably
due to the e↵ect of the size distributions. The aggregates of the smaller Ta2O5
NPs in latter confocal laser scanning microscopy experiments confirmed that
the nanoparticles had been internalised by the 9L cells (Figure 4.47, section
4.8).
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Figure 4.22: Radiation dose-survival curves of confluent cultures of 9L cells
after irradiation with a 10 MV photon beam at a dose rate of 5 Gy/min, with
or without 50 µg/ml cerium oxide (CeO2) treatment for 24 hours using T12.5
cm2 flask filled with HBSS. Each data point represents the means ± standard
deviation of three independent experiments. Experimental results modified
from Briggs et al. [2013].
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Figure 4.23: (A) XRD spectrum and (B) high resolution TEM of the Ta2O5 NP
sample. Data was acquired using an automated GBC R eMMA X-ray Di↵rac-
tometer. X-ray di↵raction peaks were assigned Miller indices in correlation
with the ICSD [Brown et al., 2013].
4.5.3.3 E cacy of Ta2O5 nanoparticles – influence of di↵erent X-
ray beams
As mentioned earlier in section 3.1.5.2, based on the atomic number, Z =
73 for tantalum (Ta), the 150kVp X-rays energy is believed to maximise the
probability of interaction between X-rays and the high-Z atoms of Ta2O5. The
peak of absorption of Ta2O5 contrast relative to water in the spectrum around
60 keV is illustrated in Figure 4.25 and it matches with the 150 kVp spectrum
output defined in section 3.1.5.2 (Figure 3.4) with the e↵ective energy of 65
keV.
150 kVp irradiation The survival curves of 9L cells following irradiation
with 150 kVp alone and radiation combined with Ta2O5 NPs (50 µg/ml for 24
hours) are presented in Figure 4.26. This shows that Ta2O5 NPs had a radia-
tion enhancement e↵ect on cells. A comparison of the 10% surviving fraction
of cells in the presence and absence of Ta2O5 NPs induced a sensitisation
enhancement ratio (SER10) of 1.07 (no sensitisation). This is also reflected
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Figure 4.24: Flow cytometric analysis of forward scatter (FSC) and side scatter
(SSC) of 9L cells incubated for 24 hours with 50 µg/ml tantalum pentoxide
(Ta2O5) (right) and its control of untreated cells (left).
Figure 4.25: Ratio of the mass energy absorption coe cient of Ta2O5 to water
relative to photon energy [Brown, 2011].
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in the ↵ value (±SD) for 9L cells irradiated with Ta2O5 NPs (0.319±0.045
Gy 1) being higher compared to irradiated cells without Ta2O5 NPs (controls)
(0.301±0.043 Gy 1) at 150kVp (Table 4.5).
6 MV irradiation The survival curves of 9L cells following irradiation with
6 MV alone and radiation combined with Ta2O5 NPs (50 µg/ml for 24 hours)
are presented in Figure 4.27. This shows that Ta2O5 has a radiation enhance-
ment e↵ect on cells. A comparison of the 10% surviving fraction of cells in
the presence and absence of Ta2O5 NPs induced a sensitisation enhancement
ratio (SER10) of 1.07. This is also reflected in the ↵ value (±SD) for 9L cells
irradiated with Ta2O5 NPs (0.335±0.055 Gy 1) being higher compared to the
value for irradiated cells without Ta2O5 NPs (controls) (0.300±0.021 Gy 1) at
6 MV (Table 4.5).
10 MV irradiation The survival curves of 9L cells following irradiation
with 10 MV alone and radiation combined with Ta2O5 NPs (50 µg/ml for 24
hours) is shown in Figure 4.28. This shows that Ta2O5 had a radiation en-
hancement e↵ect on cells. A comparison of the 10% surviving fraction of cells
in the presence and absence of Ta2O5 NPs induced a sensitisation enhance-
ment ratio (SER10) of 1.33, which is higher than the corresponding values at
the other two lower energies. This is also reflected in the ↵ value (±SD) for 9L
cells irradiated with Ta2O5 NPs (0.381±0.040 Gy 1) being higher compared to
the value of irradiated cells without Ta2O5 NPs (controls) (0.187±0.045 Gy 1)
at 10 MV (Table 4.5).This confirms a significant degree of radiation dose en-
hancement.
4.5. Utilisation of Nanoparticles 140
Figure 4.26: Radiation dose-survival curves of confluent cultures of 9L cells
after irradiation with 150 kVp photon beam at a dose rate of approximately
75 MU/min, with or without 50 µg/ml tantalum pentoxide (Ta2O5) treatment
for 24 hours using T12.5 cm2 flask with a 6 mm depth of medium. Each
data point represents the means ± standard deviation of three independent
experiments. Experimental results modified from [Brown et al., 2013].
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Figure 4.27: Radiation dose-survival curves of confluent cultures of 9L cells
after irradiation with a 6 MV photon beam at a dose rate of 5 Gy/min, with
or without 50 µg/ml tantalum pentoxide (Ta2O5) for 24 hours using T12.5
cm2 flask filled with HBSS. Each data point represents the means ± standard
deviation of three independent experiments. Experimental results modified
from [Brown et al., 2013].
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Figure 4.28: Radiation dose-survival curves of confluent cultures of 9L cells
after irradiation with a 10 MV photon beam at a dose rate of 5 Gy/min, with
or without 50 µg/ml tantalum pentoxide (Ta2O5) for 24 hours using T12.5
cm2 flask filled with HBSS. Each data point represents the means ± standard
deviation of three independent experiments. Experimental results modified
from [Brown et al., 2013].
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Table 4.5: Values of the linear-quadratic model parameters ↵ and   from 9L
cells treated with ionising radiation only and combined Ta2O5 NP plus radia-
tion survival curves at energies 150 kVp, 6 MV, and 10 MV. XIR = radiation
only; Ta2O5 NP = tantalum pentoxide nanoparticles (50µg/ml). N/A = Not
applicable.
Energies Treatment ↵ (Gy) 1   (Gy) 2
150 kVp XIR 0.301± 0.043 0.001± 0.006
Ta2O5 NP 0.319± 0.045 0.001± 0.007
6MV XIR 0.300± 0.021 N/A
Ta2O5 NP 0.335± 0.055 0.002± 0.010
10MV XIR 0.187± 0.045 0.012± 0.009
Ta2O5 NP 0.381± 0.040 N/A





The investigation of using bismuth oxide (Bi2O3) nanoparticles by the TNT
is still preliminary. The investigations of Bi2O3 NPs in the present study only
include: the synthesis of the particles, phase and structure characterisation
using di↵erent techniques (i.e. XRD and TEM), internalisation and testing
the cytotoxicity on both cancer cells (9L) and non-malignant cells (MDCK).
The cytotoxicity was described before in section 4.3.
4.5.4.1 Phase and structural characterisation of Bi2O3
The XRD pattern for bismuth oxide nanoparticles synthesised using the precip-
itate method in argon (530 C) and air (570 C) annealed are shown in Figure
4.29. Data was acquired using an automated GBC R eMMA X-ray Di↵rac-
tometer. X-ray di↵raction peaks were assigned Miller indices in correlation
with the ICSD. The Bi2O3 is included here as it is also currently used because
its smaller size was observed.
The average crystallite size was calculated to lay in the range 63 – 69 nm and
42 – 55 nm for Bi2O3 NPs synthesised via the precipitation method in argon
and citrate gel method, respectively. They are consistent with the crystallite
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Figure 4.29: XRD spectrum of Bi2O3 NP via precipitate in argon and air an-
nealed; high resolution TEM (insert). Data was acquired using an automated
GBC R eMMA X-ray Di↵ractometer. X-ray di↵raction peaks were assigned
Miller indices in correlation with the ICSD [Stewart et al., 2014].
sizes observed in the TEM image Figure 4.30 for both methods, which were flat
plates with a micron sized diameter but extremely thin as shown in Figure 4.30.
4.5.4.2 Internalisation of Bi2O3
The internalisation or cellular uptake of the Bi2O3 NPs were analysed using
flow cytometry (Figure 4.31). As for Ta2O5, this shows that the Bi2O3 NPs
did not a↵ect cell side scatter, as evidenced by only a slight increase in the
mean SSC value (Figure 4.31).
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Figure 4.30: TEM image of Bi2O3 [Stewart, 2012].
Figure 4.31: Flow cytometric analysis of forward scatter (FSC) and side scatter
(SSC) of 9L cells incubated for 24 hours with 50 µg/ml bismuth oxide (Bi2O3)
(right) and its control of untreated cells (left).
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4.5.5 Discussion
4.5.5.1 Cerium Oxide (CeO2)
Investigations using CeO2 NPs explore characteristics such as its biocompat-
ibility or toxicity [Lin et al., 2006; Sager et al., 2007; Buzea et al., 2007], the
ability to provide protection against radiation by scavenging free radicals and
the selective nature of its protection to normal and cancer cells [Tarnuzzer
et al., 2005]. However, to date, the understanding of its e↵ectiveness across a
range of beam energies has not been reported in the literature.
Cerium oxide nanoparticles also known as nanoceria are redox-active metal
oxide nanoparticles, which are used as protection against radiation-induced
damage [Rzigalinski et al., 2003] and in antioxidant therapy [Celardo et al.,
2011]. Nanoceria act as antioxidant because the presence of the mixed valence
states of Ce3+ and Ce4+, as induced by the oxygen vacancies [Tarnuzzer et al.,
2005; Celardo et al., 2011] and provide long term scavenging of reactive oxygen
species (ROS) [Rzigalinski et al., 2006].
The application of CeO2 NPs to clinical radiation protection has been the
subject of numerous studies [Madero-Visbal et al., 2012; Colon et al., 2009;
Rzigalinski et al., 2003; Tarnuzzer et al., 2005]. In this study, CeO2 NPs were
synthesised using a spray pyrolysis techniques for their application in radiation
protection. It was proposed that CeO2 NPs e cacy to function as a radiopro-
tector is dependent upon the energy of the X-rays used during treatment; we
investigated this energy-dependence using 150 kVp X-ray, 6 MV and 10 MV
photon beams.
Characterisation of the synthesised sample using XRD revealed important
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properties that are essential for our application. Figure 4.17A shows that
we have CeO2 NPs sample with a single cubic phase, existing as CeO2 upon
comparison with the ICSD, with a mean crystallite measured in the range of
6 – 8 nm.
Figure 4.21 and 4.22 clearly indicate that the CeO2 NPs provide protection
against radiation-induced damage to 9L cells when irradiated with 6 and 10
MV photon beams, respectively. This radioprotection is supported by the de-
crease in ↵ values following the using of CeO2 compared to irradiation alone
(Table 4.4).
Intriguingly, this study showed that 9L cells have a slight reduction in survival
rate when exposed with CeO2 NPs combined with 150 kVp X-rays in compar-
ison with the exposure to 6 MV and 10 MV combination. A small increase
in ↵ values was observed. This is also reflected in the linearisation of the cell
survival curve in figure 4.20, which suggests that CeO2 NPs enable more di-
rect damage e↵ects to occur at this treatment beam energy. We explained this
energy dependent e cacy through a counterbalance between the free radical
scavenging ability of CeO2 and the increased RBE of lower energy radiations,
which is in part influenced by the macroscopic dose enhancement from the
mass-energy absorption of CeO2 [McMahon et al., 2008, 2011; Robar et al.,
2002].
It is important to consider photoelectric interactions for high-Z compounds
[Attix, 2004] such as nanoparticles (e.g. Figure 4.20) and also the drugs used
in next sections (i.e. BrUdR). Energies around the K-edge maximise the prob-
ability of interaction with X-rays and Ce atoms, which leads to an increased
production of Auger electron cascades. These Auger electrons increase the
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average LET of the resultant secondary particles, maximising the e ciency of
these radiations through denser ionisations. This imparts more direct damage,
which in turn reduces the abundance of reactive oxygen species (ROS) respon-
sible for indirect damage [Tubiana et al., 1990].
4.5.5.2 Tantalum pentoxide (Ta2O5) and bismuth oxide (Bi2O3)
The use of Ta2O5 nanoceramics as novel candidates for dose enhancement
radiotherapy is one of our pioneering studies. Ta2O5 acts as biocompatible
radiation assistance high-Z agents, this finding lead to the research on Bi2O3
being used for the same function as Ta2O5.
From XRD experiments, the average particle size of our Ta2O5 NPs was 56
nm. For Bi2O3, the average size was in the range of 63 – 69 nm (synthesised
via precipitation method) and 42 – 55 nm (synthesised via citrate gel method).
Their values are both relatively large compared to the value for CeO2 (i.e. 6 –
8 nm). This is also shown in the flow cytometric analysis on 9L cells, where
the cellular uptake of CeO2 was observed but not Ta2O5 or Bi2O3.
The higher the atomic number (Z) the higher the probability that an increased
photoelectric absorption would occur due to photoelectric e↵ect is dominant
at kilovoltage beam energies. The photoelectric component of the mass energy
absorption coe cient is approximately proportional to the Z3 (Eq. 2.1).
The observed energy dependence of radiosensitisation in Ta2O5 is contrary
to the results observed in CeO2, both above as well as in a later section with
BrUdR, the sensitisation enhancement ratio is increase as the energies increase
for Ta2O5 (SER10 at 150 kVp is lower than SER10 at 6 and 10 MV energies).
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This should not be confused with the PER10 observed in CeO2, as the same
terminology used represents as no SER10 observed in MV energies. This can
be explained by an internalisation mechanism, where smaller particles such as
CeO2 are more likely to be internalised by the cells and therefore can settle
closer to the DNA. This closer proximity allows more low energy secondary
electrons (low range, high LET) to induce double strand breaks (DSB) due
to their close proximity (more details as obvious in the use of BrUdR later in
section 4.6 where they incorporated into DNA).
Another possible mechanisms to explain this inverse behaviour involves backscat-
tered electron dose enhancement, which is a well known phenomenon in radia-
tion therapy with MV photon beams (i.e titanium hip prostheses) [Reft et al.,
2003]. As with the increasing size and Z number of the NPs aggregates and
decreasing electron energy, the backscattering mechanism increases suggests
that the dose enhancement tail is produced mostly by lower energy electron,
which additionally can be associated with an increase in RBE. At 6 MV, less
secondary electrons are produced than at 10 MV, which leads to a lower SER
in general.
To our knowledge, there is currently no published research regarding the use of
Ta2O5 NPs in dose enhancement radiotherapy. Compared to research on gold
NPs, which have the greater ability to be internalised due to their much smaller
size (1.9 nm) [Butterworth et al., 2010] and concentrated (up to 100 µg/ml)
on more relative radiosensitive cell line MDA-MB-231 [Jain et al., 2011], our
results with the larger sized Ta2O5 NPs on more radioresistant cells, 9L, are
extremely interesting.
As in the case of Bi2O3, we expected its function in dose enhancement radio-
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therapy should be similar for Ta2O5, due to the value of Z = 83 for bismuth
and its average large size. In general, our results suggest that the optimum
condition for nanoparticles used as a radiosensitiser (i.e Ta2O5 and Bi2O3) is
that they should be evenly distributed throughout the tumour, and be taken
up by tumour cells. Thus, the size of the NPs has the most dominant e↵ect
on the distribution and uptake.
4.5.6 Conclusions
In the case of CeO2 (a known radioprotector) investigation on 9L cells at con-
centration of 50 µg/ml showed significant nanoparticles internalisation. In
addition, radioprotection was observed with a protection enhancement ratio
(PER) of 1.23 when irradiated in a 10 MV photon field. The high-Z prop-
erty of the nanoparticle revealed itself under kilovoltage (150 kVp) irradiation
fields where the net radioprotection was reduced to zero (i.e. PER = 1.00). It
was concluded that there exists a trade o↵ between the radioprotection and
radiosensitisation properties of the CeO2 nanoparticle. The radiosensitisation
was thought to be most prominent at 150 kVp as the nanoparticle is inter-
nalised by the 9L cells where low energy secondary electron scattering and
auger electron emission from the nanoparticle would be expected to be most
e↵ective leading to 9L cell death.
In order to try and isolate the radiosensitising component of nanoparticles, a
Ta2O5 nanoparticle was developed at TNT as a pure radiosensitiser. At an
nanoparticle concentration of 50 µg/ml (so as to directly to compare with the
CeO2 radioprotector nanoparticle), no internalisation of the nanoparticle was
measured by flow cytometry, which was consistent with the nanoparticle size
deduced from high resolution TEM. Significant radiosensitisation of the 9L
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cells was apparent under irradiation in a 10 MV photon field with an SER
of 1.33 measured. This radiosensitisation reduced to zero at 150 kVp (SER
=1.07). The less e↵ectiveness of radiosensitisation at 150 kVp is consistent
with that expected from the flow cytometry results in combination with the
interpretations from the CeO2 nanoparticle experiments. In the case of the
Ta2O5 nanoparticle, it is thought that the sensitisation is most predominant
in the 10 MV photon field due to the low energy secondary electron scattering
(leading to a very lethal radiation field) combined with the increased secondary
electron production (simply due to the presence of the high-Z nanoparticle).
In light of the Ta2O5 excellent result, an ultrahigh-Z radiosensitiser was de-
signed and produced in the form of Bi2O3, (which is still currently under
investigation at the time of writing this thesis). Cytotoxicity on the 9L glioma
cell line show great potential as a radiosensitiser in radiation therapy. The
flow cytometry data indicates that, similar to Ta2O5, the Bi2O3 will not be
significantly internalised in the 9L cells and therefore is expected to be most
e↵ective at the higher X-ray energy radiotherapy fields.
Although there are still challenges to be addressed (i.e. further refinement and
optimisation of the NPs in terms of particle size, aggregation, and concen-
tration), the ceramic NPs used in this study have shown great promise for
the development of e↵ective therapeutic materials such as radioprotectant for
CeO2 and radiosensitiser for successful treatment of the radioresistant cancer
cells in the cases of Ta2O5 and Bi2O3.
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4.6 Chemo-Auger Approach Part 1: BrUdR,
MTX, and X-rays at 125 kVp
This section focuses on the enhancement of the e cacy of kilovoltage X-ray
therapy by optimising the combination of chemotherapy drugs (BrUdR and
MTX) with external X-rays irradiation (125 kVp radiation field). As men-
tioned earlier in section 3.1.5.2, it is hypothesised that the optimal energy for
this study is 125 kVp. (The e↵ective energy calculation based on the available
filter range at the radiation oncology department, Prince of Wales Hospital).
4.6.1 Background
Need for improved radiotherapy protocols
The treatment of malignant brain tumours remains a major challenge, as the
most common brain tumour malignancies tend to recur despite significant ad-
vances in surgical techniques including radiation delivery, and chemotherapy.
One of the most di cult challenges in the treatment of brain tumours is selec-
tivity, i.e. to develop a treatment that is specific to tumours cells and which
therefore maximises the e↵ectiveness of the tumour treatment (better local
control) while minimising damage to normal healthy cells as much as possible.
Improvements in radiation dose delivery and more e cient cancer cell killing
are needed for targeted cancer treatment. These may provide an improvement
in local tumour control and reduce tumour recurrence. For instance, the im-
provement achieved with photon activation therapy (PAT) which utilises high
linear energy transfer (LET) radiations in the form of Auger electron distribu-
tions through photoactivation of a high Z-radiosensitiser atoms incorporated
into cancer cell DNA as part of a drug.
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The main study was designed to investigate a new modality for radioresistant
tumour treatments (e.g. high-grade glioma) by using the synergy of pharmaco-
logical drugs with radiation. The aim is to allow either for a reduction in the
prescribed dose of both radiation and the chemo-drugs, leading to the sparing
of critical organs, or to allow one to achieve a higher dose to the target volume
by increasing the lethal damage to tumour so as to improve local control.
A method that has been proposed to enhance the e↵ect of ionising radiation
is the addition of a high-Z atom loaded compound [Le Sech et al., 2000, 2001;
Kobayashi et al., 2002]. The novel approach of this project was to define and
optimise the process of increasing the absorbed dose to a target by investi-
gating materials with high atomic number (i.e. bromine), locally in the region
of target cancer cells. As described in section 2.4, X-rays can interact with
tissues containing such elements via the photoelectric e↵ect, which may induce
Auger e↵ects (and Auger electrons), resulting in the enhancement of the dose
delivered to the tissue. Chemotherapy drugs are combined with X-ray therapy
leading to a novel chemo-Auger methodological route to synergetic treatment.
4.6.2 Brief History of BrUdR Usage
There have been much research carried out in the past into the use of halo-
genated pyrimidine (e.g. BrUdR and IUdR) as a radiosensitiser drug. The
following paragraphs discuss the history of the research on BrUdR combined
with radiation as well as with antimetabolites.
In the early 1960s, Djordjevic and Szybalski first reported that the incorpo-
ration of BrUdR and IUdR into mammalian cells D98S in vitro [Djordjevic
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and Szybalski, 1960]. This researchers enhanced the sensitivity to ultraviolet
(UV) and X-ray irradiation of the cells then followed by others [Delihas et al.,
1962; Kriss and Revesz, 1962; Kaplan et al., 1962; Erikson and Szybalski, 1961;
Berry and Andrews, 1962]. In the present study, the enhanced radiosensitiv-
ity e↵ects of BrUdR to external X-ray irradiation was confirmed using 9L rat
gliosarcoma cells.
BrUdR has been used in the treatment of patients with malignant brain
tumours starting with work by by Japanese researchers [Sano et al., 1968;
Hoshino and Sano, 1969], who also tried to infuse it with antimetabolites. The
rationale of adding the antimetabolite was that the inhibition of thymidine
synthesis by the antimetabolite would increase the uptake of the halogenated
pyrimidine analogs, BrUdR, into DNA. It was expected to selectively increase
the sensitivity of tumour cells to radiation because these analogs were expected
to selectively incorporate into the DNA of dividing cells, which are present in
higher number in tumour cells than in normal cells [Sano et al., 1965, 1968;
Hoshino and Sano, 1969; Bagshaw et al., 1967; Brown et al., 1971]. Theoret-
ically, this halogenated pyrimidine is expected to optimally sensitise rapidly
growing tumors that are surrounded by non-proliferative normal tissues such
as in the case of brain tumors.
Fairchild et al. [1982] were the first to propose photon activation therapy (PAT)
as a technique in which high LET radiation, in the form of Auger electron dis-
tributions, are generated through the photoactivation of stable iodine atoms
incorporated in DNA via iododeoxyuridine (IUdR). The idea was develop fur-
ther investigated by Fairchild and Bond [1984], who concluded that a photon
energy just above the K-absorption edge of iodine was optimal. In 1993, Laster
et al. proposed PAT as a promising form of cancer therapy to improve the
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treatment of malignancies, particularly the highly lethal and malignant brain
tumour glioblastoma multiform (GBM).
In 2004, Corde et al. proposed this PAT concept in the presence of iodine
compounds and irradiate with energy just above the K-absorption edge of
iodine (33.2 keV). They succeeded in demonstrating that photons with an en-
ergy of 50 keV were the most e↵ective energy. Then in 2009, Laster et al.
proposed to improve the treatment of tumour malignancies by using photons
from palladium-103 (103Pd) seeds targeted to the L-absorption edge of plat-
inum (Pt) atoms, which bound to the cancer cells DNA [Laster et al., 2009].
As mentioned earlier, the novel idea of our main study is to investigate the
enhanced radiosensitising e↵ect of BrUdR. Such enhancement is achieved by
the addition of a small amount of antimetabolite (i.e. MTX or 5-FU) that
increases the uptake of BrUdR into the cells. The aims of the first part of this
study were:
• To establish irradiation conditions for the optimal enhancement of the
chemo Auger therapy using conventional kilovoltage X-ray beams from
an accessible clinical orthovoltage machine.
• To compare the radiation cell survival curves (with and without drugs)
and obtain the sensitisation enhancement ratio at 10% survival fraction
(SER10).
• To quantify the level of BrUdR incorporation in the DNA (with and
without MTX) and investigate any correlation of this with clonogenic
survival.
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4.6.3 Results
4.6.3.1 Radiosensitisation of BrUdR on 9L cells with X-rays energy
of 125 kVp
The survival curves for 9L cells following radiation alone and radiation com-
bined with BrUdR (10 µM for 72 hours) are presented in Figure 4.32. The
data shows that BrUdR administered concomitantly with 125 kVp X-rays ir-
radiation enhanced the biological e↵ect of the X-ray irradiation by reducing
the clonogenic survival of 9L cells (Figure 4.32) This is reflected in the ↵ value
(±SD) for 9L cells irradiated with BrUdR (↵=0.295±0.036 Gy 1) being higher
then that of irradiated cells without BrUdR (controls) which gave a value of
↵=0.213±0.019 Gy 1.
4.6.3.2 Radiosensitisation of methotrexate on 9L cells with X-rays
energy of 125 kVp
The survival curves for 9L cells following radiation alone and radiation com-
bined with MTX (0.01 µM for 72 hours) are presented in Figure 4.33. This
shows that MTX administered concomitantly with 125 kVp X-rays irradia-
tion led to no enhanced sensitisation e↵ect of the x-ray irradiation on the
clonogenic survival of 9L cells (Figure 4.33). This is reflected in the ↵ value
(±SD) for 9L cells irradiated with MTX (↵=0.191±0.013 Gy 1), which is not
significantly di↵erent compared to irradiated cells without exposure to MTX
(↵=0.213±0.019 Gy 1).
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Figure 4.32: Radiation dose-survival curves of confluent cultures of 9L cells
after irradiation at energies of 125kVp, with and without exposure to 10 µM
BrUdR for 72 hours. Normalised of data for BrUdR-treated cells was done
with unirradiated, BrUdR-treated cells sample. Each data point represents the
means ± standard deviation (±SD) of at least three independent experiments.
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Figure 4.33: Radiation dose-survival curves of confluent cultures of 9L cells
after irradiation, at energies of 125 kVp, with or without 0.01 µM MTX treat-
ment for 72 hours. Normalised of data for MTX-treated cells was done with
unirradiated, MTX-treated cells sample. Each data point represents the means
(±SD) of at least three independent experiments.
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4.6.3.3 Influence of methotrexate on radiosensitising e↵ect of BrUdR
The results for the combined BrUdR (10 µM) and MTX (0.01 µM) adminis-
tered concomitantly with 125 kVp X-rays irradiation on 9L cells is shown in
Figure 4.34. This shows a cell kill greater than that given by the sum of the
results obtained from the individual agents alone, with a significant increase
of the ↵-value to 0.486±0.068 Gy 1.
To clearly illustrate the synergistic e↵ect of the combination of X-ray treat-
ment with dual drug exposure, Figure 4.35 shows the cell survival curves of
the 9L cells after irradiation with 125 kVp x-rays and/or combined with 0.01
µM MTX alone, 10 µM BrUdR alone, or 0.01 µM MTX and 10 µM BrUdR.
Table 4.6 summarises the LQ parameters of 9L cells obtained following analy-
ses of the radiation dose-survival curves for irradiation alone and the combined
irradiation and drugs at a X-ray photon energy of 125 kVp. These data support
the conclusion that radiosensitisation by halogenated pyrimidines (i.e. BrUdR)
is mainly due to an increase in the linear parameter ↵ with the quadratic pa-
rameter   unchanged. This is consistent with the work of Franken et al. [2013]
who showed that   is not expected to be significantly influenced.
The sensitisation enhancement ratio at 10% surviving fraction (SER10) were
also calculated. The SER of irradiated BrUdR plus MTX-treated cells (2.3)
was higher than either BrUdR-treated (1.6) or MTX-treated (1) alone. Thus,
the e↵ects of combined BrUdR plus MTX appears to be supra additive.
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Figure 4.34: Radiation dose-survival curves of confluent cultures of 9L cells
after irradiation at energies of 125 kVp, with or without drugs combination
(0.01 µMMTX and 10 µMBrUdR) treatment for 72 hours. Normalised of data
for drugs-treated cells was done with unirradiated, drugs-treated cells sample.
Each data point represents the means (±SD) of at least three independent
experiments.
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Figure 4.35: Radiation dose-survival curves of confluent cultures of 9L cells
after irradiation at energies of 125 kVp, with or without drugs (0.01 µM MTX
and/or 10 µM BrUdR) treatment for 72 hours. Each data point represents the
means (±SD) of at least three independent experiments.
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Table 4.6: Values of the linear-quadratic model parameters ↵ and  , the
↵/  ratio, and SER10 from 9L cells treated with ionising radiation only and
MTX/BrUdR-sensitised radiation dose survival curves at energies of 125 kVp.
XIR = radiation only; MTX = methotrexate (0.01µM) and BrUdR = bromod-
eoxyuridine (10µM); N/A = not applicable; SER10 - sensitisation enhancement










XIR alone 0.213± 0.019 0.002± 0.003 N/A
BrUdR 0.295± 0.036 0.011± 0.006 1.6
MTX 0.191± 0.013 0.004± 0.002 1
MTX +BrUdR 0.486± 0.068 0.006± 0.011 2.3
4.6.3.4 Cell cycle analysis and quantification of BrUdR incorpora-
tion into DNA simultaneously
DNA measurements with propidium iodide (PI) were performed to determine
whether the drugs and/or radiation combination a↵ected the cell cycle pro-
gression and also to calculate the S-phase fraction (SPF) (Eq. 3.6). Bromod-
eoxyuridine (BrUdR) is a thymidine analog that is taken up by cells in the
S-phase of the cell cycle. These cells can be identified by immunohistochem-
ical staining using anti-BrUdR monoclonal antibodies. This technique was
developed by Gratzner and Leif [1981] and Gratzner [1982]. Originally it was
used to analyse the tumour cell cycle and replaced autoradiograph methods
that are applied at intervals after the administration of the tritiated thymidine
([3H]TdR). The latter method is time consuming, laborious, and radioactiv-
ity dependent. The quick and non-radioactive method of using bivariate flow
cytometry analysis, cell cycle distribution and the labeling index (LI) were
therefore used in this study. The measurements of LI between the two meth-
ods are comparable [Wilson et al., 1985].
Representative DNA histograms of PI stained 9L cells are shown in Figure
4.36. The histogram profile of untreated confluent cells shown in Figure 4.36
exhibited a large peak (first peak on left) representing cells that posses a 2N
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Figure 4.36: Representative of single parametric DNA diagrams of 9L cells
stained with PI – gated shown represents each cell phase. DNA histogram
were analysed with the FlowJo for Mac software.
(G0/G1 phase) DNA content. The second, smaller, peak on the right repre-
sents cells with 4N DNA content, which are the cells are in G2/M phase. The
interval between the two peaks represents the cells in S-phase.
The SPF is 12.6% under control conditions (untreated) (Figure 4.37a). The
result from cell cycle analysis for 9L cells treated with MTX alone (with SPF
is 54%) was consistent with S-phase cell cycle arrest as previously reported
[Sen et al., 1990; Dabrowska et al., 2007] as MTX treatment caused the accu-
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mulation of cells in early S-phase (Figure 4.37b). The results from cell cycle
analysis in 9L cells treated with BrUdR alone was consistent with M-phase cell
cycle arrest as previously reported [Sen et al., 1990; Dabrowska et al., 2007]
(Figure 4.37c).
The accumulation of cells into the S-phase is observed after 72 hour period of
MTX and BrUdR incubation, which rapidly elevated the SPF increase to 33%
(Figure 4.37d) compare to the control (Figure 4.37a). For the combination
of MTX and BrUdR with radiation there was only one obvious apoptotic or
pre-apoptotic peak (sub-G1 peak), the G2/M and S phase cells disappeared
completely (Figure 4.37e).
Representative bivariate flow cytometry dot plots (i.e DNA/BrUdR distribu-
tions) of cells treated with and without BrUdR alone or combined with MTX
are shown in Figure 4.38. The average percentage results (± standard devia-
tion) are presented as a percentage of BrUdR-positive cells in relation to the
total cell number determined based on the PI staining. LIs of cells treated
with BrUdR alone were 38%±3.4% whereas combined with MTX the LIs were
38.4%±3.1%.
4.6.4 Discussion
The halogenated pyrimidine, BrUdR is an agent that has a similar size and
chemical structure with the natural pyrimidines (Figure 2.26). It is hypoth-
esised that during DNA replication these base analogues are mistakenly in-
corporated into the newly formed DNA chains replacing the natural base
thymine [Chadwick and Leenhouts, 1981]. BrUdR is therefore provide high
Z-radiosensitiser atoms (i.e bromine) which are incorporated into DNA re-
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sulting in an enhancement of the biological e↵ect of ionising radiation. The
rationale to add MTX was that the inhibition of thymidine synthesis by the an-
timetabolite would increase the uptake of the halogenated pyrimidine analogs,
BrUdR, into tumour DNA.
In the present study, the clonogenic survival of 9L cells has also been correlated
with FACS results, as it was hypothesised that there might be an association
between the decreased clonogenic survival with an increased uptake of the
BrUdR by MTX. These comparisons have been motivated by the e↵ort to
clarify the radiosensitising e↵ect of BrUdR (with or without the presence of
MTX) in biological systems, especially DNA strand breaks and their depen-
dence on the number of BrUdR molecules incorporation into DNA.
As an initial approach the enhanced radiosensitising e↵ect by BrUdR has been
studied in clonogenic survival assays of the rat gliosarcoma cell line 9L. As
mentioned in earlier section 4.1.1, the 9L cell line was used due to its radiore-
sistant characteristic as compared to other rat brain tumour cell lines. The first
part of this investigation was to experimentally investigate the radiosensitis-
ing e↵ect by BrUdR (with or without the presence of MTX) on the clonogenic
survival of the x-ray irradiated 9L cell line at an energy of 125 kVp, as well as
to quantify the predicted increase of ↵ values.
In the present study, it was demonstrated that the radiosensitisation e↵ect
of BrUdR (10 µM) on 9L cells with a X-ray energy of 125 kVp resulting in
reduced clonogenic cell survival (Figure 4.32). This confirms the hypothesised
that BrUdR acts as a radiosensitiser. In turn this supports the studies in drug-
radiation interactions, which suggest that the linearisation of a cell survival
curve indicate that the agent is additive with itself [Steel and Peckham, 1979].
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Unlike the case of BrUdR, no radiosensitisation e↵ect was observed on irradi-
ation concomitantly with MTX alone (0.01 µM) (Figure 4.33). This is incon-
sistent with the potentiation described by Bagshaw and Doggett [1969], where
MTX can cause an increasing cellular damage by x-ray radiation by inhibiting
cellular repair. There are two possible explanations for this. Firstly, it could
be due to the stationary phase cells at the time of irradiation. This explana-
tion that is consistent with studies by Spittle [1978] that indicate MTX act as
radiosensitiser of log phase cells and not stationary phase cells. Secondly, it
could be due to the dose of MTX used in this study is less than two-hundredth
of the IC50 as anticancer drugs.
The addition of MTX (0.01 µM) did cause an enhancement of the radiosensi-
tising e↵ect of BrUdR (10 µM) (Figure 4.34). These results support the idea
that the addition of BrUdR concomitantly with X-ray irradiation increases
the spatial distribution of low-energy secondary electrons, resulting in an en-
hanced biological e↵ect of the radiation. This e↵ect is increased in the presence
of MTX (Figure 4.35). These results are also consistent with the hypothesis of
the drug-radiation interactions. This showed that the e↵ect of combining the
two agents used (i.e. BrUdR and MTX) concomitantly with radiation, lead to
the conclusion that they are supra additive (Figure 4.35).
It has been proposed that the loss of the ability of cells to reproduce itself
is directly related to the number of radiation-induced DNA-DSB [Chadwick
and Leenhouts, 1981]. Thus, our findings suggest that cell death was due to a
lethal accumulation of DNA strand breaks. This correlates with the greatly re-
duced cell survival in the clonogenic assay. This confirms that there is a highly
localised energy deposition when the radiosensitiser drug, BrUdR is combined
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with MTX (0.01 µM) which causes more ionisation clusters in cells. This leads
to more DNA strand breaks.
It has been shown that the degree of incorporation of halogenated pyrimidines
into DNA depends upon their concentration at the time of exposure [Phillips
et al., 1989] and with the time of exposure [Phillips et al., 1995; Lawrence et al.,
1990a], which been tested in mammalian cells [Uhl et al., 1992]. Moreover, the
amount of chromosomal damage or cell killing increases as the incorporation of
the bromodeoxyuridine increases [Kaplan et al., 1962; Erikson and Szybalski,
1963a,b]. This was quantitatively defined by Dewey and Humphrey [1965] and
Dewey et al. [1966, 1971] on synchronised Chinese hamster ovary (CHO) cells.
The incorporation of bromodeoxyuridine (BrUdR) during DNA synthesis is
frequently used for cell cycle analysis. In this study, cells that have incorpo-
rated BrUdR during drug incubation were detected by fluorescently labeled
anti-BrUdR antibodies. Dolbeare et al. [1983] developed a procedure to simul-
taneously measure the amount of BrUdR incorporated into DNA and the total
DNA content using flow cytometry. They used an anti-BrUdR monoclonal an-
tibody to analyse BrUdR-treated cells in both in vitro and in vivo of CHO
cells. The fluorescence intensity was proportional to the amount of incorpo-
rated BrUdR as determined by immunofluorescence [Gratzner and Leif, 1981;
Gratzner, 1982; Dolbeare et al., 1983]. Thus, the anti-BrdU mouse monoclonal
antibody (Clone MoBU-1) that is highly specific for BrUdR incorporated into
DNA was used in this study.
The measured PI fluorescence is directly proportional to the DNA content of
cells. The results from cell cycle analysis in 9L cells treated with MTX alone
are consistent with S-phase cell cycle arrest as previously reported by others
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[Sen et al., 1990; Spittle, 1978; Dabrowska et al., 2007] (Figure 4.37b). An
increasing number of 9L cells in the S-phase (i.e SPF), from 12.6% to 33%,
was observed when the cells were treated with a combination drugs of 10 µM
BrUdR and 0.01 µM MTX (200-fold below IC50) (Figure 4.37d). When the
drugs combined with radiation there was only one obvious apoptotic peak
(sub-G1 phase) (Figure 4.37e), indicating that most of the cells underwent
apoptosis. Some cells are able to repair the damage which is why they still
divide, producing the colonies observed in clonogenic assays.
A wide range in the degree of thyimidine replacement by BrUdR has been
documented in two previous studies. Delihas et al. [1962] reported a 1% re-
placement of thymidine by BrUdR in HEp cells. Nagashima and Hoshino [1985]
found that approximately 49% of thymidine by was replaced BrUdR in 9L cells.
Our result, that the LI was 38.4%±3.4% (Figure 4.38), is in more in agree-
ment with the results reported by Nagashima and Hoshino [1985]. The figure
of 38.4%±3.4% is higher than the SPF calculated from the DNA histogram
(33%). These results also support the conclusion that the LI obtained from
fluorescence analysis is higher than the percentage of S-phase cells obtained
from DNA histogram. Dolbeare et al. [1983] concluded that the anti-BrUdR
antibodies were very sensitive to identifying the early S-phase cells.
There seems to be a discrepancy between the LI of BrUdR/MTX combina-
tion with the cell survival analysed by clonogenic assays. The number of cells
that survived decreased significantly but no increase in the BrUdR uptake into
DNA by MTX was observed (38.4%±3.1%)(Figure 4.38). This is in agreement
with the observations of Aoyama et al. [1964] that there was no change in the
radiosensitisation as the percentage of thymidine replaced increased. Hence,
the radiosensitising e↵ect does not increased in proportion to the rate of in-
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corporation of BrUdR into DNA.
In summary, these results suggest that the increased cell death was due to a
lethal accumulation of DNA strand breaks (i.e DNA DSB). The formation of
such DNA breaks is probably due to ine cient DNA repair resulting from the
inhibition of synthesis of thymidilate and purine nucleotides by MTX. For-
nace et al. [1990] and Lawrence et al. [1990b] also suggest that the molecular
mechanism of this increase in lethality due to radiosensitisation is most likely
related to the hydrolysis of halogenated DNA (i.e. highly reactive uracil free
radicals) by ionising radiation. This radiation damages the un-substituted
complementary-strand DNA.
4.6.5 Conclusions
These data are in accordance with our theoretical expectations and that ra-
diation and BrUdR interact synergistically. In addition, the combination of
BrUdR with low doses of MTX is more cytotoxic than either of these agents
alone. Overcoming radio-resistance of 9L cells is an important challenge to im-
proving the outcomes for patients with glioma. Achieving a synergistic inter-
action by combining BrUdR, MTX, and targeted Auger-electron RT (chemo-
Auger therapy) could lead to significantly improved responses, compared with
either of these therapies alone.
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4.7 Chemo-Auger Approach Part 2: BrUdR,
MTX, and Influence of Di↵erent Energies
As described in section 2.4, a synergistic interaction was achieved by combin-
ing BrUdR, MTX, and an external X-ray beam at 125 kVp. In this section,
the influence of di↵erent physical X-ray energies on the radiosensitisation of
BrUdR on 9L cells is explored.
4.7.1 Background
The addition of high-Z materials to achieve an enhanced dose has already been
proven to be viable experimentally in vitro using low energy photons of kVp
energies (50 – 250 kVp). As mentioned in section 2.4, within this kilovoltage
range dose enhancement is mainly due to photoelectric interactions whose in-
teraction cross sections are highly Z dependant.
In order to determine the photon-energy dependence of the chemo-Auger ther-
apy on cell survival a set of experiments has been carried out to investigate
the influence of di↵erent X-ray photon energies range, including 50 kVp, 125
kVp, 250 kVp, 6 MVp and 10 MVp, so as to cover a wide range of secondary
electron spectra while maintaining the same total energy absorbed per unit
mass (the same dose delivered). This investigation was undertaken to verify
whether the observed e↵ect in section 2.4 is related to low energy secondary
electrons.
Megavoltage (MV) X-rays beam are widely used for anticancer radiotherapy
as they have the advantage of greater penetration into tissues, allowing the
treatment of deep seated tumours in the body. However, this advantage is
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limited by the inverse relationship of absorption to penetration (i.e. inverse
square law).
In the higher range of clinical relevant photon energies (6–25 MVp), photon
beams mainly interact with matter by Compton scattering and pair produc-
tion. A recent phantom based study has shown that local dose enhancement
of as much as 40% can be achieved by the introduction of high-Z materials (i.e.
gold foils) to the region of interest with 18 MV or higher energy photon beams
[Alkhatib et al., 2009]. Thus, in this project we also proposed to modify the
chemo-Auger approach to a chemo-electron/positron pair creation approach.
The aims of part 2 of this study were:
• To establish irradiation conditions for the optimal enhancement of chemo
electron/positron pair therapy by conventional megavoltage X-ray beams
(i.e. LINAC).
• To compare the radiation cell survival curves and verify the optimal
photoactivation source.
4.7.2 Results
4.7.2.1 Radiosensitisation of BrUdR + MTX on 9L cells with 50
kVp X-rays beam
The results for the combined BrUdR (10 µM) and MTX (0.01 µM) admin-
istered concomitantly with 50 kVp X-rays irradiation on 9L cells is shown in
Figure 4.39. This shows a greater cell kill than that expected with irradiation
alone with the value of ↵= 0.284±0.009 Gy 1 being larger than that of the
control, with ↵=0.151±0.019 Gy 1.
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Figure 4.39: Radiation dose-survival curves of confluent cultures of 9L cells
after irradiation at energies of 50 kVp, with or without drugs combination
(0.01 µM MTX and 10 µM BrUdR) treatment for 72 hours. Each data point
represents the means ± standard deviation of at least two independent exper-
iments.
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4.7.2.2 Radiosensitisation of BrUdR + MTX on 9L cells with 250
kVp X-rays beam
The results for the combination of BrUdR (10 µM) and MTX (0.01 µM) ad-
ministered concomitantly with 250 kVp X-rays irradiation on 9L cells is shown
in Figure 4.40. This shows a greater cell kill than that expected with irradi-
ation alone with the value of ↵= 0.319±0.025 Gy 1 being larger than that of
the control, ↵= 0.152±0.019 Gy 1.
4.7.2.3 Radiosensitisation of BrUdR + MTX on 9L cells with 6
MV X-rays beam
The results for the combination of BrUdR (10 µM) and MTX (0.01 µM) ad-
ministered concomitantly with 6 MV X-rays irradiation on 9L cells is shown in
Figure 4.41. This shows a greater cell kill than that expected with irradiation
alone with the value of ↵= 0.335±0.024 Gy 1 being larger than that of the
control, with ↵= 0.294±0.007 Gy 1.
4.7.2.4 Radiosensitisation of BrUdR + MTX on 9L cells with 10
MV X-rays beam
The results for the combination of BrUdR (10 µM) and MTX (0.01 µM) ad-
ministered concomitantly with 10 MV X-rays irradiation on 9L cells is shown
in Figure 4.42. This shows a greater cell kill than that expected with irradi-
ation alone with the value of ↵= 0.218±0.069 Gy 1 being larger than that of
the control ↵= 0.200±0.062 Gy 1.
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Figure 4.40: Radiation dose-survival curves of confluent cultures of 9L cells
after irradiation at energies of 250 kVp, with or without drugs combination
(0.01 µM MTX and 10 µM BrUdR) treatment for 72 hours. Each data point
represents the means ± standard deviation of at least two independent exper-
iments.
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Figure 4.41: Radiation dose-survival curves of confluent cultures of 9L cells
after irradiation at energies of 6 MV, with or without drugs combination (0.01
µM MTX and 10 µM BrUdR) treatment for 72 hours. Each data point repre-
sents the means ± standard deviation of at least two independent experiments.
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Figure 4.42: Radiation dose-survival curves of confluent cultures of 9L cells af-
ter irradiation at energies of 10 MV, with or without drugs combination (0.01
µM MTX and 10 µM BrUdR) treatment for 72 hours. Each data point repre-
sents the means ± standard deviation of at least two independent experiments.
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4.7.2.5 Correlation between the physical X-rays beam energies and
enhancement of radio sensitisation e↵ect of BrUdR com-
bined with MTX
Survival curves following the irradiation of 9L cells containing drugs (BrUdR
plus MTX) are plotted in Figure 4.43 with all of the control curves averaged
together.
Table 4.7 summarises the LQ parameters for 9L cells obtained from analyses of
the radiation dose-survival curves for irradiation alone and following combined
irradiation and drugs at all energies.
Table 4.7: Values of the linear-quadratic model parameters ↵ and  , the
↵/  ratio, and SER10 from 9L cells treated with ionising radiation only
and MTX/BrUdR-sensitised radiation dose survival curves of di↵erent ener-
gies.XIR = radiation only; DRUGS = MTX (0.01µM) and BrUdR (10µM)
combination; N/A = not applicable; SER10 = sensitisation enhancement ratio










50 kVP XIR 0.151± 0.019 0.018± 0.006 1.2
DRUGS 0.284± 0.009 0.011± 0.001
125 kVp XIR 0.213± 0.008 0.002± 0.001 2.3
DRUGS 0.521± 0.028 N/A
250 kVp XIR N/A 0.038± 0.000 1.3
DRUGS 0.319± 0.025 0.011± 0.004
6MV XIR 0.294± 0.007 0.010± 0.002 1.3
DRUGS 0.335± 0.024 0.011± 0.005
10MV XIR 0.200± 0.062 0.013± 0.008 1.2
DRUGS 0.218± 0.069 0.021± 0.010
The most significant increases in the ↵ value were observed in the irradiation
of cells with an energy of 125 kVp, with a SER10 of 2.3 (Figure 4.44). This ra-
diosensitisation value demonstrates that the damaged DNA was probably due
to ine cient DNA repair resulting from the inhibition of synthesis of thymidi-
late and purine nucleotides by MTX as well as the photoelectrons productions
at 125 kVp. This energy is optimal according to the peak of absorption con-
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Figure 4.43: The e↵ect of BrUdR plus MTX on 9L cells after irradiation with
di↵erent energies of radiation analysed with LQ model (Eq.2.6). Each data
point represents the means standard deviation of at least two independent
experiments are shown. Control represents as the average of the irradiated
controls from all di↵erent energies without drugs treated.
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Figure 4.44: Sensitisation enhancement ratio at 10% surviving fraction
(SER10) in function of radiation energies.
trast of bromine relative to water spectrum which occurs around ⇠40 keV.
Figure 4.45 shows the same trend as demonstrated in section 2.4, i.e. no ra-
diosensitising e↵ect was observed when the cells were irradiated at 5 Gy with
MTX alone and an enhanced radiosensitisation was observed with BrUdR plus
MTX compared to irradiation alone in all kVp energies. This is illustrated by
the reduction in number of clonogenic survival at 5 Gy of irradiated 9L cells
concomitantly with drugs (Figure 4.45). It also clearly shows that the opti-
mum energy is 125 kVp where the reduction in number of clonogenic survival
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Figure 4.45: The e↵ect of drugs on 9L cells after irradiation with energies of
50, 125, and 250 kVp at dose of 5 Gy. MTX = methotrexate (0.01 µM); Br =
bromodeoxyuridine (10 µM).
is greater compared to the 50 and 250 kVp energies (Figure 4.45).
4.7.3 Discussions
For all X-ray energies, the radiation dose-response curves of 9L cells after ir-
radiation concomitantly with 10 µM BrUdR plus 0.01 µM MTX shown an
enhanced radiosensitising e↵ect of the irradiation. The data shows the reduc-
tion in number of clonogenic survival at 50 kVp (Figure 4.39), 250 kVp (Figure
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4.40), the 6 MV (Figure 4.41), and 10 MV (Figure 4.42). These are consis-
tent with the ↵ values being larger than the corresponding irradiated controls
without drugs (i.e. BrUdR plus MTX).
To date there have been no previous reports exploring the correlation be-
tween the radiosensitising e↵ect of BrUdR combined with MTX and the exter-
nal beam radiation energy dependence assessed by comparison of cell survival
fraction. From Figure 4.43, it is concluded that the optimum energy for the
maximum enhancement of BrUdR (plus MTX) radiosensitisation of 9L cells in
vitro is obtained with an external X-ray beam irradiation using conventional
orthovoltage X-ray machine at an energy of 125 kVp, with highest SER10 of
2.3 (Figure 4.44). Such enhancement is evidenced by a linearisation of the cell
survival curve.
It is well understood from the synchrotron experiments by [Corde et al., 2004]
and [Rousseau et al., 2009a], that iodine is most e ciently ionised just above
the K-edge (33.2 keV) and the peak of absorption contrast relative to water
occurs in the spectrum at 50 keV. The results presented in this study also con-
firm the theoretical expectation according to the peak of absorption contrast
of bromine relative to water in the spectrum occurs around ⇠40 keV (Figure
3.1) and the output spectrum emitted from the orthovoltage X-ray unit used
at 125 kVp (Figure 3.3) which defined in section 3.1.5.2. Our results showed
that the influence of energy dependence is due to an increased production of
photoelectrons. Hence, the photoelectric e↵ect is the most relevant to this
study. It is also noteworthy that the spectrum calculation were only for pure
bromine atoms, not as a compound in BrUdR.
The SER10 values were similar for all x-ray energies (⇠1.2 – 1.3) except for
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the value at 125 kVp (2.3) (Table 4.7). This is explained by the fact that
although, relative to water, bromine absorbs better at all X-ray energies, the
ratio of absorption is greatest above the K-edge. Hence, given the simulated
X-ray spectrum output of 50 kVp (Figure 3.2) and 250 kVp (Figure 3.5), it
falls below the K-edge of bromine. Thus, despite the polychromatic nature of
the x-ray tube output these results indicate that orthovoltage x-rays at 125
kVp are the most e cient at photoactivating BrUdR because of optimum peak
absorption contrast of bromine relative to water occurs around ⇠40 keV.
Table 4.7 summarises the LQ parameters of 9L cells obtained following analy-
ses of the radiation dose-survival curves for irradiation alone and for combined
irradiation and drugs at all energies. These data also support the conclusion
that radiosensitisation by halogenated pyrimidines (i.e. BrUdR) is mainly due
to an increase in the linear parameter ↵, with the quadratic parameter   is
rarely influenced [Franken et al., 2013]. The exception to this is energies of 250
kVp, where the   value is dominant as represents the accumulation of damage
repair.
The sensitising e↵ects presented in this study are also in agreement with the
study by Tym and Todd [1964]. They studied the sensitising e↵ect of another
base analog, iododeoxyuridine (IUdR), on cells with di↵erent types of radia-
tion. They found a stronger sensitisation for sparsely ionising radiation (i.e
X-rays) compared to very heavy densely ionising particles (Carbon-12). In
addition, low energy high-LET Auger electrons produced by photoelectric in-
teractions that eject K-shell or other electrons [Karnas et al., 1999; Buchegger
et al., 2006] can significantly cause an increase of SSB and DSB [Corde et al.,
2003; Le Sech et al., 2001]. This can lead to more e↵ective tumour cell killing
in vitro [Laster et al., 1993]. In vivo studies showed an increased in the sur-
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vival of Fisher rats bearing glioma [Biston et al., 2004; Adam et al., 2003] and
also tumour growth delay for PAT-treated mice [Laster et al., 2009]. Thus,
the overall results in this study are in a good agreement with previous studies
that suggest the more e↵ective cell killing by novel radiosensitiser drugs (i.e
BrUdR or IUdR) was probably due to an increase in DNA strand breaks.
The change in e cacy of treatments as measured quantitatively by a signif-
icant reduction of 20% and 30% in the necessary absorbed radiation dose in
order to achieve the same 10% cell surviving fraction was found in 6 and 10
MV irradiation with BrUdR plus MTX (Figure 4.44). Even though this was
not as e↵ective as the 125 kVp, it is more feasible to use in clinical practice
and much more e↵ective compared to other modalities currently available for
the treatment of glioma. These results are also in good agreement with other
studies on the use of high-Z elements (i.e platinum) in the form of cisplatin
[Rousseau et al., 2010] and carboplatin [Rousseau et al., 2009b; Bobyk et al.,
2012]. They both demonstrated an equivalent therapeutic response when the
drug is combined with either 6 MV photons or synchrotron x-rays at the K-
edge of platinum (at 78.8 keV) [Rousseau et al., 2010; Bobyk et al., 2012].
In order to confirm the e↵ect that the combination of drugs (BrUdR plus
MTX) with radiation kills cells greater than either agent alone, we performed
a complete set of experiments with MTX-alone and/or BrUdR-alone irradiated
concomitantly at a dose of 5 Gy in 50 and 250 kVp x-rays beam. These are
shown in Figure 4.45, which shows the same trend as in section 2.4, chemo-
Auger approach part 1 that BrUdR acts synergistically with x-rays and is
supra additive in the presence of MTX.
The value of ↵ increases as the SER10 increases whereas the value for   is
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nearly constant in both drug and control curves except under exceptional cir-
cumstances. The   value for 125kVp and drugs combination was not applicable
which represents that there is no accumulation damage repair occurs. However,
most importantly, the ↵ dominance of the irradiated drug-containing survival
curves is the main principal thesis of this study. The ↵ value provide the most
information related to sensitisation that in turn leads to the most e↵ective
method in killing tumour cells, this can overshadow the  -dependence. Recall
the interpretation of the linearisation of the cell survival curve (BrUdR plus
MTX at 125 kVp). According to the cell killing mechanism defined in section
2.1.4.4, we can extract some physical meaning of the trend that our mechanism
of enhancement mimics the high-LET-like behaviour (i.e. cell survival curves
with no shoulder) (Figure 2.10)
In the mid 1960s, BrUdR was given intra-arterially [Hoshino and Sano, 1969;
Sano et al., 1965, 1968] and intravenously (i.v) infusion in 1980s [Jackson
et al., 1987] in combination with radiotherapy for malignant glioma. The ma-
jor drawback of this method is that the radiosensitisation of the tumour cells
requires them to be continuously exposed to the drugs as the liver can dehalo-
genate them rapidly [Kriss et al., 1963]. Then, Deutsch et al. [1989] reported
for the first time in vivo studies of the e↵ects of IUdR administered into cere-
brospinal fluid (CSF) and combined with irradiation of the craniospinal axes
that can be clinically applicable for glioma treatment. Thus, the optimum
mode of BrUdR administration in combination with radiotherapy is another
challenging step. Recently, Kassis et al. [2004] have proposed the administra-
tion of 125IUdR (radiolabeled IUdR) into CSF for the treatment of advanced
neoplastic meningitis. It has been used in the first human treatment of the
same disease and proved to be feasible without acute neurological toxicity [Re-
bischung et al., 2008]. We propose that the mode of IUdR administration into
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CSF could also be applied for administering BrUdR as a radiosensitiser simul-
taneously with MTX in the treatment for glioma.
4.7.4 Conclusions
The hypothesis investigated in the present study was whether a chemo-Auger
approach could be successfully applied in the clinical setting by using conven-
tional X-ray machine (e.g. LINAC) that are already widely used in clinical
radiotherapy for cancer treatment instead of using monoenergetic synchrotron
radiation.
The synergistic e↵ect of enhanced absorption contrast and tumour specificity
can still be achieved by using halogenated pyrimidines to provide high-Z ele-
ments and irradiated externally by a polychromatic orthovoltage X-rays ma-
chine. It has been shown in this study that when combining BrUdR plus
MTX with the appropriate energy photon spectrum centralised at the peak of
absorption (i.e. ⇠40 keV) the radiosensitisation per unit dose of radiation is
optimised.
BrUdR combined with X-rays of energies 125 kVp is more cytotoxic to 9L
cells than when combined with other energies (50 kVp, 250 kVp, 6 MV, or
10 MV). Even though the most e↵ective tumour cell killing can be achieved
by using orthovoltage X-rays machine, the change in e cacy of treatments as
measured quantitatively by a significant reduction of 20% and 30% in the nec-
essary absorbed radiation dose in order to achieve the same 10% cell surviving
fraction was found in 6 and 10 MV irradiation with BrUdR combined with
small quantities of MTX. This finding can be applied in clinical radiotherapy
to increase the therapeutic ratio since the LINAC is a feasible machine for
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cancer radiotherapy treatment.
The full e cacy of this combination therapy, i.e. chemo-Auger and chemo-
electron/pair production approach, which has been discarded since 1960s (BAR
therapy), can now be resumed. Our results suggest that in vivo studies and
clinical trials of BrUdR photo-activation plus MTX concomitantly with exter-
nal photon irradiation for treatment of brain tumours merit consideration.
Photoactivation studies of BrUdR combined with other anti-cancer drugs such
as 5-FU or its prodrug called Fluorodex also under way in our laboratory.
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4.8 Groundwork for Confocal Microscopy
This section describes and examines the confocal microscopy work carried out.
All experiments were performed in the Illawarra Health and Medical Research
Institute (IHMRI) of the University of Wollongong.
4.8.1 Reactive Oxygen Species Production in 9L Cells





Reactive oxygen species (ROS) are important chemical intermediates in biolog-
ical studies [Chen et al., 2010]. ROS is used to describe the number of reactive
molecules and free radicals (as in section 2.1.4.1). Thus, it is important to
be able to quantify their quantity. The most widely used technique to detect
ROS was developed more than 40 years ago. This method is based on the oxi-
dation of the non-fluorescent probe 20,70-Dichlorodihydrofluorescein (DCFH2)
to produce the highly fluorescent 20,70-Dichlorofluorescein (DCF) [Chen et al.,
2010].
In this study intracellular ROS generated by Ta2O5 nanoparticles in 9L cells
were detected using 20,70-Dichlorofluorescein diacetate (DCFD) and visualised
by the green DCFD fluorescence shown in Figure 4.46. The DCFD fluores-
cence generated by Ta2O5 nanoparticles was predominantly localised in the
cytoplasm of 9L cells (Figure 4.46B) compared to control cells (Figure 4.46A).
Figure 4.47 shows that 9L cells can uptake the Ta2O5 nanoparticles via nor-
mal endocytosis. This suggests that Ta2O5 nanoparticles can act as targeted
nanoparticles that can be specifically incorporated into the cell nucleus (Figure
4.47).
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Figure 4.46: Microphotograph of intracellular ROS induced by Ta2O5 nanopar-
ticles in 9L cells detected with DCFD dye and counterstained with PI. (A)
Untreated cells (control). (B) Cells were treated with 50 µg/ml of Ta2O5
nanoparticles for 24 hours. All the chamber slides were analysed for fluo-
rescence with a 488 nm excitation laser on a Leica confocal laser scanning
microscope and the images were captured using the same parameters to allow
comparison. Overlay image corresponding to the fluorescence of intracellular
PI and DCFD fluorescence image.
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Figure 4.47: Exposure of 9L cells to Ta2O5 nanoparticles (50 µg/ml) for 24
hours, results in uptake of agglomerates surround the cell nucleus (black dots)
(on left) and the magnification (on right). Light microscopy images were ob-
tained using a Leica confocal laser scanning microscope.
4.8.2 BrUdR as a Radiosensitiser Drug that is Specifi-
cally Incorporated into DNA in 9L Cells
Cells that had incorporated BrUdR during the drug incubation procedure were
detected using fluorescently labelled anti-BrUdR antibodies (MoBU-1) and vi-
sualised by the use of a confocal laser scanning microscope. Figure 4.48 sup-
ports the hypothesis that BrUdR is incorporated into DNA since the MoBU-
1 fluorescent image is predominantly seen only when the cells treated with
BrUdR (green signal) (Figure 4.48C) and no green signal is observed in either
untreated cells (negative control) (Figure 4.48A) or MTX-treated cells (posi-
tive control) (Figure 4.48B).
Due to all the cells have been fixed and permeabilised, all the cells are stained
with propidium iodide (PI) and appear red in the fluorescent image. The in-
tensity of the red fluorescence image for BrUdR-treated cells (Figure 4.48C)
is stronger than for both controls. A possible explanation is that PI is an in-
tercalate agent that stains DNA, the stronger the fluorescent signal indicates
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that there has been a greater cell uptake. Since BrUdR is predominantly in
the DNA, we expect that the cells are more vulnerable to permeation.
Figure 4.48: Microphotograph of intracellular 5-bromo-20-deoxyuridine
(BrUdR) in 9L cells. (A) Cells with no treatment was used as negative control.
(B) Treatment of cells with 0.01µM of MTX was used as positive control. (C)
Cells treated with 10 µM BrUdR. Detection of BrUdR by direct fluorescent
microscopy after 30 mins incubation with fluorescently labeled anti-BrUdR
antibody (MoBU-1) (green signal) and cell nuclei labeled with PI (red sig-
nal). All the chamber slides were analysed for fluorescence with a 488 nm
excitation laser on a Leica confocal laser scanning microscope and the images
were captured using the same parameters to allow comparison. Overlay image
corresponding to the fluorescence of intracellular PI and MoBU-1 fluorescence
image.
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4.8.3 Conclusions
Understanding the cellular uptake mechanism of the nanoparticles may pro-
vide important information to assist further development of targeted nanoth-
erapeutic agents in combination with radiation therapy. Further studies that
need to be conducted in the future are to continue analysing the nanoparticles
treatment in in vitro cells using the confocal laser scanning microscope.
In addition to the immunostaining of BrUdR, it is clear that the procedure
of fixation and permeabilisation worked successfully. These results also show
an excellent correlation to the flow cytometry analysis. The results support
that the assumption that BrUdR is incorporated into DNA, as evidenced by
the green fluorescence image detected using the monoclonal antibody (clone




This study investigated the influence of high-Z materials on the biological
e↵ect of X-rays on the cancer cell line 9L which is a rat gliosarcoma. Experi-
ments were designed to quantify the e↵ect of the beam energies upon radiation-
induced damage using clonogenic survival analysis.
The halogenated pyrimidine analog 5-bromo-20-deoxyuridine, also known as
bromodeoxyuridine (BrUdR), was used due to its potential as a radiosensitiser
drug for clinical radiotherapy. Dose-response curves were obtained using X-ray
energies ranging from 50 kVp to 10 MVp at single doses of 1, 2, 3, 5, and 8
Gy. Comparisons were made of the radiation response of 9L cells combined
with MTX and BrUdR.
The addition of BrUdR sensitised the 9L cells to 125 kVp X-rays irradiation
by a sensitisation enhancement factor (SER10) of 1.6 whereas sensitisation fol-
lowing the addition of MTX was either not observed or was insignificant. The
combination of MTX and BrUdR together significantly increased the sensiti-
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sation of the 9L cells (SER10 = 2.3), though flow cytometry studies showed
that it did not increase the degree of replacement of thymidine 5-bromo-20-
deoxyuridine.
The conceptual approach for clinical applications is that the dose of X-ray ra-
diation beams (orthovoltage X-rays or LINAC) absorbed in the tumor region
is enhanced by the application of a radiosensitiser drug, BrUdR, combined
with an anticancer-drug, MTX. Another suggestion arising from this study is
to investigate the general applicability of this concept by testing another com-
bination of potent drugs such as IUdR and 5-FU.
Some cancer cells may have di↵erent responses to the increase in DSBs pro-
duced by X-ray irradiation in the presence of drugs. This arises because cancer
cells are likely to di↵er in their ability to undergo DNA repair following DNA
damage. Thus it is important to predict whether all cancer patients or per-
haps only those with particular tumour types or particular genetic lesions,
since there is variation in radiosensitivity, will benefit from the combined use
of drugs. To determine the general applicability of our chemo-Auger therapy
approach additional cell lines must be investigated, including radiosensitive
lines such as MCF-7.
Understanding the molecular mechanisms leading to cancer cell death induced
by X-ray radiation in the presence of high-Z materials may provide important
information to assist in the further development of novel treatment options in
radiation therapy. Future studies that need to be conducted are to investigate
the e↵ect in other cancer cell lines as well as in vivo studies. We have used the
9L rat gliosarcoma cell line, as they will be used in subsequent in vivo models
of glioma. Thus, to determine whether the observed in vitro e↵ects can trans-
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late into a useful in vivo responses, the next step is to use a rat glioma model
(e.g. Fischer 344 gliosarcoma-bearing rat) .
In a second aspect of the project we investigated the e↵ect of radiation in com-
bination with nanoparticles containing a high-Z element: cerium oxide (CeO2),
tantalum pentoxide (Ta2O5), and bismuth oxide (Bi2O3). Although the pres-
ence of the nanoparticles enhanced the biological e↵ect of the irradiation in the
tumour volume, it is likely that adjacent normal tissue would also be a↵ected.
Thus the non-malignant MDCK cell line was chosen for investigation. Only
the groundwork, cell growth analysis and toxicity, of the MDCK cell line was
carried out in this study. However, it is clear that when lower photon X-rays
energies used the high-Z nanoparticles are not as e ciently absorbed into cells
as the radiosensitiser material BrUdR.
The main purpose of this thesis was to develop appropriate methods to al-
low a full investigation as to whether high-Z materials in combination with
anti-cancer drugs and EBRT has the potential to provide a valuable cancer
therapeutic strategy (i.e chemo-Auger therapy). The application of BrUdR
combined with chemotherapeutic drugs and radiation is predicted to bring
improvements in the biological e↵ect of a radiation dose delivered to tumour
tissue. This is expected to improve local tumour control while reducing the ir-
radiation of healthy tissue. It has been shown that the combination of BrUdR,
MTX and radiation significantly increases the biological e↵ect of radiation.
It is concluded that to achieve the best e↵ect from the presence of compounds
containing a high-Z element that this compound should not be arbitrarily ad-
sorbed into the cellular environment but must be specifically absorbed into
cancer cells. This is evidenced by the uptake of BrUdR into the tumour cell
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DNA. Then the most e↵ective cell killing occurs at an optimum radiation en-
ergy.
Finally, the sensitisation enhancement ratio (SER) from external radiation
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A.1 9L Cell Line





Depositor: ECACC (obtained fromWestmead Children hospital LOT04/E/015)




Propagation: Complete DMEM medium: DMEM + 10% FBS + 1% Pen
Strep (+5,000 Units/mL Pen; +5,000 µg/mL Strep)
Subculturing:
Ratio: Split 1:2 to 1:4
Seeding: at 2 4⇥10, 000 cells/cm2. Remove spent medium, rinse with
PBS (w/o Ca and Mg), add fresh 0.05% trypsin/EDTA, incubate
at 37 C until the cells detach. Add fresh medium, aspirate, and
transfer into new flask. Incubate in incubator at 37 C (and 5%
(v/v)CO2).
Preservation: Culture medium 90%; DMSO 10% (v/v)
Passage number: 46
Sterility: Mycoplasma negative
A.2. MCF-7 Cell Line 201
A.2 MCF-7 Cell Line










Propagation: Complete DMEM medium: DMEM + 10% FBS + 1% Pen
Strep (+5,000 Units/mL Pen; +5,000 µg/mL Strep)
Subculturing:
Ratio: Split 1:3 to 1:6
Seeding: at 2 4⇥10, 000cells/cm2. Remove spent medium, rinse with
PBS (w/o Ca2+, Mg2+), add fresh 0.05% trypsin/EDTA, incubate
at 37 C until the cells detach. Add fresh medium, aspirate, and
transfer into new flask. Incubate in incubator at 37 C (and 5%
(v/v)CO2).
Preservation: Complete culture medium 95%; DMSO 5% (v/v)
Passage number: 11
Sterility: Mycoplasma negative
A.3. U-87 MG Cell Line 202
A.3 U-87 MG Cell Line





Depositor: ECACC (obtained from Sigma-Aldrich Cat. No. 89081402)




Propagation: Complete DMEM medium: DMEM with sodium pyruvate +
10% FBS + 1% Pen Strep (+5,000 Units/mL Pen; +5, 000µg/mL Strep)
Subculturing:
Ratio: Split 1:3 to 1:6
Seeding: at 2 4⇥10, 000cells/cm2. Remove spent medium, rinse with
PBS (w/o Ca2+, Mg2+), add fresh 0.05% trypsin/EDTA, incubate
at 37 C until the cells detach. Add fresh medium, aspirate, and
transfer into new flask. Incubate in incubator at 37 C (and 5%
(v/v)CO2).
Preservation: Culture medium 95%; DMSO 5% (v/v)
Passage number: 12
Sterility: Mycoplasma negative
A.4. MDCK Cell Line 203
A.4 MDCK Cell Line





Depositor: ECACC (obtained from Sigma LOT05/L/009)




Propagation: Complete DMEM medium: DMEM + 10% FBS + 1% Pen
Strep (+5,000 Units/mL Pen; +5,000 µg/mL Strep)
Subculturing:
Ratio: Split 1:3 to 1:10
Seeding: at 1  3⇥ 10, 000cells/cm2 Remove spent medium, rinse with
PBS (w/o Ca2+, Mg2+), add fresh 0.05% trypsin/EDTA, incubate
at 37 C until the cells detach. Add fresh medium, aspirate, and
transfer into new flask. Incubate in incubator at 37 C (and 5%
(v/v) CO2). Cells attach firmly and require at least 2⇥ PBS washes
prior to addition of Trypsin/EDTA.
Preservation: Complete culture medium 90%; DMSO 10% (v/v)
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B.1 Subculture Adehrent Cells – Protocol
Materials
Sterile materials
• Healthy, 80-90% confluent cell culture in T75cm2 flask
• c-DMEM medium (complete DMEM supplemented with 10% FBS and
1% PenStrep)
• PBS (without Ca2+ and Mg2+)
• Trypsin-EDTA
• 1, 5, 10 and 25 mL pipettes
• T75 cm2 flasks
Other materials
• Pippetor, Eppendorf tubes, tube racks, hemocytometer, vortex, hand-
counter, microscope, calculator, gloves, ethanol, wipes, etc. Access to
water bath set at 37 C and incubator at 37 C (and 5% (v/v) CO2).
Procedure
1. Warm up an aliquot of the medium, PBS, and trypsin-EDTA in water
bath at 37 C
2. Check the confluence of the cells under microscope
3. Using aseptic technique, in BSC: Open and handle the lid of the flask of
the cells (dont put it on the bench)
4. Remove the spent medium
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5. Wash with PBS (e.g 10 ml)⇤; shake several times; discard the PBS
6. Add 2 ml of trypsin; shake it several times⇤
7. Placed in incubator at 37 C for 5 minutes
8. Gently tapped the edge of flask; check under microscope (the cells should
be detach/floating now)
9. Re-suspend with fresh medium⇤; gently pipette it up and down to re-
suspend it well; and aliquot small sample to perform cell count (see next
protocol)
10. Transfer the required number of cells into new-labeled flask (labeled with
initial, date, cell type, passage number, etc.).
11. Incubate in the incubator at 37 C (and 5% (v/v) CO2).
⇤ Put the pipette tip on the top of the neck of flask (and shake it while adding);
cover it all of the surface; shake it several times
Appendix C
Cells Counting – Protocol
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C.1 Cells Counting – Protocol
Materials
• Tube containing a cell line
• Hemocytometer
• Trypan blue
• Pipette and tips
• Vortex mixer
Procedure
1. Before sampling, vortex the tube containing a cell to resuspend the cells.
2. Take a 10 µl sample and add to 10 µl of Trypan blue solution (1:2 dilu-
tion); mix thoroughly (pipette up and down).
3. Remove 10 µl of cell suspension/Trypan blue sample with a pipette and
place tips to the edge of a coverslip on the haemocytometer. Gently
dispense the suspension into the space between coverslip and the haemo-
cytometer (the counting chamber) until the counting chamber is filled,
shown in Figure C.1.
4. Allow the cells to settle. Place on the microscope stage and using low
power focus on the ruled area, looking at the four corner grids where
each square millimetre is divide into 16 squares (A-D) and the middle
one (E) which divide into 25 square, as shown in Figure C.2.
5. Count the cells in each 5 grids (A-E; figure 2). Average the 5 counts to
the number of cells per grid. This value represents the number of cells in
0.1 µl of suspension applied to the haemocytometer. Thus, to calculate
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Figure C.1: A typical hemocytometer
Figure C.2: Counting chamber of a hemocytometer
the concentration of cells in the original suspension: (Average number








• Healthy, 80-90% confluent cell culture in T75cm2 flask (need at least 4
flasks)
• c-DMEM medium (complete DMEM supplemented with 10% FBS and
1% PenStrep)
• Cell culture freezing medium (mix well and store at 2  to 8 C / in ice
bucket until use)
• PBS (without Ca2+ and Mg2+)
• Trypsin-EDTA
• 1, 5, 10 and 25 mL pipettes
• Centrifuge tubes
• 2mL Cryogenic vials (labelled before)
Other materials
• Pippetor, Eppendorf tubes, tube racks, hemocytometer, vortex, hand-
counter, microscope, calculator, gloves, ethanol, wipes, etc. Access to
bench centrifuge, water bath set at 37 C and incubator at 37 C (and 5%
(v/v) CO2).
Procedure
1. The culture medium should be replaced 24h prior to freezing
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2. Gently detach the cells: Discard all the old media; wash the cell mono-
layer with 10 ml of PBS (twice) and discard; treated with 2 mL of the
trypsin-EDTA; put in incubator at 37 C for 2–5 mins; check under mi-
croscope (cells should be detach now)
3. Resuspend with fresh c-DMEM medium (pre-warmed) and pipette it up
and down. Transferred into the centrifuged tubes and placed on ice.
Take a small aliquot of cells to an Eppendorf tube, vortex and count the
viability cells (with the Trypan blue) using hemocytometer
4. Obtain cell pellet: centrifuge at 1500 rpm for 7mins
5. Discard the supernatant from the centrifuged cells and resuspend the cell
pellet in the appropriate freezing medium to give final cell concentration
2–4 ⇥106 cells/mL; pipette 1 mL into each Cryogenic vials
6. Place the Cryogenic vials in Mr. Frosty container (containing 250 mL
isopropanol and should be cooled prior to use); place in –80 C freezer
(at least 4 hour)
7. After 24h, transfer all the Cryogenic vials to a gas phase liquid nitrogen
permanent storage vessel.
A schematic diagram of creating batch of master and working stocks of cells
is shown in figure D.1.
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Figure D.1: Schematic diagram of master and working stocks of cells (e.g.
U–87 MG cells)




• c-DMEM medium (complete DMEM supplemented with 10% FBS and
1% PenStrep)
• T75cm2 or T25cm2 flasks
• 50 mL FalconTM tubes
Other materials
• Pippetor, Eppendorf tubes, tube racks, hemocytometer, vortex, hand-
counter, microscope, calculator, gloves, ethanol, wipes, etc. Access to
bench centrifuge, water bath set at 37 C and incubator at 37 C (and 5%
(v/v) CO2).
Procedure
1. Warm up an aliquot of media (e.g. cDMEM) at 37 C water bath
2. Get 1 cryovial of frozen cells
3. Using antiseptic technique, in BSC class 2, hold a tissue soaked in 70%
ethanol around the cap of the frozen sample and turn the cap a quarter
turn. Re-tighten the cap.
4. Quickly and gently warm the frozen sample (Put the vial in the tube with
pre-warmed ethanol) in 37 C water bath until just thawed (1–2 min).
5. Using antiseptic technique, in BSC class 2, transfer the thawed cells into:
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New sterile flask⇤ and add warm media to the cells drop wise while
gently swirling the flask in a circular motion to slowly equilibrate the
cells to the medium first few mLs very slow (e.g. 1 drop per second
then speed up)
Or
New conical tube with 5ml pre-warmed media and may centrifuge on
low spin.
6. Lay the flask down and check the cells condition under the microscope.
If highly clumped, gently pipette the cells up and down a bit to disperse
them
7. Take a small aliquot of cells and count the viability cells
8. Incubate cells in incubator at 37 C (and 5% (v/v) CO2) and leave for
couple hours or until attached (or leave overnight)
9. Once the cells have attached and had a chance to expel the DMSO,
remove the media and add fresh media
10. Maintain the cells and subculture as necessary
⇤ Flask size depends on cell number T25cm2 for low cell number or cells
requiring close contact or T75cm2 for higher cell number or extremely fast
growing cells. For T25cm2 flask, use 5-8 mls total volume of media. For
T75cm2 flask, use 10-20 mls total volume of media.
Appendix E
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E.1 9L Cell Line
Materials
Sterile materials
• Healthy, 80-90% confluent cell culture in T75cm2 flask (need at least 4
flasks)
• c-DMEM medium (complete DMEM supplemented with 10% FBS and
1% PenStrep)
• PBS (without Ca2+ and Mg2+)
• Trypsin-EDTA
• 1, 5, 10 and 25 mL pipettes
• Centrifuge tubes
• BD FalconTM Primaria petri dishes 60 ⇥ 15 mm (growth area = 21.3
cm2; vol. = 6 –7 mL)
Other materials
• Pippetor, Eppendorf tubes, tube racks, hemocytometer, vortex, hand-
counter, microscope, calculator, gloves, ethanol, wipes, etc. Access to
bench centrifuge, water bath set at 37 C and incubator at 37 C (and 5%
(v/v) CO2).
Procedure
1. Gently detach the cells: Discard all the old media; wash the cell mono-
layer with 10 ml of PBS and discard; treated with 2 mL of the trypsin-
EDTA; put in incubator at 37 C for 2 mins; check under microscope.
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2. Resuspend with 10 ml of fresh c-DMEM medium (pre-warmed) and
pipette it up and down. Take a small aliquot of cells to an Eppendorf
tube, vortex and count the cells using haemocytometer.
3. Adjust the final cell concentration of 5 ⇥104cells/petri dish (to be opti-
mum, it should be 5 ⇥105 cells/petri dish based on 2 – 4 ⇥104 cells/cm2).
4. Take 5 mL into each petri dish (triplicate for each day data points for
14 days (make up total of 42 petri dishes).
5. Place all 42 petri dishes in incubator at 37 C (and 5% (v/v) CO2).
6. Counts the cells from triplicate petri dishes daily for 14 days (repeat the
first two procedure above, but with only 5 ml PBS, 1 ml Trypsin-EDTA,
and 5 ml c-DMEM).
7. The cells counted will be averaged for each time interval and the doubling
time of cell will the calculated from the linear phase of the growth curve.
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E.2 MCF–7 Cell Line
Materials
Sterile materials
• Healthy, 80-90% confluent cell culture in T75cm2 flask (need at least 4
flasks)
• c-DMEM medium (complete DMEM supplemented with 10% FBS and
1% PenStrep)⇤
• PBS (without Ca2+ and Mg2+)
• Trypsin-EDTA
• 1, 5, 10 and 25 mL pipettes
• Centrifuge tubes
• BD FalconTM Primaria petri dishes 100 ⇥ 15 mm (growth area = 58.95
cm2; vol. = 16 –17.5 mL)
Other materials
• Pippetor, Eppendorf tubes, tube racks, hemocytometer, vortex, hand-
counter, microscope, calculator, gloves, ethanol, wipes, etc. Access to
bench centrifuge, water bath set at 37 C and incubator at 37 C (and 5%
(v/v) CO2).
Procedure
1. Gently detach the cells: Discard all the old media; wash the cell mono-
layer with 10 ml of PBS and discard; treated with 2 mL of the trypsin-
EDTA; put in incubator at 37 C for 2 mins; check under microscope.
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2. Resuspend with 10 ml of fresh c-DMEM medium (pre-warmed) and
pipette it up and down. Take a small aliquot of cells to an Eppendorf
tube, vortex and count the cells using haemocytometer.
3. Adjust the final cell concentration of 2 ⇥105cells/petri dish (to be opti-
mum, it should be 5 ⇥105 cells/petri dish based on 2 – 4 ⇥104 cells/cm2).
4. Take 10 mL into each petri dish (triplicate for each day data points for
10 days (make up total of 30 petri dishes).
5. Place all 30 petri dishes in incubator at 37 C (and 5% (v/v) CO2).
6. Counts the cells from triplicate petri dishes daily for 10 days (repeat the
first two procedure above, but with only 5 ml PBS, 2 ml Trypsin-EDTA,
and 5 ml c-DMEM).
7. The cells counted will be averaged for each time interval and the doubling
time of cell will the calculated from the linear phase of the growth curve.
⇤ Or complete RPMI-1640 supplemented with 5% FBS and 1% PenStrep.
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E.3 U–87 MG Cell Line
Materials
Sterile materials
• Healthy, 80-90% confluent cell culture in T75cm2 flask (need at least 4
flasks)
• c-DMEM medium (complete DMEM with sodium pyruvate – supple-
mented with 10% FBS and 1% PenStrep)
• PBS (without Ca2+ and Mg2+)
• Trypsin-EDTA
• 1, 5, 10 and 25 mL pipettes
• Centrifuge tubes
• BD FalconTM Primaria petri dishes 60 ⇥ 15 mm (growth area = 21.3
cm2; vol. = 6 –7 mL)
Procedure
1. Gently detach the cells: Discard all the old media; wash the cell mono-
layer with 10 ml of PBS and discard; treated with 2 mL of the trypsin-
EDTA; put in incubator at 37 C for 2 mins; check under microscope.
2. Resuspend with 10 ml of fresh c-DMEM medium (pre-warmed) and
pipette it up and down. Take a small aliquot of cells to an Eppendorf
tube, vortex and count the cells using haemocytometer.
3. Adjust the final cell concentration of 5 ⇥104cells/petri dish (to be opti-
mum, it should be 5 ⇥105 cells/petri dish based on 2 – 4 ⇥104 cells/cm2).
4. Take 5 mL into each petri dish (triplicate for each day data points for
14 days (make up total of 42 petri dishes).
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5. Place all 42 petri dishes in incubator at 37 C (and 5% (v/v) CO2).
6. Counts the cells from triplicate petri dishes daily for 14 days (repeat the
first two procedure above, but with only 5 ml PBS, 1 ml Trypsin-EDTA,
and 5 ml c-DMEM).
7. The cells counted will be averaged for each time interval and the doubling
time of cell will the calculated from the linear phase of the growth curve.
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E.4 MDCK Cell Line
Materials
Sterile materials
• Healthy, 80-90% confluent cell culture in T75cm2 flask (need at least 4
flasks)
• c-DMEM medium (complete DMEM supplemented with 10% FBS and
1% PenStrep)⇤
• PBS (without Ca2+ and Mg2+)
• Trypsin-EDTA
• 1, 5, 10 and 25 mL pipettes
• Centrifuge tubes
• BD FalconTM Primaria petri dishes 100 ⇥ 15 mm (growth area = 58.95
cm2; vol. = 16 –17.5 mL)
• T75cm2 and T175cm2 flasks
Other materials
• Pippetor, Eppendorf tubes, tube racks, hemocytometer, vortex, hand-
counter, microscope, calculator, gloves, ethanol, wipes, etc. Access to
bench centrifuge, water bath set at 37 C and incubator at 37 C (and 5%
(v/v) CO2).
Procedure
1. Gently detach the cells: Discard all the old media; wash the cell mono-
layer with 10 ml of PBS and discard; treated with 5 – 10 mL of the
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trypsin-EDTA; put in incubator at 37 C for 5 – 10 mins; check under
microscope.
2. Resuspend with 10 ml of fresh c-DMEM medium (pre-warmed) and
pipette it up and down (at least 10 times). Take a small aliquot of cells
to an Eppendorf tube, vortex and count the cells using haemocytometer.
3. Adjust the final cell concentration of 2 ⇥105cells/petri dish (to be opti-
mum, it should be 5 ⇥104 cells/petri dish based on 2 – 4 ⇥104 cells/cm2).
4. Take 10 mL into each petri dish (triplicate for each day data points for
10 days (make up total of 30 petri dishes).
5. Place all 30 petri dishes in incubator at 37 C (and 5% (v/v) CO2).
6. Counts the cells from triplicate petri dishes daily for 10 days (repeat the
first two procedure above, but with only 5 ml PBS, 2 ml Trypsin-EDTA,
and 5 ml c-DMEM).
7. The cells counted will be averaged for each time interval and the doubling
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F.1 Drugs Treatment and Cytotoxicity – Pro-
tocol
This appendix provide an example of the complete procedure start from prepa-
ration of the cells (Day 0) until the last day of experiment (Day 28) on 9L cells.
Cell Culture Preparation (24/03/11)
Sterile Materials
• Cell culture (9L cells) in T75 cm2 flasks (Passage 55)
• Complete DMEM medium (DMEM contain L-glutamine supplemented
with
• FBS + 1% PenStrep)
• PBS (without Ca2+ and Mg2+)
• 0.05% Trypsin-EDTA
• 2, 5, and 10 mL pipettes
• T12.5 cm2 flasks (with vented cap)
Other materials
• Pippetor, Eppendorf tubes, tube racks, hemocytometer, vortex, hand-
counter, microscope, calculator, gloves, ethanol, wipes, etc. Access to
bench centrifuge, water bath set at 37 C and incubator at 37 C (and 5%
(v/v) CO2).
Procedure
1. Pre-warmed the DMEM, PBS, and Trypsin-EDTA at 37 C water bath.
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2. Remove the spent medium from the flask; wash the cell monolayer with
10 ml of PBS and discard; treated with 2 ml of trypsin-EDTA; put in
incubator at 37 C for 5mins; check under microscope (cells should be
detach now).
3. Resuspend with 10 ml of DMEM pipetting the cells up and down; take
a small aliquot in Eppendorf tube; count with hemocytometer; Adjust
the number of cells required (i.e 100,000 cells/flask).
4. Pipette the amount of volume of cells required (e.g. ⇠100µl) into each
new T12.5 cm2 flask labeled .
5. Add 5 ml of fresh DMEM into each flask; wiped with ethanol; place in
cell culture incubator at 37C (with 5% (v/v) CO2).
6. After 5 days of culture (at ⇠60% confluence), the drugs (5-FU,MTX,
and BrUdR) will be added to each flask (according to the dose as shown
in F.1).
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Cell Culture – Drugs incubation (29/03/11)
Sterile Materials
• 16 flasks of the 9L cells seeded on 24/3/11
• P20-P1000 pipette tips
• Drugs dilution (5-FU,MTX, and BrUdR)
Other Materials
• Pippetor, Eppendorf tubes, tube racks, hemocytometer, vortex, hand-
counter, microscope, calculator, gloves, ethanol, wipes, etc. Access to
bench centrifuge, water bath set at 37 C and incubator at 37 C (and 5%
(v/v) CO2).
Procedure
1. Add the required volume of drugs (5-FU,MTX, and BrUdR) according
to the dose into each appropriate flask (Table F.1); wipe the flask with
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EtOH; place in cell culture incubator at 37 C (with 5% (v/v) CO2) for
3 days.
Cytotoxicity Test and Clonogenic Assays (01/04/11)
After 3 days incubated with drugs, the toxicity of the drugs will be assessed
and the clonogenic survival assays will be performed.
Sterile Materials
• 16 flasks of the 9L cells
• c-DMEM medium (complete DMEM supplemented with 10% FBS + 1%
PenStrep)
• PBS (without Ca2+ and Mg2+)
• 0.05% Trypsin-EDTA
• 2, 5, and 10 mL pipettes
• P20-P1000 pippete tips
• 50 ml FalconTM tubes
• BD FalconTM Primaria petri dishes 100 ⇥ 15 mm (growth area = 58.95
cm2; vol. = 16 –17.5 mL) (total needed = 14 flasks ⇥ 3 densities ⇥
3plicates = 126 + 6 controls = 132 plates) (Table F.2)
Other Materials
• Pippetor, Eppendorf tubes, tube racks, hemocytometer, vortex, hand-
counter, microscope, calculator, gloves, ethanol, wipes, etc. Access to
bench centrifuge, water bath set at 37 C and incubator at 37 C (and 5%
(v/v) CO2).
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Procedure
1. Pre-warmed the DMEM, PBS, and Trypsin-EDTA at 37 C water bath
(while waiting labeled each 132 petri dish).
2. Remove the spent medium from the flask; wash the cell monolayer with
5ml of PBS and discard; treated with 1ml of trypsin-EDTA; put in incu-
bator at 37 C for 5mins; check under microscope (cells should be detach
now).
3. Resuspend with 1ml of DMEM pipetting the cells up and down; transfer
100 µl of cells into 2 ml of DMEM (or HBSS bu↵er) for dilution in 50
ml FALCONtubes; count with haemocytometer (dispense the cells inside
the BSC).
4. Adjust the number of cells required for seeding based on the percent-
age toxicity rate (r%) of each treated cells condition compared to the








where N is the number of cells and r is the toxicity death rate of the
treated cells. We will make a set of three di↵erent densities for each flask
(of treated cells only) in order to get a good range number of cells plating
for the next experiment. See the template for more details (Table F.2),
5. Fill all the 132 plates with 10ml of fresh complete DMEM.
6. Vortex the cells before pipetting the into each petri dish.
7. Pipette the amount of volume required according to the number of cells/petri
dish (Table F.2) into each appropriate petri dish labeled (For each cell
sample density in triplicates).
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8. When finished (e.g. 6 petri dishes plated), shake the petri dish clockwise,
anti-clockwise, up-down and right-left directions; wiped with ethanol;
place in cell culture incubator at 37 C (with 5% (v/v) CO2); start again
for plating the next one.
9. After 21 days of culture, the cell colonies will fix and stain with crystal
violet.
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Fix and Staining – 22/04/11
After 21 days, the cells will fix and stain with mixture solution of 25% crystal
violet + 75% of EtOH (v/v).
Materials
• All plates of the 9L cells seeded on 01/04/11
• Dulbeccos PBS (with Ca2+ and Mg2+)
• Crystal violet
• 70% ethanol
• 2 ml pipettes
• waste jerry can or container
• Pipettor, gloves, ethanol, wipes, access to tap water
Procedure
1. Remove the spent medium from each plate; wash the cell monolayer
with approximate 5 ml of DPBS and discard; add approximate 2ml of
mixture solution of 25% crystal violet and 75% ethanol and leave for
about 5 minutes.
2. Rinse with tap water into waste container; invert the plates and allow
them to dry (on a carton cover with wipes paper).
Then, only the number of colonies containing more than 50 cells will counted
and check by microscope.
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Table F.2: Template for the cytotoxicity test of drugs and clonogenic assays
on 01/04/11
Cytotoxicity test of drugs and clonogenic assays on 01/04/11
Flask 5-FU MTX BrUdR Plate no. cells cells/plate µL
no. (µM) (µM) (µM) (µL)
1-control – – – 1–3 1500
2-control – – – 4–6 1500
3 0.01 7–9 N=
10–12 3N=
13–15 9N=
4 0.1 16–18 N=
19–21 3N=
22–24 9N=
5 0.01 25–27 N=
28–30 3N=
31–33 9N=
6 0.1 34–36 N=
37–39 3N=
40–42 9N=
7 1 43–45 N=
46–48 3N=
49–51 9N=
8 10 52–54 N=
55–57 3N=
58–60 9N=
9 0.01 1 61–63 N=
64–66 3N=
67–69 9N=
10 0.1 1 70–72 N=
73–75 3N=
76–78 9N=
11 0.01 10 79–81 N=
82–84 3N=
85–87 9N=
12 0.1 10 88–90 N=
91–93 3N=
94–96 9N=
13 0.01 1 97–99 N=
100–102 3N=
103–105 9N=
14 0.1 1 106–108 N=
109–111 3N=
112–114 9N=
15 0.01 10 115–117 N=
118–120 3N=
121–123 9N=
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• Healthy, ⇠80-90% confluent cell culture in T75cm2 flask
• c-DMEM medium (complete DMEM supplemented with 10%(v/v) FBS
and 1%(v/v) PenStrep)
• DPBS (without Ca2+ and Mg2+)
• 0.05% Trypsin-EDTA
• 2, 5, 10, and 25 mL pipettes
• BD FalconTM Primaria Petri dish 60 ⇥ 15 mm (growth area = 21.3 cm2;
vol. = 6 – 7 ml)
• BD T12.5cm2 flasks (with vented cap)
• P20-P1000 pipette tips
Other Materials
• Pippetor, Eppendorf tubes, tube racks, hemocytometer, vortex, hand-
counter, microscope, calculator, gloves, ethanol, wipes, etc. Access to
bench centrifuge, water bath set at 37 C and incubator at 37 C (and 5%
(v/v) CO2).
Procedure
1. Pre-warmed c-DMEM, DPBS, and Trypsin in water bath at 37 C
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2. Gently detach the cells: Discard the old media; wash the monolayer cells
with 10 mL of DPBS and discard; treated with 2mL Trypsin-EDTA;
placed in incubator at 37 C for 2-3mins
3. Re-suspend with 10mL of fresh DMEM; pipette it gently up and down.
Take a small aliquot of cells to an Eppendorf tube, vortex and count the
cells using haemocytometer
4. Adjust the final cell concentration of ⇠4 ⇥105 cells/flask (total make up
to 2 flasks 1 flask of treated cells and 1 flasks of control) and place in
incubator at 37 C (and 5% (v/v) CO22) for 2 days (cell should be reach
⇠70% confluence)
5. After 2 days, add the sterile NP prepared (refer to NP preparation step
below) into 1 flasks (labeled +NP).
6. After 1day incubation time, counts the cells as followed:
• Gently detach the cells: Discard the old media; wash the monolayer
cells with 5mL of DPBS and discard; treated with 1mL Trypsin-
EDTA; placed in incubator at 37C for 2-3mins.
• Re-suspend with 2mL of fresh DMEM; pipette it gently up and
down. Take a small aliquot of cells to an Eppendorf tube, vortex
and count the cells using hemocytometer.
• Adjust the number of cells required for seeding based on the per-
centage toxicity rate (r%) of each treated cells condition compared








where N is the number of cells and r is the toxicity death rate of the
treated cells. We will make a set of three di↵erent densities for each
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flask (of treated cells only) in order to get a good range number
of cells plating for the next experiment. See the template for more
details (Table G.1).
Table G.1: An example of template for the cytotoxicity test and clonogenic
assay of nanoparticles on 9L cells
Cytotoxicity and clonogenic test of Bi2O3 on 9L cells (22–24 Nov 2011)
Flask no. Bi2O3 (µg/ml) Plate no. cells/µL cells/plate µL
1-control – 1–3 1500
DAY1 50 4–6 N=
50 7–9 2N=
50 10–12 4N=
2-control – 13–15 1500
DAY2 50 16–18 N=
50 19–21 2N=
50 22–24 4N=
Nanoparticle (NP) Samples Preparation
Drying the NP samples
• Crush the NP into powder and place on foil. Place in 70 C oven (includ-
ing the glass vials) for no less than 2 hours, and then transfer the NP
into the glass vial.
Sterilising the NP samples
• Placed the glass vial containing the NP, into a small beaker cover with
foil and autoclave at 121 C.
• Upon completion, if doing the experiments on the same day, start im-
mediately step 3. Otherwise, placed the glass vial into a drying oven
(70 C) for couple hours (to avoid condensation) then it can be stored
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at room temperature (placing the vial inside a tube containing silica to
avoid moisture re-absorption).
Suspend the NP samples in PBS
• Inside the BSC, transferred the sterile NP (e.g. 5 mg) into 50 mL
FalconTM tube and add 10 mL of sterile PBS (make up concentration
of 500 µg/mL). To have the required concentration of 50 µg/mL of the
NP, the volume of 1ml will need to be added into each flask.
Sonicate the NP samples
• Wipe the fine tip probe of the sonifier with 70% ethanol.
• Place the FalconTM tube (containing the NP) into a beaker filled with
water (make sure about 2 – 3 cm of the fine tip probe is immersed in
the water without touching the side or the bottom of the beaker). Then,
place the beaker into another bigger beaker or container surrounding
with ice (to avoid the probe overheating the solution).
• Set-up the sonifier (depend on what sonifier to be used high or ultra-
high): strength at level 7 (no higher than 7!); duty cycle control at
constant; and timer for 5 minutes (repeat 6 times to give total duration
of 30 mins).
Add the NP samples into cells
• Immediately after the sanitation finish, inside the BSC, adds the volume
of NP required (e.g. 1 ml) into flask prepared before (containing ⇠1⇥106
cells).
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H.1 Experimental dose rate on LINAC
Cell Culture Preparation
1. Healthy, ⇠90% confluent cell culture in T12.5cm2 flasks with vented cap
– seeding at 1 ⇥105 cells cells/flask 3 days before X-ray irradiation.
2. After 3 days incubation, just prior the irradiation, fill the flask of cells
with approximately 30ml of pre-warm HBSS bu↵er (w/Phenol); sealed
the lid with parafilm (not to cover the filter on top).
3. Placed vertically all the flasks in the container surround by silica gel;
then in a carry bag.
4. Transport to POWH.
Cells Irradiations
Irradiate the cells in flask vertically at room temperature randomly (as showed
previously in methods section). After irradiation of all cell samples completed,




• Cell culture in T12.5cm2 flasks
• c-DMEM medium (complete DMEM supplemented with 10% FBS and
1% PenStrep)
• PBS (without Ca2+ and Mg2+)
• Trypsin-EDTA
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• 1, 5, 10 and 25 mL pipettes
• BD FalconTM Primaria petri dishes 100 ⇥ 15 mm (growth area = 58.95
cm2; vol. = 16 –17.5 mL)
• 50mL FalconTM tubes
• P20-P1000 pipette tips
Other materials
• Pippetor, Eppendorf tubes, tube racks, hemocytometer, vortex, hand-
counter, microscope, calculator, gloves, ethanol, wipes, etc. Access to
bench centrifuge, water bath set at 37 C and incubator at 37 C (and 5%
(v/v) CO2).
Procedure
1. Pre-warmed the c-DMEM, PBS, and Trypsin-EDTA 37 C water bath
(while waiting – labeled each petri dish).
2. Prepare for assay: Transfer 10ml of DMEM into each petri dish.
3. Remove the spent medium from the flask; wash the cell monolayer with
5 ml of PBS and discard; treated with 1ml of trypsin-EDTA; put in
incubator at 37 C for 2 mins; check under microscope (cells should be
detach now).
4. Resuspend with 1 ml of DMEM pipetting the cells up and down; transfer
either 300 or 500 µl of cells into 5 ml of DMEM for dilution in 50ml
FalconTM tubes; count with hemocytometer; Adjust the number of cells
required (Table H.1)
5. Vortex the cells before pipetting the into petri dish.
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Figure H.1: Schematic diagram of cell culture technique (i.e clonogenic assay).
6. Pipette the amount of volume required according to the number of cells/petri
dish (Table H.1) into each appropriate petri dish labeled (for each cell
sample density in triplicates).
7. When finished (e.g. 6 petri dishes plated), shake the petri dish clockwise,
anti-clockwise, up-down and right-left directions; wiped with ethanol;
place in cell culture incubator at 37 C (with 5% (v/v) CO2); start again
for plating the next flask.
8. After 15 doubling time (e.g 21 days for 9L) of culture, the cell colonies
was fix and stain with mixture solution of 25% crystal violet (v/v) and
75% (v/v) ethanol.
A schematic diagram of the clonogenic assay procedure is illustrated in figure
H.1.
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Table H.1: A representative of summarised of X-rays irradiation of 9L cells for
clonogenic assay. The number of cell densities used are di↵erent depend on
the energy of X-rays and the cell line
.
Irradiation of 9L cells with 10 MV X-rays (HDR and LDR)
Flask Dose (Gy) Dose rate Petri dish no. cells/petri dish Cells/µL µL
no.
1 Control 1-0 — 1–3 1500
2 Control 2-0 — 4–6 1500
3 1 HDR 7–9 2100
4 2 HDR 10–12 2300
5 3 HDR 13–15 2300
16–18 3400
19–21 4200
6 5 HDR 22–24 4000
25–27 6000
7 8 HDR 28–30 8000
31–33 12000
34–36 16000
8 1 LDR 37–39 1500
9 2 LDR 40–42 1500
43–45 2300
10 3 LDR 46–48 2300
49–51 3400
11 5 LDR 52–54 4500
55–57 6000
12 8 LDR 58–60 12000
61–63 14000
64–66 16000
HDR: High-Dose Rate (5 Gy/min); LDR: Low-Dose Rate (0.5 Gy/min).
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H.2 Chemotherapy Drugs Combination
Cell Culture Preparation
1. Healthy, ⇠90% confluent cell culture in T12.5cm2 flasks with vented cap
– seeding at 1 ⇥105 cells cells/flask, incubate for 2 days before adding
the drugs.
2. After 3 days incubation with drugs, just prior the irradiation, fill the flask
of cells with approximately 30ml of pre-warm HBSS bu↵er (w/Phenol)
for the controls (no drugs). For the drugs-treated cells, the concentration
being adjusted; sealed the lid with parafilm (not to cover the filter on
top).
3. Placed vertically all the flasks in the container surround by silica gel;
then in a carry bag.
4. Transport to POWH.
Cells Irradiations
refer to previous section in Appendix F1 cells irradiations.
Clonogenic Assays Plating
refer to previous section in Appendix F1 clonogenic assays plating.
Only the tables are di↵erent. A representative tables are shown below (Table
H.2 and Table H.3).
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Table H.2: A representative of summarised of kVp X-rays irradiation of 9L cells
for clonogenic assay. The number of cell densities used are di↵erent depend on
the energy of X-rays used
.
Irradiation of 9L cells with 125 kVp X-rays (NO DRUGS)
Flask Dose (Gy) Dose rate Petri dish no. cells/petri dish Cells/µL µL
no.
1 Control 1-0 – 1–3 1500
2 Control 2-0 – 4–6 1500
3 1 – 7–9 2000
4 2 – 10–12 2300
5 3 – 13–15 2500
16–18 3400
6 5 – 19–21 4000
22-24 6000
7 8 – 25–27 8000
28–30 10000
31–33 12000
Table H.3: A representative of summarised of kVp X-rays irradiation of 9L cells
for clonogenic assay. The number of cell densities used are di↵erent depend on
the energy of X-rays and single/combination of drugs used
.
Irradiation of 9L cells with 125 kVp X-rays (0.01 µM MTX)
Flask Dose (Gy) Dose rate Petri dish no. cells/petri dish Cells/µL µL
no.
1 Control 1-0 – 1–3 4000
2 Control 2-0 – 4–6 4000
3 1 – 7–9 4000
– 10–12 8000
– 13–15 16000
4 2 – 16–18 5000
– 19–21 10000
– 22–24 20000
5 3 – 25–27 8000
28–30 16000
– 31–33 32000
6 5 – 34–36 16000
37–39 32000
– 40–42 64000
7 8 – 43–45 50000
46–48 100000
49–51 200000
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H.3 Nanoparticles Combination
Nanoparticle (NP) Samples Preparation
Drying the NP samples
• Crush the NP into powder and place on foil. Place in 70 C oven (includ-
ing the glass vials) for no less than 2 hours, and then transfer the NP
into the glass vial.
Sterilising the NP samples
• Placed the glass vial containing the NP, into a small beaker cover with
foil and autoclave at 121 C.
• Upon completion, if doing the experiments on the same day, start im-
mediately step 3. Otherwise, placed the glass vial into a drying oven
(70 C) for couple hours (to avoid condensation) then it can be stored
at room temperature (placing the vial inside a tube containing silica to
avoid moisture re-absorption).
Suspend the NP samples in PBS
• Inside the BSC, transferred the sterile NP (e.g. 5 mg) into 50 mL
FalconTM tube and add 10 mL of sterile PBS (make up concentration
of 500 µg/mL). To have the required concentration of 50 µg/mL of the
NP, the volume of 1ml will need to be added into each flask.
Sonicate the NP samples
H.3. Nanoparticles Combination 248
• Wipe the fine tip probe of the sonifier with 70% ethanol.
• Place the FalconTM tube (containing the NP) into a beaker filled with
water (make sure about 2 – 3 cm of the fine tip probe is immersed in
the water without touching the side or the bottom of the beaker). Then,
place the beaker into another bigger beaker or container surrounding
with ice (to avoid the probe overheating the solution).
• Set-up the sonifier (depend on what sonifier to be used high or ultra-
high): strength at level 7 (no higher than 7!); duty cycle control at
constant; and timer for 5 minutes (repeat 6 times to give total duration
of 30 mins).
Add the NP samples into cells
• Immediately after the sanitation finish, inside the BSC, adds the volume
of NP required (e.g. 1 ml) into flask prepared before (containing ⇠1⇥106
cells).
Cells Irradiations
1. Healthy, ⇠90% confluent cell culture in T12.5cm2 flasks with no vented
cap (with or without nanoparticles).
2. After 1 days incubation with nanoparticles, just prior the irradiation,
fill the flask of cells with approximately 30 ml of pre-warm HBSS bu↵er
(w/Phenol) for MV irradiations only (6 ml in total volume for kV irra-
diation; sealed the lid with parafilm.
3. Placed horizontally all the flasks in the container surround by silica gel;
then in a carry bag.
4. Transport to POWH.
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5. Irradiate the cells in flask horizontally at room temperature randomly
(as showed previously in methods section). After irradiation of all cell
samples completed, bring all the cell samples back to IHMRI lab and
plate immediately.
Next procedure of clonogenic assay plating are exactly the same like in previous
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I.1 Cell Cycle Analysis
Materials
• Healthy, ⇠100% confluent cell culture in T12.5cm2 flask
• c-DMEM medium (complete DMEM supplemented with 10% FBS and
1% PenStrep)
• PBS (without Ca2+ and Mg2+)
• 0.05% trypsin-EDTA
• 50 mL FalconTM tube
Reagents and other Materials
• Ice-cold 70% Ethanol and PBS
• PI master mix (100 µg/mL RNase A, 40µg/mL PI, and PBS pH 7.4)
• Fluorescence-activated cell sorting (FACS) machine, FACS tube, pip-
petor, pippets and tips, Eppendorf tubes, tube racks, hemocytometer,
vortex, hand-counter, microscope, calculator, gloves, ethanol, wipes, etc.
Access to bench centrifuge, water bath set at 37 C and incubator at 37 C
(and 5% (v/v) CO2).
Procedure
1. Pre-warmed the DMEM, PBS and trypsin-EDTA at 37 C water bath.
2. Harvest the cells in the appropriate manner (refer to Appendix B of cell
culture protocol).
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3. Take a small aliquot of cells in Eppendorf tube; count with haemocy-
tometer.
4. Transfer the amount of cells required (2 ⇥104 – 1 ⇥106 cells/200 µL)
into 50 ml tubes.
5. Wash: Top up with cold PBS and centrifuge (4 C) at 1500rpm for 5mins.
This step removes the serum.
6. Fixation: Aspirate the supernatant. Gently resuspend the cells pellet
with 1 mL cold 70% Ethanol by adding drop-wise with a Pasteur pipette
while vortexing (note: this is to prevent clustering of cells during the
fixation). Leave the cells for at least 60 mins up to a week at – 20 C.
7. Remove ethanol by centrifuge (4 C) at 1500rpm for 5mins and wash twice
with PBS (as in step 5). This step removes the fixative. Aspirate the
supernatant.
8. Stain: Add 200 µL PI master mix and incubate for 60 mins at 37 C
protected from light (cover w/foil).
9. Put sample on ice. Run sample on FACS machine.
10. Analyse by flow cytometry: using BD LSR II FACSort flow cytometry
collecting 10,000 events per sample. DNA content was then measured
and the proportion of cells in G0/G1, S and G2/M phases of cell cycle
were calculated on the basis of histograms using FlowJo software.
Notes:
• Master stock for both PI and RNase is made of 1mg/ml. Aliquot can be
stored for up to 2 months at 4 C or 2 years at –20 C for PI (protected
from light) and RNase for up to 6 months at 4 C or frozen at –20 C.
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• PI is very light sensitive. Do not keep it long at RT. Discard if it turns
to dark red colour. It is also suspected as carcinogen. Take appropriate
safety precautions when working with this dye.
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I.2 Immunocytochemical Protocol
Analysis of DNA content and BrUdR incorporation simultane-
ously
Materials
• Cells culture in appropriate medium.
• FACS tube (or round bottom polysterene tubes/centrifuge tube)
• 50 mL FalconTM tubes
• Pipette tips and pipettes
• Centrifuge, vortex, Ice bucket, timer
• Fluorescence-activated cell sorting (FACS) machine
Reagents
• Phosphate Bu↵ered Saline (PBS)
• 0.05% Trypsin-EDTA
• Cells and culture media (fresh complete DMEM)
• Ice-cold 70% Ethanol
• 4N Hydrochloric acid (HCl)
• Phosphate/citric acid bu↵er, pH 7.4
– Mix 182 ml of 0.2 M Na2HPO4 with 18 ml of 0.1 M citric acid.
Check the pH, which should be 7.4. if not, adjust with 1 M HCl or
1 M NaOH. Store up to 2 months at 2 C to 6 C.
• Antibody diluting bu↵er (prepare fresh). PBS containing:
I.2. Immunocytochemical Protocol 255
– 0.1% (v/v) Triton X-100
– 1% (w/v) bovine serum albumin (BSA)
• Propidium Iodide staining solution (protect from light)
– 100 µg PI
– 1 mg RNase A
– 10 mL PBS




1. Add BrUdR to the cell culture medium to obtain a final concentration
of 10 µM. Incubate for 3 days at 37 C.
Harvest and fix the cells
2. Harvest cells by Trypsin-EDTA. Transfer into centrifuge tubes.
3. Centrifuge the tube at at 1500 rpm for 5mins at room temperature.
Discard the supernatant.
4. Wash: Top up the cells with 10 mL PBS and mix well. Centrifuge at
1500 rpm for 5mins at room temperature. Discard the supernatant. This
step removes the serum.
5. Dislodge the cells by shaking.
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6. Fixation: Add 10 mL ice-cold 70% ethanol by adding drop-wise to the
cell pellet while vortexing.
7. Store for a minimum of 4 hour (and for as long as several months) at –
20 C.
Prepare the cells for labelling
8. Remove the cell suspension from the freezer and centrifuge at 1500 rpm
for 5mins at room temperature. Discard the supernatant.
9. Dislodge the cells by shaking.
10. Wash: Top up the cells with 10 mL PBS and mix well. Centrifuge at
1500 rpm for 5 mins at room temperature. Discard the supernatant.
This step removes the fixative.
11. Dislodge the cells by shaking.
12. Denaturation: Add 2 mL of 4 M HCl to the cell pellet and mix well.
Incubate for 20 minutes at room temperature.
13. Add 10 mL phosphate/citric acid bu↵er, mix well, and centrifuge at 1500
rpm for 5mins at room temperature. Discard the supernatant.
14. Dislodge the cells by shaking.
15. Add 10 mL antibody diluting bu↵er to the cell pellet, mix well, and
centrifuge at 1500 rpm for 5mins at room temperature. Discard the
supernatant.
16. Repeat the wash as described in step 13.
17. Dislodge the cells by shaking.
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18. Resuspend the cells at a concentration of 1⇥107 cells/mL in antibody
diluting bu↵er.
19. Add 100 µL of cells suspension to FACStube.
Label the cells with antibody to detect BrUdR
20. Stain: Add 5 µL of BrdU-Mouse monoclonal antibodies-clone MoBU-
1 Alexa Fluor 488 conjugate (Invitrogen-B35139) and incubate for 30
minutes, protected from light.
21. Wash: add 3 mL antibody diluting bu↵er into each tube, mix well, and
centrifuge at 1500 rpm for 5 mins at room temperature. Discard the
supernatant.
Label with DNA staining dye
22. Counter-stain: Add 0.5 ml of PI solution.
23. Incubate for 30 minutes at room temperature, protected from light.
Set up flow cytometric data collection
24. Acquire events on flow cytometer, collecting at 10,000 events. Collect
fluorescence as follows:
• Collect green fluorescence using 488-nm excitation for detection of
Alexa Fluor 488 anti-BrUdR






3D-CRT three-dimensional conformal external radiotherapy
9L mouse gliosarcoma cell line
5-FU 5-fluorouracil
A adenine
ATCC American type culture collection
ATM ataxia telangiectasia mutated
BBB blood-brain barrier
BIM biologically important molecule
Bi bismuth
Bi (NO3)3 bismuth (III) nitrate pentrhydrate
Bi2O3 bismuth oxide
BrUdR 5-bromo-20-deoxyuridine
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EBRT external beam radiation therapies
EC electron capture
ECACC european collection of cell cultures
Eq equation
F fluorine
FFF flattening filter free
FH2 dihydrofolate
FH4 tetrahydrofolate
FACS fluorescence-activated cell sorting
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FCS flow cytometer standard
FdUMP 20-deoxyuridylic acid monophosphate
FSC forward scatter
G0 phase where cells are quiescent
G1 gap 1; phase where cells are preparing for DNA synthesis











ICRU International Commission on Radiation Units and Measurements
ICSD Inorganic Crystal Structure Database
IHMRI Illawarra Health and Medical Research Institute
IMAT intensity modulated arc therapy
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LAS AF Leica application suite advanced fluorescence
LDR low-dose rate
LET linear energy transfer
LINAC linear accelerator
LMDS local multiply damaged sites
LQ linear-quadratic
M-phase mitosis, phase where cells divide into two daughter cells
MCF-7 human breast carcinoma
MDA-MB-231 human breast carcinoma






NIGMS National Institute of General Medical Science
NIST National Institute of Standards and Technology
NHEJ non-homologous end joining
NP nanoparticle
NSP nanostructure particle
NADP+ nicotinamide adenine dinucleotide phosphate
NADPH reduced form of NADP+
OH• hydroxyl radical
P phosphorus
PAT photon activation therapy




PER protection enhancement ratio
PI propidium iodide
PMT photomultiplier tube
POWH Prince of Wales hospital
RBE relative biological e↵ectiveness
RNA ribose nucleic acid
ROS reactive oxygen species
RT radiation therapy
S-phase phase where DNA synthesis occurs
SD standard deviation










TEM transmission electron microscopy
TNT targeted nano-therapies team
Trypin-EDTA trypsin-ethylenediaminetetraactic acid
TS thymidilate synthetase
U-87MG human glioblastoma cell line
UOW University of Wollongong






















rpm revolution per minute
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The following publications are associated with the work contained in this the-
sis.
1. A. Briggs, S. Corde, S. Oktaria, R. Brown, A. Rosenfeld, M. Lerch, K.
Konstantinov, M. Tehei, Cerium oxide nanoparticles: influence of the
high-Z component revealed on radioresistant 9L cell survival under X-
ray irradiation. Nanomedicine: Nanotechnology, Biology, and Medicine
(2013); 9:1098-1105.
2. R. Brown, M. Tehei, S. Oktaria, A. Briggs, C. Stewart, K. Konstanti-
nov, A. Rosenfeld, S. Corde, M. Lerch, High-Z nanostructured ceramics
in radiotherapy: first evidence of Ta2O5-induced dose enhancement on
radioresistant cancer cells in an MV photon field. Particle and Particle
Systems Characterisation (2013) (Accepted for publication).
3. C. Stewart, K. Konstantinov, M. McDonald, D. Cardillo, K. Bogusz,
S. Oktaria, D. Shi, M. Lerch, T. Devers, S. Corde, A. Rosenfeld, M.
Tehei. Engineering of bismuth oxide nanoparticles to induce di↵erential
biochemical activity in malignant and non-malignant cells. Particle and
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Particle Systems Characterisation (2014) (Accepted for publication).
4. S. Oktaria, S. Corde, M. Lerch, A. Rosenfeld, M.Tehei. In vitro investiga-
tion of the dose-rate e↵ect on the biological e↵ectiveness of megavoltage
X-ray radiation doses (2014) (submitted).
5. S. Oktaria, S. Corde, M. Lerch, A. Rosenfeld, M.Tehei, Radiation in-
duced chemo-beta therapy I: in vitro demonstration of the radiosensiti-
sation enhancement on a rat gliosarcoma cell line (2014) (submitted).
6. S. Oktaria, S. Corde, M. Lerch, A. Rosenfeld, M.Tehei, Radiation in-
duced chemo-beta therapy II: in vitro demonstration of the radiosen-
sitisation enhancement on a rat gliosarcoma cell line and influence of
di↵erent X-ray energies (2014) (manuscript in preparation).
The following poster and oral presentations have been made at conferences
connected with the work in this thesis.
1. The 14th International Congress of Radiation Research, Warsaw, Poland,
28th August 1st September 2011, In vitro investigation of the dose-rate
e↵ect on the biological e↵ectiveness of megavoltage X-ray radiation doses.
(Poster)
2. The 25th Annual Chemistry & IPRI Conference, Fitzroy Falls Conference
Centre, NSW, Australia 31st 2nd November 2011, In vitro investigation
of the dose-rate e↵ect on the biological e↵ectiveness of megavoltage X-ray
radiation doses. (Oral)
3. Australian Institute of Physics (AIP) and Royal Australian Chemical
Institute (RACI), Sydney, Australia, 10th November 2011, In vitro in-
vestigation of the dose-rate e↵ect on the biological e↵ectiveness of mega-
voltage X-ray radiation doses. (Poster)
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Australia, 29th November 2011, In vitro investigation of the dose-rate
e↵ect on the biological e↵ectiveness of megavoltage X-ray radiation doses.
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5. The 6th Student Research Symposium of the ACT/NSW Branch of the
Australian College of Physical Scientists and Engineering in Medicine
(ACPSEM), University of Sydney, Australia, 1st December 2011, Inves-
tigation of the dose-rate e↵ect on the biological e↵ectiveness of 10 MV
X-ray in cancer cell lines assessed by clonogenic assay. (Oral)
6. Radiation 2012 Conference, AINSE, Lucas Heights, NSW, Australia, 15-
17th February 2012, Investigation of the dose-rate e↵ect on the biological
e↵ectiveness of 10 MV X-ray in cancer cell lines assessed by clonogenic
assay. (Oral)
7. Radiation 2012 Conference, AINSE, Lucas Heights, NSW, Australia, 15-
17th February 2012, Enhanced radiosensitisation of resistant tumour
cells to radiotherapy: a novel approach on biomodulation in DNA by
chemotherapy drug. (Poster)
8. 2012 Engineering and Physical Sciences in Medicine (EPSM) Conference,
Gold Coast, QLD, Australia, 2-6th December 2012, Enhanced radiosen-
sitisation of resistant tumour cells to radiotherapy: a novel approach on
biomodulation in DNA by chemotherapy drug. (Poster)
9. Mini- Micro- Nano- Dosimetry (MMND 2012) and International Prostate
Cancer Treatment (IPCT 2012) International Workshop, The University
of Wollongong, 6-9th December 2012, Enhanced radiosensitisation of re-
sistant tumour cells to radiotherapy: a novel approach on biomodulation
in DNA by chemotherapy drug. (Oral)
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New South Wales, 9-13th December 2012, Enhanced radiosensitisation
of resistant tumour cells to radiotherapy: a novel approach on biomod-
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